Isolating The Effects Of Body Mass And Energy Balance On Sleep And Metabolic Health by Perron, Isaac Jeffrey
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2017
Isolating The Effects Of Body Mass And Energy
Balance On Sleep And Metabolic Health
Isaac Jeffrey Perron
University of Pennsylvania, ijperron@gmail.com
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Neuroscience and Neurobiology Commons, and the Physiology Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2838
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Perron, Isaac Jeffrey, "Isolating The Effects Of Body Mass And Energy Balance On Sleep And Metabolic Health" (2017). Publicly
Accessible Penn Dissertations. 2838.
https://repository.upenn.edu/edissertations/2838
Isolating The Effects Of Body Mass And Energy Balance On Sleep And
Metabolic Health
Abstract
Obesity is associated with numerous metabolic and behavioral abnormalities, including excessive daytime
sleepiness independent of sleep disorders (e.g., sleep apnea). In humans, obesity is traditionally classified by
weight metrics such as body mass index (BMI); over one-third of Americans are obese based on BMI. The
most common cause of obesity is chronic positive energy balance due to overconsumption of calorically-
dense diets. However, it is difficult to isolate the independent effects of ‘overnutrition/positive energy balance’
and ‘excess body weight’ on metabolic and behavioral parameters since the former causes the latter. Therefore,
the focus of this dissertation is to discover how diet/energy balance, independent from body weight, affect
sleep/wake behavior and metabolic health using the high-fat diet (HFD)-induced obese mouse model. In
Chapter 2, I introduce the Diet Switch (DS) feeding paradigm which generates two groups of mice of similar
body weight by divergent energy balance. Using the DS protocol, I show that diet-induced changes to energy
balance can affect sleep and wakefulness independent of actual body weight. In Chapter 3, I explore the role of
a central regulator of energy balance, peroxisome proliferator-activated receptor gamma (PPARg), on HFD-
induced sleep abnormalities; our results indicate that central PPARg does not influence sleep/wake behavior.
In Chapter 4, I again use the DS feeding paradigm, but instead measure various molecular (blood biomarkers
and hypothalamic gene expression), behavioral (spontaneous activity), and metabolic (indirect calorimetry)
outcomes. Using linear regression modeling, I quantify the relative influence of body weight and diet/energy
balance on these parameters, and relate these key findings to the results from Chapter 2. Taken together, these
studies offer novel insights into the pathogenesis and reversibility of obesity-related sleep and metabolic
disorders.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Neuroscience
First Advisor
Sigrid C. Veasey
Second Advisor
Allan I. Pack
Keywords
diet switch, energy balance, high fat diet, mice, obesity, sleep
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2838
Subject Categories
Neuroscience and Neurobiology | Physiology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2838
 
 
ISOLATING THE EFFECTS OF BODY MASS AND ENERGY BALANCE ON SLEEP 
AND METABOLIC HEALTH 
 
 
Isaac Jeffrey Perron 
 
 
A DISSERTATION 
 
In 
 
Neuroscience 
 
 
Presented to the Faculties of the University of Pennsylvania 
 
in 
 
Partial Fulfillment of the Requirements for the 
 
Degree of Doctor of Philosophy 
 
2017 
 
Supervisor of Dissertation     Co-Supervisor of Dissertation 
 
______________________                  ______________________ 
 
Sigrid C. Veasey, M.D.             Allan I. Pack, M.B.Ch.B., Ph.D. 
Professor of Neuroscience         Professor of Neuroscience 
Graduate Group Chairperson 
 
               ________________________    
 
       Joshua I. Gold, Ph.D.                            
 
                 Professor of Neuroscience     
 
 
Dissertation Committee                        
Matthew R. Hayes, Ph.D., Professor of Psychiatry          
David M. Raizen, M.D., Ph.D., Professor of Neurology     
Joseph A. Baur, Ph.D., Professor of Physiology      
Teresa M. Reyes, Ph.D., Professor of Neuroscience
ii 
 
Dedication Page  
 
To my mentors, who told me I could; 
To my teachers, who showed me how; and 
To my friends and family, who supported me throughout. 
 
“Anything is possible” – Kevin Garnett 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGMENTS 
 
I must first thank my two thesis advisors—Drs. Sigrid Veasey and Allan Pack—
for their continuous support, patience, and encouragement throughout my studies. Their 
infectious optimism and excitement for science made graduate school an experience I 
will remember fondly. This, of course, was supplemented by their technical and scientific 
expertise, which was necessary to conceive of and complete my dissertation work. I will 
remember Sigrid best for consistently pushing me to be the best I could be—challenging 
my thoughts and forcing me to defend my logic and rationale—and for that, I will be 
eternally grateful. Allan is the master of the ‘big picture’ and sees multiple steps ahead of 
any problem I brought to his attention, but I will remember him best for his unwavering 
support and generosity. I have learned immensely from them both, and I am honored to 
have worked with and learned from them during my graduate studies. 
I must also thank the rest of my thesis committee: Drs. Matthew Hayes, David 
Raizen, Joseph Baur, and Teresa Reyes. Their insightful comments, challenging 
questions, and endless support made me a better, more confident scientist.  
I would also like to thank the many researchers and STEM educators I have 
learned from, especially Drs. David Shreiber and Shirley Masand. You took a chance on 
an undergraduate with no experience, and made me believe I belonged in science. 
Doctoral training wasn’t even a consideration, let alone a possibility, without your support 
and guidance. 
Additionally, I give my sincerest thanks to all the members of the Sleep Center, 
especially Ray Galante, Brendan Keenan, Sophie Guo, Polina Fenik, Guanxia Zhan, 
Yan Zhu, Jing Xu Zhu, Dan Barrett, and Karen McLaughlin.   It takes a village  to  raise a  
iv 
 
child, and that is no different for a graduate student. Separately, I must mention Sarah 
Ly who is not only an integral member of the Sleep Center, but one of my best friends. 
Not only a phenomenal colleague, she is the perfect person to bring you up when times 
are tough, to keep you humble when things go well, and to help you focus when you just 
don’t want to. I couldn’t have done it without you, Sarah; thank you.  
I must thank all of my wonderful “Penn Pals” who made graduate school some of 
the best years of my life. Every single one of them is immensely talented, brilliant, and 
hardworking, and every one of them deserves the success that they will undoubtedly 
find. In particular, I must mention my OG “Penn Pals”—Leonardo, Morgan, Shachee, 
Noam, Sarah, Chris, and Russ—who were the ideal crew to endure “PhD puberty” with. 
Finally, I must thank the people behind that curtains who make NGG, MINS, and BGS 
run smoothly, especially Drs. Joshua Gold, Chris Pierce, Kelly Jordan-Sciutto, John 
Dani, Mikey Nusbaum, and Rita Balice-Gordon, as well as Christine Clay, Thomas 
Hindman, and Jane Hoshi. 
Last, but certainly not least, I must thank my closest friends and family. From my 
“RU Crew” to my lifelong friends, Chris and Lauren, and everyone in between—you are 
the most important people in my life, and I am thankful every day that I get to spend time 
with you all.  Finally, to my mother, Judy, who pushes me to my limits because she 
knows what I am capable of—thank you. And to my father, Paul, whom I share a 
birthday with 51 years to the day—you once told me you were unsure if you’d live to see 
my high school graduation; thanks for sticking around. I learned patience and 
perseverance from you, and those life-skills have been enormously helpful in all walks of 
life. I love you both and cannot thank you enough. 
 
v 
 
ABSTRACT 
ISOLATING THE EFFECTS OF BODY MASS AND ENERGY BALANCE ON SLEEP 
AND METABOLIC HEALTH 
Isaac J. Perron 
Sigrid C. Veasey  
Allan I. Pack 
 
Obesity is associated with numerous metabolic and behavioral abnormalities, including 
excessive daytime sleepiness independent of sleep disorders (e.g., sleep apnea). In 
humans, obesity is traditionally classified by weight metrics such as body mass index 
(BMI); over one-third of Americans are obese based on BMI. The most common cause 
of obesity is chronic positive energy balance due to overconsumption of calorically-
dense diets. However, it is difficult to isolate the independent effects of 
‘overnutrition/positive energy balance’ and ‘excess body weight’ on metabolic and 
behavioral parameters since the former causes the latter. Therefore, the focus of this 
dissertation is to discover how diet/energy balance, independent from body weight, 
affect sleep/wake behavior and metabolic health using the high-fat diet (HFD)-induced 
obese mouse model. In Chapter 2, I introduce the Diet Switch (DS) feeding paradigm 
which generates two groups of mice of similar body weight by divergent energy balance. 
Using the DS protocol, I show that diet-induced changes to energy balance can affect 
sleep and wakefulness independent of actual body weight. In Chapter 3, I explore the 
role of a central regulator of energy balance, peroxisome proliferator-activated receptor 
gamma (PPARg), on HFD-induced sleep abnormalities; our results indicate that central 
PPARg does not influence sleep/wake behavior. In Chapter 4, I again use the DS 
feeding paradigm, but instead measure various molecular (blood biomarkers and 
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hypothalamic gene expression), behavioral (spontaneous activity), and metabolic 
(indirect calorimetry) outcomes. Using linear regression modeling, I quantify the relative 
influence of body weight and diet/energy balance on these parameters, and relate these 
key findings to the results from Chapter 2. Taken together, these studies offer novel 
insights into the pathogenesis and reversibility of obesity-related sleep and metabolic 
disorders. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
I. Obesity and Sleepiness: Counter-evolutionary traits in modern society 
Overview 
 At the most fundamental level, sleep and food intake are mutually exclusive. 
When an animal does not have access to food, sleep is foregone to induce food-seeking 
behavior (increased exploratory activity). However, sleep itself reduces metabolic rate, 
and body temperature is lower during resting states (Fontvieille, Rising et al. 1994; Van 
Someren 2006), making the trade-off between ‘food-seeking’ and ‘sleep’ a crucial 
conundrum in evolutionary behavior.  
In our modern society, sufficient sleep (≥ 7 hours) is difficult to get because of 
socioeconomic factors, light/sound pollution, and sleep disorders, such as sleep apnea 
and insomnia (Grandner, Patel et al. 2010; Ohayon, Wickwire et al. 2017). Strikingly, 
studies from the Centers for Disease Control and Prevention found that >30% of people 
report unintentionally falling asleep during the day, regardless of how much sleep they 
get on average (CDC 2011). Therefore, excessive daytime sleepiness (EDS) is 
commonplace in our society, although the exact causes are unknown. Importantly, EDS 
itself is a public health concern (e.g., >300,000 police-reported car crashes per year 
result from ‘drowsy-driving’) and can reduce productivity at work, potentially costing the 
U.S. economy upwards of $63 billion annually (Kessler, Berglund et al. 2011; Tefft 
2014).  
Concomitant with prevalent daytime wake impairments, our modern society is in 
the midst of an obesity epidemic. As of 2012, >70% of adults are overweight and roughly 
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half of those people are obese, as determined by body mass index (Ogden, Carroll et al. 
2014). The links between obesity and sleep are well-established. Specifically, insufficient 
sleep (<7 hours) as a risk factor for developing obesity (Taheri 2006). Conversely, obese 
individuals report being much sleepier during the day compared to their lean 
counterparts, even when controlling for metabolic and sleep disorders (Vgontzas, Bixler 
et al. 1998; Panossian and Veasey 2012). Therefore, the central theme of this 
dissertation is:           what contributes to excessive sleepiness in states of overnutrition 
and obesity? 
In the remainder of this chapter, I will detail past research and current 
perspectives on the requirements and regulation of sleep (Section II), with a focus on its 
relation to metabolism (Section III). I will then explore molecular signatures and brain 
areas relevant to both metabolic and sleep regulation (Section IV). Finally, I will pose 
open questions in the field, and detail how the experiments presented herewithin begin 
to address these important topics (Section V). 
 
II. Theories about the Requirement for Sleep 
Sleep conservation across animal species 
Along with reproduction and eating, sleep is one of the most evolutionary 
conserved behaviors across the animal kingdom (Siegel 2005; Zimmerman, Naidoo et 
al. 2008). Humans spend approximately one-third of their lives asleep, mostly during the 
nighttime. Every observed mammal exhibits stereotypical sleep behavior, although sleep 
duration, bout architecture, and chronotype vary greatly between species (Siegel 2005). 
However, due to highly conserved sleep-regulating pathways, multiple animal models 
are employed in sleep research. The microscopic roundworm, Caenorhabitius elegans, 
exhibits sleep-like states during development and following stress exposure (Raizen, 
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Zimmerman et al. 2008; Trojanowski, Nelson et al. 2015), while Drosophila 
melanogaster (the common fruit fly) is a crepuscular organism with strong circadian 
rhythms (Hendricks, Finn et al. 2000).  Importantly, these sleep-like states share many 
key characteristics with mammalian sleep, including periods of quiescence, increased 
arousal threshold to external stimuli, quick reversibility to wakefulness, and regulation by 
homeostatic and circadian mechanisms (Hendricks, Finn et al. 2000; Raizen, 
Zimmerman et al. 2008; Zimmerman, Naidoo et al. 2008). Further, advanced genetic 
manipulation tools exist for these animal models, making them pivotal to understanding 
the core evolutionary need for sleep. Notwithstanding, rodents remain the most 
commonly studied animals in sleep science because they are the simplest organism in 
which electroencephalographic (EEG) and electromyographic (EMG) recordings can be 
easily conducted. There are three distinct advantages of EEG/EMG to quantify sleep 
behavior. First, simpler organisms require locomotor-estimates of sleep and 
wakefulness, since they cannot be fit with EEG electrodes (Zimmerman, Naidoo et al. 
2008).  Locomotor- and EEG-based quantification of sleep allows investigators to 
measure both total time within sleep/wake states and sleep/wake fragmentation (i.e., the 
duration of sleep/wake bouts and the frequency of transitioning between bouts). 
However, EEG-measured sleep remains superior to locomotor estimates because 
activity and wake patterns can be decoupled (Pack, Galante et al. 2007; Fisher, Godinho 
et al. 2012). For example, immobility during waking can overestimate sleep time, while 
sleep movement disorders could underestimate sleep time. Thus, while EEG/EMG 
recordings are more laborious and time consuming, they allow for well-defined, accurate 
quantification of sleep and wakefulness. Second, EEG/EMG recordings allow for the 
detection of rapid eye movement (REM) sleep, a unique sleep-state characterized by 
wake-like EEG waves but muscle atonia. Third, EEG-measured sleep can be used to 
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measure intensity of sleep (Franken, Malafosse et al. 1999; Franken, Chollet et al. 
2001). Following sleep deprivation, the EEG power spectra becomes much greater in 
the delta range (0.5-4 Hz) during non-REM (NREM) sleep. Thus, the importance of 
animal models in sleep research cannot be overstated, each with distinct advantages 
and disadvantages.  
 
Regulation of sleep by homeostatic and circadian mechanisms 
Sleep/wake cycles are primarily regulated by two processes: circadian rhythms 
and homeostasis (Borbely 1982). Circadian rhythms are internal clocks with 
approximately 24-hour periods that are maintained by endogenous transcriptional-
translational feedback loops and entrained or shifted by exogenous cues, such as light 
and food (Zeng, Qian et al. 1996; Reppert and Weaver 2001; Kohsaka and Bass 2007).  
In mammals, these cell autonomous circadian rhythms are synchronized by the ‘master 
clock’ in the suprachiasmatic nucleus of the hypothalamus to generate behavioral 
circadian rhythms, or sleep/wake cycles (Gillette and Tischkau 1999). In healthy 
animals, these rhythms persist in complete darkness and exogenous cues, such as a 
light pulse or food presentation, and can generate anticipatory increases in locomotor 
behavior (Ebihara, Tsuji et al. 1978; Antle and Silver 2009; Mistlberger 2011). Many core 
components of the clock are well-defined, and research continues to identify novel 
genetic, epigenetic, and hormonal influencers of circadian rhythms.  On the other hand, 
homeostatic processes are required to sense environmental pressures and adjust 
subsequent sleep/wake duration and intensity accordingly, but the mechanistic 
processes are much less understood. Adenosine is a potential biomarker for ‘sleep 
need’, since its levels rise with sleep deprivation, fall with sleep recovery, and 
exogenous administration can induce sleepiness (Porkka-Heiskanen and Kalinchuk 
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2011). While the hypnotic effects of adenosine are mediated in part by the cholinergic 
system, it remains unclear how adenosine interacts with other known sleep- or wake-
inducing brain areas to affect behavior (Bjorness and Greene 2009). Furthermore,  sleep 
deprived animals exhibit numerous behavioral abnormalities, including difficulty learning, 
inattention, mood swings, and hyperphagia (Graves, Heller et al. 2003; Walker and 
Stickgold 2004; Knutson, Spiegel et al. 2007; Goel, Rao et al. 2009; Abel, Havekes et al. 
2013). Continuous sleep deprivation causes stereotyped changes to sleep architecture 
when sleep is allowed, specifically shorter NREM and REM latency, longer NREM and 
REM sleep bouts, and increased NREM delta power (0.5-4 Hz) (Mistlberger, Bergmann 
et al. 1983; Tobler and Borbely 1990). However, these stereotyped homeostatic 
rebounds are absent in animals chronically sleep restricted across multiple days, 
suggesting allostatic changes to sleep architecture can occur following prolonged 
disruption (Kim, Laposky et al. 2007). Indeed, chronic intermittent sleep loss can elevate 
stress hormones and induce death of wake-promoting neurons, which may contribute to 
long-lasting sleep changes (Meerlo, Koehl et al. 2002; Zhu, Fenik et al. 2016). 
Therefore, it is important to determine how sleep/wake-modifying factors affect individual 
components of circadian rhythms and sleep homeostasis.  
 
Theories of sleep function and regulation 
Multiple theories on the requirements and regulation of sleep have emerged from 
the work with humans and animal models, although there is no clear consensus on 
which core function sleep serves. Sleep is necessary for learning and consolidating that 
information into long-term memories, as shown by behavioral and electrophysiological 
experiments (Graves, Heller et al. 2003; Walker and Stickgold 2004; Abel, Havekes et 
al. 2013; Prince and Abel 2013). However, some research shows that sleep is important 
6 
 
for building and strengthening synapses, while other studies have found synaptic 
pruning following sleep (Frank, Kennedy et al. 2006; Tononi and Cirelli 2006). These 
discrepancies in direction and magnitude of sleep-dependent synaptic plasticity may 
relate to the functional task, brain area, and/or individual synapses.  Nonetheless, it is 
clear that sleep and sleep restriction profoundly impact synaptic function. Second, sleep 
may serve to clear cellular and metabolic waste from the brain, which may explain the 
link between sleep loss and increased risk for neurological diseases defined by protein-
aggregation, such as Alzheimer’s and Parkinson’s (Xie, Kang et al. 2013; Zhu, Fenik et 
al. 2016). However, the mechanisms driving waste removal during sleep is unclear, as 
well as why anesthesia (which shares some, but not all, properties with sleep) also 
augments waste clearance. Third, sleep restriction increases stress, both intracellularly 
(e.g., endoplasmic reticulum stress) and systemically (e.g., elevated cortisol levels) 
(Leproult, Copinschi et al. 1997; Naidoo 2009). Further, artificially augmenting stress, via 
either behavioral or molecular stressors, can alter sleep/wake architecture (Pawlyk, 
Morrison et al. 2008; Brown, Chan et al. 2014). Relatedly, proper immune function is 
closely tied with sleep, since sleep restriction can increase the risk of developing 
infections (Everson 1993; Besedovsky, Lange et al. 2012). Bacterial infections not only 
increase total sleep, but this sleep is required for the animals' survival post-infection 
(Kuo and Williams 2014). Therefore, sleep critically maintains homeostasis of stress and 
immune pathways. 
Of all the known theories of sleep need, however, metabolic homeostasis 
(specifically, body temperature) was the first described association. In the mid-1800s, 
both Drs. James George Davy and William Ogle reported circadian fluctuations of their 
own body temperature, independent of external influences (Pollak, Thorpy et al. 2010). 
Since then, there has been a wealth of strong evidence—both experimental and 
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epidemiological—linking sleep to metabolic homeostasis. While the remainder of this 
text will focus on the profound bi-directional effects of sleep and metabolism, it is 
important to note that all of these theories have one thing in common—to keep the 
organism at healthy homeostasis. While possible that a singular theory of sleep need 
emerges over time, it is likely that most or all of these theories are not mutually 
exclusive, with mammals evolving to maximize ‘homeostatic recovery’ of a variety of 
systems during rest.   
 
III. Sleep and Metabolism: Phenotypes and Behaviors 
Body Mass Index (BM I): An Incomplete Measure of Metabolic Status 
BMI is the most common metric for characterizing obesity because of its simple 
calculation (Weight / Height2 [in kg/m2]). Further, increased BMI (>30 kg/m2 is defined as 
‘obese’) is associated with a myriad of cardiac, metabolic, and mental health 
consequences, which in turn is associated with higher healthcare costs (Ostbye, Stroo et 
al. 2014). Further, some insurance companies use BMI as an indicator of ‘health’, 
charging greater premiums for individuals with a BMI > 30 kg/m2. However, BMI does 
not take into account the location of fat or the ratio of muscle to fat, both of which are 
much stronger indicators of cardio-metabolic or neurological health (Sharma and 
Campbell-Scherer 2017). Further, one study estimates that 30% of individuals within 
normal BMI ranges are cardio-metabolically unhealthy (Tomiyama, Hunger et al. 2016). 
Thus, there is great economic and medical incentive to discover better correlative 
metrics than BMI for determining obesity-related health issues. This is especially true for 
obesity-related excessive daytime sleepiness. While waist circumference is a better 
indicator than BMI for assessing sleep apnea risk, currently no measure is available for 
EDS without sleep disorders (Seidell 2010). Nonetheless, since recording body weight 
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and height are easily measured both at home and routine medical visits, BMI remains 
widely used despite these known shortcomings.  
 
Metabolic Rate and Energy Balance Regulate Body Weight 
Healthy animals regulate their body weight by controlling energy balance, or the 
difference between calories consumed and calories burned. These two behavioral 
characteristics—consumption (measured by caloric intake) and expenditure (measured 
by calories burned into heat)—can dictate whether an animal is gaining or losing weight. 
Specifically, positive energy balance (Consumption > Expenditure) leads to weight gain, 
while negative energy balance (Consumption < Expenditure) leads to weight loss. 
Further, depending on the type and amount of diet consumed, the body could burn either 
carbohydrates, lipids, or proteins as fuel, as measured by the respiratory exchange ratio 
(RER). Calculated as the ratio of carbon dioxide exhaled (vCO2) over the volume of 
oxygen inhaled (vO2), the RER equals 0.7 if lipids are burned exclusively, 1.0 if 
carbohydrates are burned exclusively, 0.8 – 0.9 if amino acids (from proteins) are 
burned exclusively, and ~0.85 if an even mix of all are burned (Speakman 2013). 
Research in obese people has found that a high-fat, low-carb diet reduces RER and 
causes greater weight loss compared to a low-fat, high-carb diet (Hall, Bemis et al. 
2015).  However, no study to date as attempted to link diet/energy balance, RER, and 
sleep/wake behavior, mostly due to technical limitations. RER is calculated in air-tight 
metabolic chambers, preventing EEG/EMG signal acquisition via traditional methods. 
Locomotor activity can be used to estimate sleep/wake states, but as previously 
mentioned, this is an imperfect measure. 
  
The Impact of Sleep on Metabolism 
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Overwhelming evidence supports that normal amounts of sleep are required for 
proper metabolic health. The most extreme example of this stemmed from studies done 
with rats that underwent total sleep deprivation (TSD) until death. In addition to stomach 
ulcers and skin lesions, TSD rats became profoundly hyperphagic (~50% increase in 
food intake), but paradoxically lost weight (~25% decrease) (Rechtschaffen and 
Bergmann 2002). Further, TSD reduced core body temperature, but dramatically 
increased energy expenditure, the latter of which was mediated in part by 
hyperthyroidism (Rechtschaffen and Bergmann 2002). Many of these core observations 
have persisted with more modest sleep deprivation protocols in humans. Specifically, 
either one-night of total sleep deprivation or consecutive nights of shortened sleep 
causes people to overeat, specifically choosing fat-rich foods (Greer, Goldstein et al. 
2013; Spaeth, Dinges et al. 2013). Further, epidemiological evidence has found a strong 
association between short sleep (<7 hours per night on average) and increased risk for 
developing obesity (Taheri 2006). This phenomenon could result from physiological 
changes inducing hunger or a greater opportunity to ingest calories. In mice, caloric 
consumption during the ‘inactive’ period is sufficient to induce weight gain and obesity, 
even if 24-hour caloric consumption is similar between groups (Hatori, Vollmers et al. 
2012). Furthermore, circadian misalignment per se is sufficient to induce weight gain and 
pre-diabetic symptoms (Scheer, Hilton et al. 2009). Taken together, sleep disruption 
and/or circadian misalignment are strong risk factors for morbid obesity. 
 
Metabolic Dysregulations Affect Sleep 
The reverse association—metabolic challenges impacting sleep behavior—is 
also well-established. The first study to show this correlation was performed by Danguir 
and colleagues, observing that NREM duration following a meal was correlated with that 
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meal’s size (Danguir, Nicolaïdis et al. 1979). Following studies found that starvation 
greatly increased wakefulness, with an almost complete abolishment of REM sleep 
(Jacobs and McGinty 1971; Danguir and Nicolaidis 1979); the strong wake-promoting 
effects of starvation are also observed in Drosophila (Masek, Reynolds et al. 2014). 
While this extreme intervention may hinder proper sleep (i.e., contribute to insomnia), 
obese individuals who underwent bariatric surgery report dramatic improvements in 
subjective sleepiness, even before significant weight loss presents (Varela, Hinojosa et 
al. 2007; Panossian and Veasey 2012). In normally weighted individuals, caloric 
restriction has been shown to improve subjective sleepiness (Martin, Bhapkar et al. 
2016). These observations indicate that caloric restriction and/or weight loss may 
improve subjective sleepiness independent of body weight, although this hypothesis has 
yet to be tested. On the other hand, obesity is strongly associated with sleep 
abnormalities, in addition to diagnosed sleep disorders (Panossian and Veasey 2012). 
Indeed, obesity is the strongest risk factor for developing obstructive sleep apnea, and 
weight loss can often reduce frequency of apneic episodes (Romero-Corral, Caples et 
al. 2010). However, obese individuals without diagnosed sleep disorders (i.e., sleep 
apnea or narcolepsy) are still hypersomnolent compared to lean controls (Vgontzas, 
Bixler et al. 1998). This association between obesity and excess sleepiness has also 
been observed in animal models of obesity (Mavanji, Billington et al. 2012). Transgenic 
mouse strains of obesity, including ob/ob and db/db mice (which lack either leptin or the 
leptin receptor, respectively), spend more time in NREM, less time awake and in REM 
sleep, and exhibit increased sleep/wake fragmentation (Laposky, Shelton et al. 2006; 
Laposky, Bradley et al. 2008). Early work by Danguir found that rats fed a ‘cafeteria diet’ 
rapidly gain weight and exhibit increased NREM and sleep/wake fragmentation (Danguir 
1987). These results have been reproduced using various hypercaloric diets that induce 
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obesity in both mice and rats (Jenkins, Omori et al. 2006; Mavanji, Billington et al. 2012). 
Further, providing diet-induced obese (DIO) mice with normocaloric diets (to stimulate 
weight loss) completely restores normal sleep/wake patterns (Guan, Vgontzas et al. 
2008). Obesity susceptible (OS) rats, which were inbred to respond to hypercaloric, 
high-fat diets (HFD) with massive weight gain, show similar sleep/wake abnormalities to 
diet-induced obese (DIO) rodents (Mavanji, Teske et al. 2010). Importantly, obesity 
resistant (OR) rats, which were inbred to remain resistant to HFD-induced weight gain, 
maintain normal sleep/wake patterns (Mavanji, Teske et al. 2010). While this suggests 
that weight gain and/or obesity plays a stronger role in defining sleep behavior than diet 
per se, one cannot rule out genetic or epigenetic differences mediating this effect. Taken 
together, there is strong behavioral evidence that obesity/hyperphagia/weight gain can 
worsen sleep, as shown by increased subjective sleepiness (in humans) and increased 
total sleep time and sleep/wake fragmentation (in rodents). Further, weight 
loss/hypophagia can rescue all of these wake impairments, although it is unclear 
whether the weight loss or lack of excess body weight contribute to this improved 
phenotype.   
As previously mentioned, sleep/wake patterns are regulated by circadian and 
homeostatic processes, and some studies have investigated how HFD and/or 
overweightness can affect these processes. Sleep homeostasis was tested in both ob/ob 
and db/db mice following acute (6-hour) sleep deprivation (Laposky, Shelton et al. 2006; 
Laposky, Bradley et al. 2008). These mice were able to mount a significant increase in 
NREM delta power during recovery sleep, indicating intact homeostatic processes. 
However, baseline NREM delta power (during undisturbed sleep/wake recordings) was 
initially reduced then subsequently higher in these genetically obese mice, suggesting 
circadian misalignment of sleep pressure. Surprisingly, no study to date has looked at 
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sleep homeostasis in DIO rodents. Instead, much more work has focused on the 
circadian disruptions in DIO rodents. Kohsaka et al found that HFD increases free-
running period lengths, as well significant increases in food consumption during the light 
period (when food intake should be minimal) (Kohsaka, Laposky et al. 2007). Further, 
they found attenuated transcriptional rhythms of core clock proteins in peripheral tissues, 
and abnormal levels of various blood metabolites and brain neuropeptides. Taken 
together, there is evidence that obesity can disrupt circadian rhythms, with less defined 
roles affecting homeostatic processes. 
 
IV. Sleep and Metabolism: Molecular Perspectives 
Criteria for candidate signaling pathway(s) 
The complex mechanisms that control energy balance (and potentially 
sleep/wake behavior) can generally be divided into three parts: 1) peripheral organs and 
their secreted hormones, 2) effector organs, including the vagus nerve and 
circumventricular brain areas, and 3) central nervous system (CNS) feedback to the 
periphery. Following chronic positive energy balance and subsequent weight gain and 
obesity, this regulatory system is disrupted. Specifically, effector cells become resistant 
to hormonal binding; insulin resistance is the hallmark symptom of type II diabetes, and 
leptin resistance signifies pathological obesity (Schenk, Saberi et al. 2008; Myers, Leibel 
et al. 2010). Further, this resistance phenotype blunts the central nervous feedback to 
the periphery, and hormone levels continue to rise in the bloodstream—a key symptom 
of hormone resistance. Importantly, this process is reversible, as weight loss can restore 
circulating hormone levels and cellular sensitivity to hormone binding (Agardh and Ahren 
2012). However, it is not clear whether weight loss (i.e., negative energy balance) or 
reduced body weight (i.e., lean vs obese) underlie the restitution of this signaling 
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pathway. Ongoing research is aimed towards dissecting the ‘chicken-versus-egg’ 
paradox around ‘central insulin/leptin resistance’ and ‘obesity’ (Myers, Leibel et al. 
2010). Further, it is an open question how hormone resistance relates to sleep 
abnormalities. 
It is unclear which molecular mechanisms or pathways drive obesity-related 
sleep/wake changes, as many different molecules can recapitulate some, but not all, 
sleep phenotypes. Nonetheless, one would expect a mediator of obesity-related 
excessive sleepiness to fulfill the following three criteria: 
 
Expression or signaling in relevant brain areas. A candidate protein that links 
metabolic dysregulation to sleep behavioral changes should be part of a signaling 
cascade within a brain area that can both sense circulating hormones/nutrients and 
project to sleep-regulatory brain areas. Circumventricular brain areas sit at the interface 
between the periphery and CNS, allowing circulating signals to easily enter the CNS. 
Indeed, many circumventricular nuclei, including the neurons in the circumventricular 
hypothalamus (CVH), express receptors for metabolic hormones. While other 
circumventricular brain areas exist (in the hindbrain), the CVH neurons contain a variety 
of neuropeptides that signal to intra- and extra-hypothalamic areas to induce sleep, 
induce wake, or stabilize wake states (Szymusiak and McGinty 2008). Therefore, the 
CVH is uniquely situated to sense, integrate, and respond to energetic status and modify 
sleep/wake behavior.  
 
Response to energetic status. If a hormone, receptor, or brain area is a crucial 
integrator linking metabolic changes to sleep abnormalities, than this integrator should 
sense and respond to changes in energy balance. In other words, if an endogenous 
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signaling pathway mediates behavioral differences caused by DIO, then DIO must 
directly impact some or all parts of this pathway. In DIO, circulating levels of many 
hormones are dysregulated, including glucose, insulin, leptin, and ghrelin. Further, the 
brain areas they signal to (such as the CVH) show alterations in receptor expression, 
responsivity, and expression of neuromodulatory peptides (Blouet and Schwartz 2010; 
Morton, Meek et al. 2014). Section IVD details how many of these CVH genes respond 
to metabolic and wake challenges, and the role they have in regulating food intake and 
sleep behavior.  
 
Necessary for sleep behavior changes. Most crucially, causal experiments are 
needed to demonstrate the necessity of a receptor or its downstream signaling pathways 
in mediating sleep changes. To discover the involvement of individual receptors, either 
transgenic knockout or pharmacologic antagonism could be used. Further, 
chemogenetic or optogenetic manipulations of circuits could discover specific neuronal 
connections required for diet-induced sleep changes. In this case, one would expect 
interfering with this signal during states of positive energy balance or obesity will prevent 
or rescue sleep abnormalities, but will not affect sleep behavior in normally-weighted 
animals. However, no single manipulation has been able to completely prevent or 
recapitulate diet-induced sleep changes, highlighting the redundancy of these parallel 
pathways. While these loss-of-function experiments are the most time consuming, they 
are also the most important.  
 
The remainder of this section will focus on what is currently known about 
circulating hormones and nutrients (such as glucose, insulin, leptin, and ghrelin) and the 
brain areas that respond to these signals (such as circumventricular brain areas and the 
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vagus nerve), with an emphasis on brain areas that can regulate sleep and wakefulness. 
While other sources describe these factors more broadly [see (Suzuki, Jayasena et al. 
2011; Perry and Wang 2012; Shukla and Basheer 2016)], the following sections detail 
how select circulating signals respond to metabolic and sleep challenges and how either 
gain- or loss-of-function manipulations influence both energy balance and sleep 
behavior. 
 
B. Blood metabolites and hormones 
The following information related to circulating factors is summarized in Tables 1 and 2. 
 
Glucose and Insulin. Blood glucose levels are tightly regulated, most notably by insulin 
and glucagon (Elrick, Hlad et al. 1956). When blood glucose levels begin to fall (such as 
during negative energy balance), glucagon signals to the liver to break down glycogen 
into glucose, which is released into the blood stream. Conversely, when blood glucose is 
elevated (e.g., following caloric consumption), insulin is released from pancreatic beta-
cells to facilitate glucose uptake and clearance from the bloodstream. During periods of 
chronic positive energy balance (e.g., obesity), insulin levels remain elevated but its 
effect diminishes (Kahn and Flier 2000). This chronic hyperglycemia and 
hyperinsulinemia are key symptoms of type II diabetes. Interestingly, wake challenges 
can also affect glucose levels and clearance by insulin. Although blood glucose levels 
are fairly stable, Scheen et al found that glucose levels rise during early (NREM-
dominant) sleep; this effect is blocked by sleep deprivation (Scheen, Byrne et al. 1996). 
Further, evidence of insulin resistance presents after a single day of total sleep 
deprivation or one week of sleep restriction, even though insulin levels remain stable 
(Buxton, Pavlova et al. 2010; Donga, van Dijk et al. 2010). 
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Investigators have attempted to use either loss- or gain-of-function experiments 
to determine the causal role of glucose and insulin in regulating energy balance and 
sleep behavior. However, glucose manipulations cause obligate changes to insulin 
levels and vice versa, thus making it difficult to isolate their sole effect. Nonetheless, 
human studies found that either gastrointestinal or intravenous infusion of glucose 
reduces food intake and increases sleep (Danguir and Nicolaidis 1980; Tordoff and 
Friedman 1986; Gregory, McFadyen et al. 1987). Further, direct glucose administration 
can excite the sleep-promoting neurons of the ventrolateral preoptic nucleus of the 
hypothalamus and induce NREM sleep (Varin, Rancillac et al. 2015). Conversely, 
hypoglycemia promotes hunger and food intake (Kalra, Mukherjee et al. 2013). 
Nocturnal hypoglycemia can cause sleepiness but an inability to maintain long bouts of 
sleep, although some diabetics have trouble awakening when their blood sugar is low 
(Kalra, Mukherjee et al. 2013).  Similar to glucose infusions, either systemic or central 
administration of insulin can reduce food intake and induce NREM sleep (Danguir 1984; 
Danguir and Nicolaidis 1984). Loss-of-function experiments with insulin have been 
conducted with either streptozotocin (STZ), which selectively kills pancreatic beta-cells, 
or an insulin-targeting antibody. Both manipulations show similar effects—reduced 
circulating insulin, decreased food intake, increased NREM sleep, and increased 
sleep/wake fragmentation, all of which can be rescued by exogenous insulin (Danguir 
1984; Bruning, Gautam et al. 2000; Plum, Schubert et al. 2005). In summary, glucose 
and insulin form a highly sensitive counterregulatory system that can influence food 
intake and sleep behavior, although it is near impossible to disentangle their effects from 
one another. 
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Ghrelin. Classically considered the ‘hunger’ hormone, ghrelin is increased during 
periods of negative energy balance to stimulate food intake; ghrelin levels reduce 
following caloric intake (Tschop, Smiley et al. 2000; Nakazato, Murakami et al. 2001; 
Wren, Seal et al. 2001). Furthermore, ghrelin has a causal role in regulating energy 
balance. Both systemic and central infusions of ghrelin promote hyperphagia, while 
genetic or pharmacological blockage of central ghrelin signaling reduces food intake and 
protects against DIO (Asakawa, Inui et al. 2003; Shaw, Irani et al. 2005). Interestingly, 
short sleep duration is associated with elevated ghrelin levels (Taheri, Lin et al. 2004). 
Indeed, both acute and chronic forced wakefulness protocols increase circulating 
ghrelin, which may underlie the hyperphagia phenotype observed in individuals with 
sleep debt (Schmid, Hallschmid et al. 2008; Broussard, Kilkus et al. 2016).  However, 
the causal link between ghrelin and sleep is less clear. Using rats, one group found 
intravenous ghrelin increased total wakefulness, while a different group found central, 
but not systemic, ghrelin injections increased wake time (Tolle, Bassant et al. 2002; 
Szentirmai 2012). Despite these differences, one would expect a ‘hunger’ hormone 
would increase wakefulness, in accord with wake-inducing effects of starvation (Danguir 
and Nicolaidis 1979; Masek, Reynolds et al. 2014). However, Wiekel et al found that 
intravenous ghrelin induced NREM sleep (with moderate reductions in REM sleep) in 
humans; total wake time was unaffected (Weikel, Wichniak et al. 2003). Conversely, 
ghrelin receptor knockout mice have normal sleep/wake rhythms, but do not exhibit 
stereotypical hyperarousal after introduction to a novel environment, suggesting 
hypersomnolence when challenged (Esposito, Pellinen et al. 2012). Thus, ghrelin alone 
has moderate effects on sleep and wakefulness, with potentially confounding effects of 
metabolic status and/or interactions with other hormones underlying individual 
differences.  
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Leptin. Primarily secreted by adipose tissue, leptin signals to the CNS to inhibit future 
food intake. Both systemic and central injections of leptin reduce food intake, increase 
energy expenditure, and lower body weight in both lean and obese animals (Halaas, 
Gajiwala et al. 1995; Mistry, Swick et al. 1997; Friedman and Halaas 1998). Conversely, 
injection of neutralizing antibodies against leptin acutely increases food intake and 
weight gain in rats (Brunner, Nick et al. 1997). Additionally, both ob/ob and db/db mice 
(which lack functional leptin and leptin receptor, respectively) become strikingly 
overweight, approximately double the weight of age-matched, wild-type controls (Grubb, 
Bult et al. 2014). Therefore, leptin is both necessary and sufficient to maintain normal 
body weight and metabolic homeostasis. 
As previously mentioned, both ob/ob and db/db mice exhibit massive sleep 
abnormalities, specifically increased NREM and REM sleep and increased sleep/wake 
fragmentation (Laposky, Shelton et al. 2006; Laposky, Bradley et al. 2008). These 
abnormalities can be partially rescued by leptin injections in ob/ob, but not db/db, mice 
(Pho, Hernandez et al. 2016). However, gain-of-function experiments with leptin in lean 
mice revealed only moderate sleep-modifying effects. Specifically, leptin shortened REM 
sleep and lengthened NREM sleep in fed rats (with no effect on wakefulness or bout 
architecture), but surprisingly, fasted rats did not show altered sleep architecture 
following leptin administration (Sinton, Fitch et al. 1999). Therefore, leptin alone does not 
explain these sleep phenotypes, suggesting interaction and/or masking by other 
hormones.  
 
Fatty acids. Defined as carboxylic acid-containing hydrocarbon chains of varying 
lengths, fatty acids have diverse roles in biological organisms. In particular, fatty acids 
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can be esterfied to glyercol, allowing them to be stored as an energy source 
(triglycerides) or become an integral part of cell membranes (phospholipids). Further, 
fatty acids can be liberated from their ester bonds and become metabolically active; free 
fatty acids (FFA) can become oxidized to generate cellular energy.  Fatty acids have 
diverse functions depending on their structure. They are categorized depending on the 
number of double bonds they contain (zero, one, or many define saturated, mono-
unsaturated, and poly-unsaturated, respectively) and where the double bonds occur. For 
example, omega-3 poly-unsaturated fatty acids (PUFA) are anti-inflammatory and 
promote cardiovascular health, while omega-6 PUFA are pro-inflammatory and 
associated with poor cardio-metabolic health outcomes (Schwalfenberg 2006; 
Simopoulos 2016). Fatty acids are also categorized by the number of carbons they 
contain, with short fatty acids easily traversing cell membranes while long-chain fatty 
acids (LCFA) require transporters and/or chaperones to move in and out of cells (Panov, 
Orynbayeva et al. 2014). Furthermore, dietary composition correlates with fatty acids in 
the CNS, suggesting that dietary fats can enter and affect CNS functions (Dyall 2015).  
Therefore, both the amount and type of fatty acids consumed can have massive 
implications on many physiological processes.  
Following a meal, FFA levels rise in the blood stream, which are lowered in an 
insulin-dependent manner (Boden 2008).  In obesity, insulin resistance prevents normal 
FFA clearance and adipose tissue releases more FFA into the bloodstream; thus, 
obesity is associated hyperlipidemia (Boden 2008). During periods of fasting, circulating 
FFA levels rise because of adipocyte-derived triglycerides are catabolized and FFA are 
released into the bloodstream. Further, wake challenges can also affect FFA levels. A 
single night of sleep restriction is sufficient to elevate FFA levels (Donga, van Dijk et al. 
2010; Broussard, Chapotot et al. 2015). Thus, circulating fatty acids are capable of 
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responding to both metabolic challenges and sleep disruptions. Lipid emulsion, which 
directly infuses fatty acids into the stomach, decreases objective and subjective 
measures of hunger (Gregory and Rayner 1987; Matzinger, Degen et al. 2000). In 
addition, one study found subjective sleepiness increased following lipid emulsion 
compared to either saline or sucrose infusions (Wells, Read et al. 1998). The sleep-
promoting effects of both lipid-based prostaglandins and endocannabinoids are also well 
established (Urade and Hayaishi 2011; Prospero-Garcia, Amancio-Belmont et al. 2016).   
However, it is unclear how low FFA levels alone affect energy balance and sleep/wake, 
since lipid-lowering compounds also affect other hormones such as insulin (Santomauro, 
Boden et al. 1999). Therefore, the role of dietary fats and their influence on sleep/wake 
behavior remains unclear.  
 
Brain Regions 
There are several brain regions which directly respond to nutrients and hormones 
to affect energy balance: the hypothalamus, the dorsal vagal complex, and the 
mesolimbic circuit (Grill, Schwartz et al. 2002; Figlewicz, Evans et al. 2003; Naleid, 
Grace et al. 2005; Huang, Qiu et al. 2011; Abraham, Filippi et al. 2014; Filippi, Bassiri et 
al. 2014).  The mesolimbic circuit (MLC) encodes ‘reward’ and is important for hedonic 
‘wanting’ of food (Volkow, Wang et al. 2011). In its simplest form, the MLC consists of 
dopaminergic neurons in the ventral tegmental area (VTA) which project to the nucleus 
accumbens (NAc), hippocampus, and medial prefrontal cortex to motivate ‘reward-
driven’ behaviors, including food intake (Volkow, Wang et al. 2011). Indeed, both the 
VTA and NAc express functional leptin and ghrelin receptors, which modulate the 
subjective desirability of food (Figlewicz, Evans et al. 2003; Volkow, Wang et al. 2011). 
The dorsal vagal complex (DVC) consists of three distinct nuclei—the area postrema, 
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the nucleus of the solitary tract, and the dorsal motor nucleus of the vagus nerve—which 
work in concert to regulate food intake and energy expenditure. The DVC receives input 
(and can modulate output) of the vagus nerve, which has dense innervations in the 
gastrointestinal tract, making it uniquely situated to quickly respond to changes in 
nutrient status (Grill and Hayes 2012). Further, the DVC expresses functional receptors 
for numerous circulating nutrients and hormones, including glucose, leptin, insulin, and 
ghrelin (Grill, Schwartz et al. 2002; Huang, Qiu et al. 2011; Grill and Hayes 2012; Filippi, 
Bassiri et al. 2014). Last, there are reciprocal connections between the DVC and 
hypothalamus, allowing for coordinated control of energy balance.  
The hypothalamus consists of distinct nuclei defined by their anatomical location 
and can be generally defined as the: 1) circumventricular hypothalamus (CVH) [including 
the arcuate nucleus (ARC), ventromedial nucleus (VMN), dorsomedial nucleus (DMN), 
and paraventricular nucleus (PVN)], and 2) lateral hypothalamus (LH).  Early studies first 
conducted in the 1950s attempted to define the function of these nuclei via lesion studies 
(Anand and Brobeck 1951; Hervey 1959; Ahima and Antwi 2008). Indeed, lesions of the 
VMH led to spontaneous, uncontrolled eating while lesions to the LH caused voluntary 
starvation (Anand and Brobeck 1951; Hervey 1959). However, we now know that these 
original lesion studies were imprecise and damaged adjacent nuclei and axonal tracts 
(Elmquist, Elias et al. 1999). Further, we now know that many of these anatomically 
distinct nuclei contain different neuronal subpopulations, some of which have opposing 
actions to one another (Elmquist, Elias et al. 1999). A more detailed review describing 
how these various hypothalamic nuclei interact to affect sleep and energy balance can 
be found here: (Schwartz and Roth 2008; Morton, Meek et al. 2014). 
 
Hypothalamic Neuropeptides  
22 
 
These neuronal subpopulations can be defined by the neuropeptides they 
express, and many of these neuropeptides have defined roles in regulating both 
metabolic and sleep behavior. The following section will detail many of these 
neuropeptides—including agouti-related peptide (AgRP), neuropeptide Y (NPY), 
cocaine- and amphetamine-related transcript (CART), proopiomelanocortin (POMC), 
thyrotropin-releasing hormone (TRH), orexin/hypocretin (ORX), and melanin-
concentrating hormone (MCH)—with a focus on their role in mediating nutrient and 
hormonal changes to sleep and metabolic behavior.  
 
AgRP and NPY. AgRP is predominately expressed within the ARC, and nearly every 
AgRP+ neuron is co-expressed with NPY (Broberger, Johansen et al. 1998). In general, 
these AgRP/NPY neurons in the ARC are critical for promoting food intake.  First, during 
states of negative energy balance, both NPY and AgRP mRNA is increased and these 
neurons are hyperactive; the opposite is observed in obesity (Diano, Liu et al. 2011; 
Klockener, Hess et al. 2011; Baver, Hope et al. 2014).  Second, AgRP/NPY neurons 
express functional leptin, insulin, and ghrelin receptors, with leptin and insulin inhibiting 
and ghrelin enhancing neuronal activation (Leibowitz and Wortley 2004). Third, direct 
infusion of either the AgRP or NPY peptide into the brain promotes food intake and 
weight gain (Hagan, Rushing et al. 2000; Rohner-Jeanrenaud 2000; Korner, Wissig et al. 
2003). Fourth, ablating AgRP/NPY neurons greatly decreases food intake (Gropp, 
Shanabrough et al. 2005). However, one surprising wrinkle is that germline ablation of 
both agrp and npy (so that these animals do not express the neuropeptide) does not 
significantly impact food intake or body weight (Qian, Chen et al. 2002), suggesting that 
the intact neuronal circuitry is more important than the actual neuropeptides for 
regulating energy balance. In all, AgRP/NPY neurons are both necessary and sufficient 
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to induce food intake, while AgRP/NPY neuropeptides are sufficient, but not necessary, 
to stimulate ingestion.  
A few studies have examined the role of AgRP/NPY in sleep, but current 
research is inconclusive. Forced wakefulness paradigms increase both AgRP and NPY 
mRNA expression in the ARC (Koban, Sita et al. 2008; Romanova and Mikhrina 2013). 
Using rats, some studies have shown ICV NPY increases sleep while others have 
shown wake-promoting effects (Dyzma, Boudjeltia et al. 2010). Differences in dosing or 
time of injections may explain these biphasic results. Further, one human study found 
intravenous NPY reduced sleep latency and promoted REM sleep (Antonijevic, Murck et 
al. 2000).  No studies to date have critically tested the importance of AgRP peptide in 
sleep regulation. However, cutting-edge research from the Carter lab has shown both 
optogenetic and DREADDs activation of AgRP/NPY ARC neurons can reduce sleep-to-
wake latency and fragment sleep (unpublished results, Matthew Carter, Williams 
College). Therefore, emerging evidence has implicated AgRP/NPY ARC neurons with 
sleep regulation, although this field is in its infancy.   
 
CART and POMC. While both CART and POMC peptide expression is detectable 
outside the hypothalamus, they are most densely expressed together in a subset of ARC 
neurons (Elias, Lee et al. 1998; Hurd and Fagergren 2000).  POMC itself is an inert 
peptide, but it can be broken down into many different peptides, including melanocyte-
stimulating hormones (MSHs) and adrenocorticotropic hormone (ACTH) (Coll 2007). 
POMC-derived MSHs and ACTH activate melanocortin receptors within the 
hypothalamus to inhibit food intake and promote negative energy balance (Williams, 
Bing et al. 2001; Leibowitz and Wortley 2004; Schulz, Paulus et al. 2010). ICV CART 
also inhibits feeding, although the putative CART receptor has not yet been 
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characterized (Lau and Herzog 2014). Furthermore, activation of POMC/CART neurons 
potently inhibits food intake. POMC/CART neurons respond to leptin and insulin, and 
activation of these hormone receptors causes increased POMC mRNA within the ARC 
(Cheung, Clifton et al. 1997; Benoit, Air et al. 2002). Leptin not only directly 
hyperpolarizes POMC/CART neurons, but inhibitory inputs from NPY/AgRP neurons 
augment this hyperpolarizing effect (Cowley, Smart et al. 2001). Interestingly, HFD-
induced obesity does not increase ARC POMC mRNA, but does increase CART mRNA 
(Harrold, Williams et al. 1999; Wang, Zhou et al. 1999). Taken together, CART/POMC 
respond to circulating hormones and act to inhibit food intake and promote weight loss.  
POMC mRNA in the ARC exhibits a diurnal rhythm, with lowest expression levels 
at lights off (Steiner, Kabigting et al. 1994). REM sleep deprivation decreases POMC 
mRNA compared to undisturbed controls (Koban, Le et al. 2006). While the effects of 
exogenous POMC on sleep have not been examined, ICV αMSH increases wakefulness 
and decreases both body temperature and NREM sleep in rabbits (Opp, Obal et al. 
1988). The effects of forced wakefulness protocols on ARC CART expression have not 
been tested, but ICV CART potently increases total wake time, consolidates sleep/wake 
bouts, and decreases both NREM and REM sleep in rats (Keating, Kuhar et al. 2010). 
Last, pioneering work from Dr. Carter’s group found that optogenetic activation of POMC 
neurons consolidates sleep bouts, but does not affect wake-to-sleep latency 
(unpublished results, Matthew Carter, Williams College). Altogether, POMC/CART 
neurons appear to promote wakefulness and consolidate sleep/wake bouts. 
 
TRH. Expressed in a subset of PVN neurons, TRH initiates the hypothalamic-pituitary-
thyroid (HPT) axis, causing thyroid-stimulating hormone (TSH) release from the pituitary 
gland which in turn stimulates triiodothyronine (T3) and thyroxine (T4) release from the 
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thyroid (Boelen, Wiersinga et al. 2008). The T3/T4 hormones initiate a negative 
feedback loop, lowering levels of TRH and inhibiting TSH release. TRH+ neurons 
express both functional leptin and melanocortin receptors (specifically type 4, or MC4R), 
the latter of which is activated by the POMC-product αMSH and inhibited by AgRP 
(Barsh and Schwartz 2002). Further, there is a bi-directional relationship between the 
HPT axis and energy balance. Fasting robustly decreases TRH, TSH, and T3/T4 levels, 
which is a consequence of differential MC4R and leptin receptor activation (Boelen, 
Wiersinga et al. 2008; Perello, Cakir et al. 2010). Conversely, DIO increases TRH and 
TSH levels; these hormone changes are absent in leptin-deficient obese rats, suggesting 
the necessity of leptin for this response (Perello, Cakir et al. 2010). Central 
administration of TRH or TRH analogues significantly decreases food intake (Steward, 
Horan et al. 2003). Therefore, energetic status can impact TRH levels in a leptin-
dependent manner, and TRH administration can promote negative energy balance. 
Research has shown that the HPT axis can respond to wake challenges. 
Specifically, sleep deprivation increases PVN TRH mRNA, does not affect TSH levels, 
and decreases T4 (Everson and Nowak 2002). Together, this suggests that TRH-TSH-
T4 cascade is blunted under sleep deprived conditions. Further, intravenous TRH 
administration in healthy adults fragments sleep and promotes arousal (Chihara, Kato et 
al. 1977), although a different group was unable to reproduce these effects (Buckley, 
Tormey et al. 1979). It is unclear why these groups found disparate results, as there 
have not been any follow-up studies on the matter. Thus, the HPT axis is capable of 
sensing changes to the sleep homeostat, but its role in affecting sleep/wake behavior is 
unclear.  
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ORX and MCH. Non-overlapping populations of ORX+ and MCH+ neurons are found 
interspersed throughout the LH and perifornical area (Leibowitz and Wortley 2004). 
These two neuronal populations have similar roles in responding to and regulating 
energy balance. Specifically, fasting augments both ORX and MCH mRNA expression 
(Qu, Ludwig et al. 1996; Sakurai, Amemiya et al. 1998). While both MCH and ORX 
expression decreases in ob/ob mice, ORX expression increases and MCH expression is 
unchanged in HFD-induced obese mice, indicating the necessity of leptin for inducing 
MCH and ORX expression decreases (Mondal, Nakazato et al. 2000; Gao, Ghibaudi et 
al. 2002; Wortley, Chang et al. 2003; Leibowitz and Wortley 2004). Further, ICV 
administration of either ORX or MCH dose-dependently increases food intake (Qu, 
Ludwig et al. 1996; Sakurai, Amemiya et al. 1998). Conversely, MCH null mice are 
hypophagic, hyperactive, and weigh less than wildtype controls (Shimada, Tritos et al. 
1998; Takase, Kikuchi et al. 2014). Curiously, ORX knockout mice are hypophagic, but 
they develop obesity later at older time points, likely due to decreases in energy 
expenditure (Hara, Beuckmann et al. 2001). Thus, both MCH and ORX neurons respond 
to nutrient status to promote positive energy balance, although gene ablation studies 
reveal dissimilar effects on weight gain.  
Unlike their similar roles in energy balance, ORX and MCH have opposing 
influences on sleep/wake behavior. Using cFOS as a marker for neuronal activation, 
ORX neuronal activity is highest and MCH activity is lowest following sleep deprivation 
compared to rested and recovered controls (Modirrousta, Mainville et al. 2005). Further, 
ICV MCH increases both NREM and REM sleep, while ICV ORX has strong wake-
promoting effects (Mieda, Hasegawa et al. 2011; Monti, Torterolo et al. 2013).  Mice 
lacking the MCH receptor exhibit moderate increases in total wake time, fragmentation, 
and body temperature (Ahnaou, Dautzenberg et al. 2011).  ORX knockout animals have 
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a striking sleep phenotype, exhibiting moderately increased NREM sleep times but 
profound sleep/wake fragmentation, which closely resembles narcolepsy (Hara, 
Beuckmann et al. 2001). Indeed, we now know that human narcoleptics lack either 
functional ORX or its receptor (Nishino, Ripley et al. 2000; Thannickal, Moore et al. 
2000). Thus, MCH and ORX have strong sleep-modifying effects, with MCH promoting 
sleep and ORX promoting wake and wake stabilization.  
 
V. Open Questions: Novel Associations and Signaling Pathways 
Diet/Energy Balance vs Body Weight: Impact on Sleep 
While the exact cause of the obesity epidemic in our society is under debate, 
there is no doubt that the increased prevalence and portion size of hypercaloric meals 
have a significant impact. However, it is unclear whether overconsumption or 
overweightness primarily contribute to sleep problems in our society. Indeed, research 
has shown evidence for both. Separate studies have found a positive correlation 
between meal size and post-prandial sleep duration, in addition to excessive sleepiness 
and weight gained on a HFD (Danguir and Nicolaidis 1979; Jenkins, Omori et al. 2006; 
Mavanji, Billington et al. 2012). Therefore, one open question in the field is whether 
diet/energy balance and body weight both independently contribute to sleep and wake 
abnormalities. In Chapter 2, I introduce the ‘Diet Switch’ paradigm which allows me to 
dissociate the relative effects of ‘diet/energy balance’ from ‘body weight’ on regulating 
sleep/wake abnormalities.  
 
Novel mechanisms of HFD-induced sleep changes 
Through a literature search, I found that peroxisome proliferator activated 
receptor-gamma (PPARg) is a potential candidate to mediate HFD-induced sleep 
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changes. First, multiple reports found PPARg expressed throughout the hypothalamus, 
including the circumventricular areas required for metabolic homeostasis (Sarruf, Yu et 
al. 2009; Lu, Sarruf et al. 2011). Further, CVH PPARg are functional, since PPARg 
agonists and antagonists into the third ventricle induce positive and negative energy 
balance, respectively (Ryan, Li et al. 2011). Second, hypothalamic PPARg mRNA is 
increased in DIO mice compared to lean controls, suggesting that PPARg can sense 
changes to energetic status (Diano, Liu et al. 2011). Third, DIO mice lacking PPARg in 
all neurons exhibit two-fold increase in activity compared to DIO wildtype controls (Lu, 
Sarruf et al. 2011). Since hyperlocomotion is highly correlated with wakefulness (Pack, 
Galante et al. 2007), we hypothesized that these mice may exhibit hyperarousal, thus 
indicating protection from DIO-associated sleep abnormalities. The experiments 
exploring the role of central PPARg in mediating obesity-related sleep changes are the 
focus of Chapter 3. 
 
Diet/Energy Balance vs Body Weight: Impact on Metabolic Processes 
There are many peripheral and central factors implicated in both ‘nutrient-
sensing’ and ‘adiposity’. For example, the hormone leptin is released following food 
consumption, signaling to the CVH to cease further food intake. Further, circulating leptin 
levels directly correlate with the amount of body fat (Benoit, Clegg et al. 2004).  
Therefore, it is unclear how leptin can act both as an ‘adiposity’ signal and ‘nutrient-
sensing’ signal (e.g., what happens to leptin levels in an obese person in negative 
energy balance?). Further, many neuropeptides in the CVH respond to changes in 
energetic status (with defined roles in regulating food intake), but it is unclear if these are 
‘adiposity’ or ‘nutrient’ signals. Last, similar to sleep/wake behavior, it is unclear which 
metabolic phenotypes (such as energy expenditure) are related to ‘diet/energy balance’ 
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versus ‘body weight’. In Chapter 4, we again use the ‘Diet Switch’ feeding paradigm and 
take advantage of two unbiased approaches—RNA-sequencing (to measure CVH gene 
expression) and indirect calorimetry (to measure metabolic phenotypes)—to 
disassociate ‘diet/energy balance’ effects from ‘body weight’ effects. We then attempt to 
relate this to our results in Chapter 2, informing us of novel relationships between blood 
biomarkers, CVH genes, and metabolic and sleep phenotypes. 
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Table 1.1: Blood biomarkers in response to energetic and wake challenges. See 
text for literature citations. 
 
 
 
 
 
 
 
 
 
 
Hormone/ 
Metabolite 
Source 
Relative Abundance 
Negative 
Energy 
Balance 
Positive  
Energy 
Balance 
Acute 
Sleep 
Deprivation 
Chronic 
Sleep 
Restriction 
Glucose 
Diet or 
Hepatic 
glycogen 
 
Decreased Increased 
Prevents 
NREM-
associated 
increase 
Increased, 
due to 
impaired 
clearance 
Insulin 
Pancreatic 
Beta-cells 
Decreased 
Increased, 
plus central 
resistance 
Stable, but 
central 
resistance 
Stable, but 
central 
resistance 
Ghrelin Stomach Increased Decreased Increased Increased 
Leptin 
Adipose 
Tissue 
Decreased Increased Unchanged Decreased 
FFA 
Diet or fat 
stores 
Increased Increased Increased Increased 
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Hormone/ 
Metabolite 
Metabolic Effect Sleep Effect 
Gain-of-function 
Loss-of-
function 
Gain-of-
function 
Loss-of-
function 
Glucose 
Decreases food 
intake 
Increases Food 
Intake 
Increases 
NREM sleep 
 
Decreases 
sleep quality 
 
Insulin 
Reduces food 
intake and body 
weight 
Conditional KO 
of receptor in 
brain increases 
body weight  
Increases 
NREM sleep 
and 
consolidates 
sleep bouts 
Decreases 
NREM sleep 
and 
fragments 
sleep bouts 
Ghrelin 
Increases food 
intake and body 
weight 
Reduces food 
intake and body 
weight 
Controversial 
findings support 
both 
somnogenic 
and arousing 
effects 
Normal 
sleep/wake 
patterns, but 
excessively 
sleepy during 
wake 
challenges  
Leptin 
Reduces food 
intake and body 
weight 
Increases food 
intake and body 
weight  
Increases 
NREM sleep in 
fed animals, but 
no effect in 
fasted animals 
Increases 
NREM sleep 
and 
sleep/wake 
fragmentation 
FFA 
Decreases food 
intake 
Unclear 
Increases 
subjective 
sleepiness; 
Lipid derivatives 
promote sleep 
Unclear 
 
Table 1.2: Gain- and loss-of function experiments testing how blood biomarkers 
affect energy balance and sleep/wake behavior. See text for literature citations. 
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ABSTRACT 
Study Objectives: Excessive daytime sleepiness commonly affects obese people, even 
in those without sleep apnea, yet its causes remain uncertain.  We sought to determine 
whether acute dietary changes could induce or rescue wake impairments independent of 
body weight. 
Design: We implemented a novel feeding paradigm that generates two groups of mice 
with equal body weight but opposing energetic balance. Two subsets of mice consuming 
either regular chow (RC) or high fat diet (HFD) for eight weeks were switched to the 
opposite diet for one week. Sleep recordings were conducted at Week 0 (baseline), 
Week 8 (pre-diet switch), and Week 9 (post-diet switch) for all groups. Sleep 
homeostasis was measured at Week 8 and Week 9. 
Participants: Young adult, male C57BL/6J mice 
Measurements and Results: Differences in total wake, NREM, and REM time were 
quantified, in addition to changes in bout fragmentation/consolidation. At Week 9, the 
two diet switch groups had similar body weight. However, animals switched to HFD (and 
thus gaining weight) had decreased wake time, increased NREM sleep time, and 
worsened sleep/wake fragmentation compared to mice switched to RC (which were in 
weight loss). These effects were driven by significant sleep/wake changes induced by 
acute dietary manipulations (Week 8 → Week 9). Sleep homeostasis, as measured by 
delta power increase following sleep deprivation, was unaffected by our feeding 
paradigm.  
Conclusions: Acute dietary manipulations are sufficient to alter sleep and wakefulness 
independent of body weight and without effects on sleep homeostasis.  
Keywords: obesity, sleep, diet switch, high fat diet, fragmentation 
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INTRODUCTION 
Currently in the United States, over 78 million adults and nearly 13 million 
children are obese and hundreds of millions more are overweight (Ogden, Carroll et al. 
2014). In addition to its strong association with numerous negative health 
consequences, obesity is a risk factor for excessive daytime sleepiness (EDS) and poor 
sleep quality, which negatively impacts quality of life (Rosekind, Gregory et al. 2010; 
Panossian and Veasey 2012). Obstructive sleep apnea (OSA) is a clear source of both 
EDS and poor sleep quality, especially in the obese population, but mounting evidence 
suggests that EDS persists in obese individuals who have either never developed OSA 
or have been effectively treated for OSA (Stradling 2009; Antic, Catcheside et al. 2011; 
Koehler, Apelt et al. 2011; Panossian and Veasey 2012). Further, weight loss treatment 
in obese patients (with or without OSA) markedly improves both EDS and nighttime 
sleep quality.  Specifically, obese individuals who have had sleepiness tested before and 
after bariatric surgery show that EDS drastically improves after one month, even though 
these patients are still obese (Dixon, Schachter et al. 2005; Varela, Hinojosa et al. 2007; 
Holty, Parimi et al. 2011; Panossian and Veasey 2012). Thus, daytime fatigue and 
sleepiness improve with weight loss, but it is unclear which factors are driving this effect. 
Two possible explanations are negative energy balance (i.e., caloric imbalance 
promoting weight loss) and reduced body mass or adiposity (i.e., direct relationship 
between body weight and/or fat and wake impairments). In other words, could an obese 
individual in negative energy balance have better or worse sleep quality and EDS than a 
relatively lean individual in positive energy balance? If energy balance (and not obesity 
per se) is in fact the primary contributor to sleep/wake abnormalities, novel strategies to 
improve wakefulness and sleep quality in both the obese and non-obese populations 
may be discovered.  
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Animal models of obesity recapitulate the human sleep phenotype (fragmented 
sleep and EDS), without evidence of OSA (Mavanji, Billington et al. 2012). Transgenic 
mice with impaired leptin signaling exhibit increased total sleep time and an inability to 
sustain wakefulness (Laposky, Shelton et al. 2006; Laposky, Bradley et al. 2008). 
Chronically feeding non-transgenic animals high fat diet (HFD) causes diet-induced 
obesity (DIO), which significantly reduces wakefulness in both rats and mice in 
correlation to the amount of weight gained (Jenkins, Omori et al. 2006; Guan, Vgontzas 
et al. 2008; Luppi, Cerri et al. 2014). Further, chronically feeding DIO mice a leptogenic 
diet normalizes body weight and sleep abnormalities (Guan, Vgontzas et al. 2008). 
However, it is unclear whether weight, adiposity, diet and/or energy balance influence 
sleep/wake activity in these animal models.  
To begin to decipher the relative roles of weight/adiposity and diet/energy 
balance, we developed a novel feeding paradigm using two diets: regular chow (RC) and 
HFD (45% kcal from fat). Sleep/wake patterns were measured at baseline (while all 
animals consumed RC), after 8 weeks on either diet (Week 8; RC or HFD), and, finally, 
after either a 1 week switch to the alternative diet (Week 9; RC → HFD or HFD → RC) 
or an additional week under the current diet (Week 9; RC → RC or HFD → HFD). At this 
final time point, the two former groups (referred to as ‘diet switch’ conditions) had similar 
weights, but different energy balances. We hypothesized that the animals in positive 
energy balance (weight gain) would have increased total sleep time and sleep/wake 
fragmentation in the dark phase (i.e., EDS) compared to the mice in negative energy 
balance (weight loss). Last, in order to better define which components of sleep/wake 
regulation are disrupted, we examined how acute and chronic dietary changes affected 
sleep homeostasis following forced wakefulness. Collectively, this study provides 
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evidence that factors besides body weight, in particular diet and/or energy balance, 
significantly contribute to total sleep/wake time and bout fragmentation.  
 
METHODS 
Animals 
Male C57BL/6J mice (12-14 weeks of age) were used for these experiments. The 
Institutional Animal Care and Use Committee (IUCAC) at the University of Pennsylvania 
approved experimental protocols prior to initiation of studies. Animals remained 
individually housed throughout the experiment at 23°C on a 12:12 hour light dark cycle, 
with lights-on (ZT 0) beginning at 7:00 am.  
 
Experimental Protocol Overview 
The experimental paradigm is shown in Figure 1. All mice underwent a 24-hour 
undisturbed baseline recording (Week 0) while consuming regular chow (RC). Following 
this recording, mice were pair-matched by weight and randomized to receive either high 
fat diet (HFD; n = 13) or remain on RC (n = 13). After eight weeks, we recorded 
undisturbed sleep/wake (24 hours), followed by sleep deprivation (ZT0-6) and recovery 
sleep (ZT6-12). Animals were sleep deprived using a combination of enrichment with 
novel objects and gentle handling (Vecsey, Wimmer et al. 2013). Immediately following 
the Week 8 time point, mice within each dietary condition were then randomized to either 
continue on their respective diets (RC → RC, n = 5; HFD → HFD; n = 6) or switched to 
the opposite diet (RC → HFD, n = 8; HFD → RC, n = 7). After one week post-diet switch 
(Week 9), animals underwent another undisturbed 24-hour recording followed by sleep 
deprivation and recovery. Animals were removed from analysis if their headmount 
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detached prior to completion of the study (n = 3) or an infection developed (n = 1). This 
contributed to the different numbers of animals per condition.  
 
Diet 
All mice were initially provided regular chow (RC, LabDiet, 5001), which has 
13.5% of calories from fat and contains 3.36 kcal/gram. When indicated by the protocol, 
subsets of mice were switched to high fat diet (HFD, Research Diets, R12451), which 
provides 45% of calories from fat and contains 4.73 kcal/gram. We chose this diet 
because of its well-characterized effects on weight gain, locomotor activity, and circadian 
rhythms in C57BL/6 mice (Kohsaka, Laposky et al. 2007; Matsui, Hirasawa et al. 2010) 
and because of its similar fat content to western diets (Last and Wilson 2006; Meek, 
Eisenmann et al. 2010). Mice were allowed ad libitum access to water and their 
indicated diet. Food intake and body weight were recorded weekly before the diet switch 
(Week 0 → 8). Following the diet switch or maintenance, food intake was recorded daily 
and body weight was recorded one week later (Week 9).  
 
EEG/EMG electrode implantation 
Mice were individually housed and acclimated to gentle handling for one-week 
prior to electrode implantation surgery for EEG/EMG recordings. Headmounts were 
prepared by soldering Teflon-coated silver wire (A-M Systems, 787000) to gold socket 
contacts (Plastics One, E363/0). These constructs were then pushed into 6-pin 
pedestals (Plastics1, MS363) and secured with dental cement (Pearson Dental, 8101 & 
8501). Prior to surgical implantation, mice were anesthetized with vaporized isoflurane. 
After the skull was exposed and cleaned, three holes were drilled above frontoparietal 
areas—one right frontal (anteroposterior, +1.0 mm; mediolateral, +1.5 mm from bregma) 
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and two parietal (anteroposterior, -2.0 mm; mediolateral, ± 2.0 mm from bregma)—and 
EEG electrodes were inserted and fixed with screws (JI Morris Co., F00CE125). EMG 
electrodes were inserted into nuchal muscles, and headmounts were affixed with dental 
cement. Mice were allowed one-week to recover from surgery, prior to connecting 
counter-weighted cables for sleep/wake recordings. Mice had one additional week to 
acclimate to the cable before studies and recordings were initiated.   
 
Acquisition and Analysis of Sleep/Wake Data 
EEG/EMG signals were amplified using the Neurodata amplifier system (Astro-
Med, Model M15). All signals were acquired at 256 Hz sampling, amplified (20,000x), 
and conditioned with neuroamplifiers/filters (Astro-Med, Model 15A94). EEG and EMG 
signals were subjected to cut-off frequencies between 0.5 – 30 Hz and 1 – 100 Hz, 
respectively. All data was acquired using Grass Gamma software (Astro-Med). For each 
experimental time point and mouse, an experienced investigator blinded to the 
experimental condition manually scored the 24-hour recordings (ZT 0–24; binned into 4-
second epochs) as wake, non-REM (NREM), or REM using SleepSign for Animals 
(Kissei Comtec). All data analysis, including the time spent in each behavioral state, bout 
lengths, bout numbers, and bout distributions, was performed using MATLAB, as 
previously described (Lim, Elkind et al. 2013). To calculate delta power, we exported 
each animal’s power spectra following sleep scoring and analyzed the data two ways. 
For the ‘interval method’, NREM epochs were sequentially binned into intervals (one 
interval = 225 NREM epochs, or 15 minutes) and delta power (1 – 4 Hz) was averaged 
within each interval (Franken, Chollet et al. 2001). Thus, within each interval, the number 
of NREM epochs averaged is equal regardless of when they occur during the recording. 
For the ‘time of day method’, the delta power for all NREM epochs within the indicated 
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time window was averaged (Vecsey, Wimmer et al. 2013). Since the number of NREM 
epochs vary by time of day, the number of NREM epochs averaged per time point is not 
the same for the ‘time of day method’. Both undisturbed and post-sleep deprivation delta 
power were normalized within each animal (NREM delta power during the sleep 
recording from ZT8-12 in the day preceding the sleep deprivation) (Franken, Chollet et 
al. 2001; Vecsey, Wimmer et al. 2013).  
 
Statistics  
 Data is presented as the average ± standard error of the mean (SEM). All 
statistical analyses were performed in PRISM, except for multiple linear regression 
analysis, which was performed in Microsoft Excel using the Data Analysis Toolbox. 
Comparisons of only two groups (e.g., RC vs HFD body weight and fragmentation at 
Week 8) were analyzed using a student’s t-test. Linear correlations were determined 
using Spearman’s rank correlations, and both the correlation coefficient (ρ) and 
statistical significance were reported. Analysis following the diet switch (when four 
dietary conditions were generated) was conducted using a one-way ANOVA. If the 
ANOVA detected a significant difference among groups, we performed pre-planned 
between group comparisons based on the outcome. When all four groups were being 
compared (e.g., body weight), we utilized Holm-Sidak’s post-hoc correction for 
determining significance. When only select group comparisons were required (e.g., 
acute diet switch from Week 8 → 9), we used a Bonferroni corrected level of significance 
equal to p<0.05/[number of pairwise comparisons]. Analyses comparing the four dietary 
groups across multiple days (e.g., body weight gain or caloric intake) or within a day 
(e.g., light vs dark phase) was conducted using a two-way repeated measures ANOVA 
with day/time as the between subjects factor followed by Holm-Sidak’s post-hoc 
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correction. The wake bout distribution histograms and delta power graphs were analyzed 
with a two-way ANOVA followed by Holm-Sidak’s post-hoc correction. Statistical 
significance was achieved at p<0.05, although trends towards significance (p<0.1) were 
reported when appropriate.  
 
RESULTS 
Chronic HFD increases both total sleep time and sleep/wake fragmentation 
Previous studies have found that DIO mice exhibit abnormal sleep architecture, 
specifically increased transitions between sleep/wake states and decreased wake time 
in correlation to the amount of weight gained (Jenkins, Omori et al. 2006; Guan, 
Vgontzas et al. 2008). We first sought to reproduce these results. All mice underwent a 
baseline recording (Week 0), were then pair-matched by weight, and randomized to 
receive either RC or HFD.  At Weeks 8 and 9, both body weight (p<0.0001 and p<0.001, 
respectively) and percent change in body weight (p<0.0001 and p<0.01, respectively) 
were significantly increased in mice chronically fed HFD compared to RC-fed mice 
(Figures 2A and 2B). Remarkably, caloric intake was similar between groups at Week 0, 
Week 8 (Figure S1F), and Week 9 (Figure 5B: Day 7, RC → RC and HFD → HFD 
conditions). At Week 8, DIO mice spent significantly less time awake than RC-fed 
controls, with post-hoc analysis indicating the effect being driven by differences in the 
beginning of the dark phase (Figure 2C: ZT12-18, p<0.05). This decrease in 
wakefulness was concomitant with an increase in NREM sleep during the first six hours 
of the dark phase (Figure 2D: ZT12-18, p<0.05). Additionally, HFD-fed mice exhibited 
significant increases in REM sleep during the light phase at Week 8 (Figure 2E: ZT0-6 & 
ZT6-12, p<0.05).  We observed similar effects on sleep/wake at Week 9 for mice 
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maintained on HFD relative to RC-fed mice (Figure S1A-C). Therefore, DIO mice exhibit 
decreased total wake time and increased sleep time. 
We found evidence of increased fragmentation of all behavioral states 
(sleep/wake instability) in HFD-fed mice relative to RC-fed mice (Table 1). Chronic HFD 
significantly increased wake bout number and decreased wake bout length, especially 
during the dark phase (p<0.0001 for both). Since bout lengths are highly variable across 
the day, we also plotted a histogram of wake bout lengths during the light and dark 
phase (Figure S1D and S1E). We found short wake bouts (defined as ≤16 seconds long) 
were significantly more prevalent in HFD-fed mice compared to RC-fed controls (Table 
1: p<0.0001), with >2-fold increase during the dark phase. Therefore, DIO mice exhibit 
increased wake bout instability, especially during their subjective night when they are 
usually most active. NREM fragmentation was also worsened by HFD, with increased 
number of NREM bouts across the day (Table 1: p<0.001) and decreased bout lengths 
during the dark phase (p<0.0001). Lastly, we found evidence of increased REM 
fragmentation in HFD fed mice, specifically increased REM bouts during the light phase 
(Table 1: p<0.0001). 
We wanted to confirm if body weight changes correlated with sleep/wake 
architecture, as previously reported (Jenkins, Omori et al. 2006). Indeed, we found a 
negative relationship between body weight changes and total wakefulness at Week 8 for 
mice fed HFD (Figure 2F: ρ = -0.7198, p<0.01) and a positive relationship between body 
weight change and NREM time (Figure 2G: ρ = 0.6648, p<0.05). Additionally, we found a 
near significant correlation between body weight changes and REM sleep (Figure S1G: 
ρ = 0.5440, p=0.0582). Therefore, wakefulness and NREM sleep exhibit the strongest 
correlations with body weight changes induced by chronic administration of HFD (i.e., 
pre-diet switch). 
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One week diet switch generates groups of mice with similar body weight and opposing 
energetic states 
Chronically feeding mice HFD increases body weight by putting the animals into 
positive energy balance. Thus, it is impossible to disentangle the effects of diet, energy 
balance, and body weight by chronic feeding alone. Therefore, we used an acute diet 
switch protocol (Figure 1) to generate groups of mice with similar body weights, but 
different energetic balances and diet, to parse out the influence of body weight and 
these other factors on sleep/wake behavior. One week following the diet switch (Week 
9), acute HFD trended towards increasing weight (Figure 3C: RC → RC vs. RC → HFD, 
p<0.1) and acute RC caused a significant reduction in body weight (Figure 3C: HFD → 
RC vs. HFD → HFD, p<0.01). Importantly, both diet switch conditions were of similar 
body weight at Week 9 (Figure 3C: RC → HFD vs. HFD → RC, p=0.395). We also 
conducted within animal analysis of body weight change from Week 0 to control for 
interanimal variability (Figures 3B and 3D). At Week 9, both diet switch groups (RC → 
HFD and HFD → RC) had significantly more weight gain compared to mice maintained 
on RC (Figure 3D: RC → RC, p<0.05) and significantly less weight gain than mice 
maintained on HFD (HFD → HFD, p<0.05). Further, the two diet switch groups had 
similar weight change from Week 0 to Week 9 (Figure 3D: p=0.924), even though they 
were in opposing energetic balances. Therefore, Week 9 measurements of both body 
weight and weight change from baseline demonstrate that diet switch groups are 
different from non-diet switch conditions, but similar to one another.  
 
Acute diet switch affects sleep architecture independent of body weight  
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The two diet switch conditions have opposing energetic statuses; RC → HFD 
mice are gaining weight, while HFD → RC mice are losing weight (see Figure 3A and 
3B). However, they have statistically similar weight one week following the diet switch 
(Figures 3C and 3D). Sleep/wake was recorded at this time point to determine if body 
weight is the primary determinant in driving wake impairments, as previously 
hypothesized (Jenkins, Omori et al. 2006). At Week 9, HFD → RC mice were awake for 
over one hour longer during the 24 hour recording than RC → HFD mice, based on 
either total wake time (Figure 4A: p<0.05) or change in wakefulness from Week 0 
(Figure 4B: p<0.05). Conversely, RC → HFD mice were in NREM sleep significantly 
longer than HFD → RC mice at Week 9 (Figure 4C: p<0.05), although their NREM 
change from baseline only trended towards significance (Figure 4D: p=0.065). While 
differences in wake and NREM time were observed in both the light and dark periods 
(not shown), only the summated 24-hour differences for each behavioral state reached 
statistical significance. We did not find any differences in either absolute REM time or 
REM change from baseline (Figure 6E and 6F). We did, however, observe increased 
sleep/wake fragmentation in RC → HFD mice compared to HFD → RC animals (Table 
2). During the dark phase, RC → HFD mice exhibited significant increases in both total 
wake bouts (Table 2: p<0.05) and short wake bouts (Figure 4E: ≤16 seconds, 
p<0.0001). Further, NREM sleep bout number was also increased in RC → HFD mice 
during the dark period (Table 2: p<0.05), suggesting that these mice have increased 
bout instability during the active phase compared to HFD → RC mice.  
We used multiple linear regression modeling to assess the relative contributions 
of diet/energetic status (i.e., RC → HFD vs. HFD → RC conditions) and body weight on 
sleep/wake behavior (Table 3). First, we tested which factors affected absolute wake 
time and wake change from Week 0. We found that a model using absolute body weight 
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as a covariate showed borderline significance for both dietary condition (p=0.088) and 
body weight (p=0.064). However, when we controlled for interanimal variability of weight 
gain (i.e., by using percent change in weight from Week 0 as the weight variable), our 
model showed that both the dietary condition (RC → HFD) and elevated body weight 
significantly contributed to the reduction in wake time (p=0.0017 and p=0.0018, 
respectively). Thus, our models indicate that both diet/energetic status and body weight 
contribute independently towards total wakefulness. Second, we modeled which factors 
contributed to wake fragmentation in the dark phase. We fit models to wake bout 
number, wake to NREM transitions, and short wake bouts (Table 3). Our models for 
wake bout number and wake to NREM transitions failed to reach significance (p>0.1). 
However, both models for short wake bouts, which used either absolute body weight or 
percent change in body weight as a covariate, reached statistical significance. We found 
a strong association between the increased number of short wake bouts and the RC → 
HFD dietary condition/positive energy balance (p=0.012 and p=0.0085), but no 
association with either absolute body weight (p=0.725) or percent increase in body 
weight (p=0.923). Taken together, our results suggest that body weight and dietary 
condition both contribute to changes in total wake time. Body weight is, however, not 
associated with wake bout instability in the active phase, unlike dietary condition.  
 
Acute dietary modifications bidirectionally influence weight change and sleep/wake 
behavior  
We hypothesized that acute diet-induced alterations to energy balance might 
induce changes to both weight and sleep architecture. To test this hypothesis, we used 
Week 9 measurements to compare groups that consumed the same chronic diet, but 
differed by the diet consumed from Week 8 → Week 9 (i.e., RC → RC vs. RC → HFD 
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and HFD → HFD vs. HFD → RC). At Week 8, there were no differences in weight 
between RC → RC vs. RC → HFD groups and HFD → HFD vs. HFD → RC conditions 
(not shown, p=0.932 for both). However, in the week following the diet switch, RC → 
HFD animals gained significantly more weight than RC → RC animals while HFD → RC 
mice lost significantly more weight than HFD → HFD mice (Figure 5A: p<0.0001 for 
both). Additionally, caloric intake was dramatically increased and decreased immediately 
after switching mice to HFD and RC, respectively (Figure 5B: Day 1, p<0.0001 for both). 
However, caloric intake was similar between all four conditions by 7 days following the 
diet switch (when the sleep/wake recordings occurred; see Figure 5B). Therefore, the 
immediate differences in caloric intake following the diet switch contributed to the 
changes in energy balance and body weight, but it is less clear how caloric intake per se 
affects sleep and wakefulness.  
We found that one week of HFD (RC → RC vs. RC → HFD) significantly 
decreased wakefulness while one week of RC (HFD → HFD vs. HFD → RC) 
significantly increased wake time (Figure 5C: p<0.05 for both). These wake changes 
were accompanied by compensatory changes in NREM sleep (Figure 5D: p<0.05 for 
both); REM sleep was unaffected. We also assessed how absolute wakefulness was 
affected at Week 9 between these comparisons. One week of HFD trended towards a 
significant reduction in wake time (Figure S2A: p<0.05), but did not hold following the 
Bonferroni corrected significance cutoff (p>0.025). Conversely, reverting DIO mice back 
to RC for one week significantly increased total wakefulness (Figure S2A: p<0.025) 
compared to DIO mice maintained on HFD for the final week. These changes to total 
wake time were again accompanied by concomitant changes in NREM sleep time 
(Figure S2B).   
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We found large changes to bout architecture one week following the diet switch, 
with acute HFD fragmenting and acute RC consolidating both sleep and wakefulness. 
One week of HFD significantly increased the number of wake bouts during the dark 
phase (Figure 5E: RC → RC vs. RC → HFD, p<0.05), while feeding RC to DIO mice for 
one week significantly decreased the number of wake bouts during the dark phase (HFD 
→ HFD vs. HFD → RC, p<0.001). Additionally, wake bout length during the active phase 
was decreased in RC → HFD mice and increased HFD → RC mice compared to their 
respective controls (Figure 5F: p<0.01 and p<0.0001).  We observed similar trends for 
NREM bout number and length during the dark phase (Figure S2C and S2D). Further, 
short wake bouts (≤16 seconds long) were significantly affected by acute diet switch, 
with acute HFD increasing and acute RC reducing their prevalence during the dark 
phase (Figure S2E: p<0.01 and p<0.001, respectively). We also analyzed how absolute 
bout architecture compared at Week 9. One week of HFD trended towards fragmenting 
wakefulness during the dark phase, but one week of RC significantly consolidated 
wakefulness and NREM sleep during the dark phase (Table 2).  
 Since we observed significant changes to both body weight and sleep/wake 
architecture following the acute diet switch (Week 8 → Week 9), we examined the 
correlations between these measures. We found that changes in wake time, NREM time, 
and wake to NREM transitions in the dark phase all significantly correlated (p<0.0001 for 
all) with percent changes in body weight (Figures 5G and 5H, Figure S2F). Thus, the 
acute diet switch puts mice into opposite energy balance and induces proportional 
changes to both body weight and sleep/wake architecture. These results indicate that 
one week of an obesogenic or leptogenic diet is sufficient to induce bidirectional 
changes to body weight, sleep/wake time, and sleep/wake fragmentation. Thus, HFD or 
RC consumption for one week can significantly alter sleep and wakefulness. 
47 
 
 
Acute diet negates the sleep/wake effects of chronic diet 
Previous studies have shown that switching DIO mice back to RC for at least 4 
weeks can rescue sleep behavior and even cognitive ability (Guan, Vgontzas et al. 2008; 
Sobesky, Barrientos et al. 2014). We tested the hypothesis that wake impairments could 
be normalized (or induced) after a much shorter acute diet switch by comparing groups 
of mice that consumed the same diet from Week 8 → 9 (i.e., RC → RC vs. HFD → RC 
and HFD → HFD vs. RC → HFD). We found sleep architecture was similar between 
groups of mice that consumed the same diet during the final week, regardless of their 
chronic diet. We found no differences in total wake, NREM, or REM time between either 
RC → RC and HFD → RC comparisons or HFD → HFD and RC → HFD comparisons 
(Figure 6: p>0.05 for all). Further, we found no differences in sleep/wake fragmentation 
for these same comparisons (Table 2: p>0.05 for all). Thus, the acute diet switch/energy 
balance changes have profound effects on sleep/wake architecture which negate the 
sleep-related effects of the chronic diet.  
 
Sleep homeostasis is unaffected by either acute or chronic HFD 
We analyzed delta power using two different methods, both of which are 
commonly used in sleep research (Franken, Chollet et al. 2001; Vecsey, Wimmer et al. 
2013). We found that baseline delta power is similar between the four groups of animals 
at all intervals (Figure 7A: p>0.05 at each interval) and all times of day (Figure 7B: 
p>0.05 at each time point). We performed sleep deprivation during ZT0-6 by a 
combination of novel enrichment and gentle handling (Vecsey, Wimmer et al. 2013). Our 
sleep deprivation was >97% effective, with no intrusion of any REM bouts (not shown).  
We found no differences in delta power following sleep deprivation among all four diet 
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groups (Figure 7C and 7D: p>0.05 at each interval and time point). Last, we found no 
differences in total wake, NREM, or REM time during the light period following sleep 
deprivation (Figures 7E-G: p>0.05 for all). We found similar sleep/wake and delta power 
trends at Week 8 (not shown). Thus, we found no evidence to indicate that sleep 
homeostasis is affected by either acute or chronic dietary manipulations.  
 
DISCUSSION 
This study provides strong evidence that diet and/or energy balance can 
influence both the amounts and quality of sleep and wakefulness.  Further, the effects of 
diet/energy balance on sleep behavior is independent from, and potentially greater than, 
the effects of body weight. Additionally, we found no differences in recovery sleep 
following forced wakefulness, indicating that the changes observed cannot be explained 
by alterations in sleep homeostasis. 
Multiple reports, including this present study, have found that wakefulness is 
decreased in obese animal models (Jenkins, Omori et al. 2006; Laposky, Shelton et al. 
2006; Guan, Vgontzas et al. 2008; Laposky, Bradley et al. 2008; Mavanji, Teske et al. 
2010; Mavanji, Billington et al. 2012; Luppi, Cerri et al. 2014). Further, all of these 
studies have demonstrated a concomitant increase in NREM sleep. However, the effect 
of HFD/obesity on REM sleep has been much less consistent. Both strains of transgenic 
leptin-deficient mice spent less time in REM sleep compared to wildtype controls 
(Laposky, Shelton et al. 2006; Laposky, Bradley et al. 2008). Conversely, Luppi et al. 
found that DIO rats had increased REM sleep compared to lean controls (2014). Last, 
two separate studies with C57BL/6 mice showed that total REM time was either 
unaffected or moderately increased in DIO mice (Jenkins, Omori et al. 2006; Guan, 
Vgontzas et al. 2008). The present study found significant increases in REM sleep but 
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only during the light phase. There are a few methodological differences that may explain 
these disparities. First, experiments with DIO animals require long periods (6+ weeks) of 
social isolation while weight gain manifests, whereas genetically-induced obese animals 
are only isolated directly prior to sleep recordings (Jenkins, Omori et al. 2006; Laposky, 
Shelton et al. 2006; Laposky, Bradley et al. 2008; Luppi, Cerri et al. 2014). Prolonged 
periods of social isolation are known to induce depressive-like behaviors (Carnevali, 
Mastorci et al. 2012; Grippo, Ihm et al. 2014), one of which is increased REM sleep 
(Palagini, Baglioni et al. 2013). Second, previous experiments testing diet-induced sleep 
effects used older adult mice (6 months of age) (Jenkins, Omori et al. 2006; Guan, 
Vgontzas et al. 2008) compared to the young adult mice we used (3 months of age). 
Younger animals are more susceptible to depressive-like symptoms following stress, 
such as isolation (Saavedra-Rodriguez and Feig 2013). Therefore, it is possible that 
young adult, HFD-fed mice are more susceptible to depressive-like symptoms, which 
may explain the increases in REM time at Week 8. Future studies could use advanced 
sleep recording techniques (i.e., telemetry) or paired housing while weight gain develops 
to avoid isolation effects. Additionally, it is possible that REM sleep is also affected by 
acute diet switch. Although REM time was similar between all four dietary conditions at 
Week 9 (Figure 6E and 6F: p>0.1 for both), this analysis may be underpowered due to 
the moderate changes observed with REM sleep and the reduced sample size following 
the diet switch. Nonetheless, our results suggest diet/energy balance/body weight has 
greater effects on wakefulness and NREM sleep compared to REM sleep, which is 
consistent with previous literature (Jenkins, Omori et al. 2006; Laposky, Shelton et al. 
2006; Guan, Vgontzas et al. 2008; Laposky, Bradley et al. 2008; Mavanji, Teske et al. 
2010; Mavanji, Billington et al. 2012; Luppi, Cerri et al. 2014).  
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Previous studies have consistently found worsened wake and sleep 
fragmentation in both genetically obese and DIO animals (Jenkins, Omori et al. 2006; 
Laposky, Shelton et al. 2006; Guan, Vgontzas et al. 2008; Laposky, Bradley et al. 2008; 
Mavanji, Teske et al. 2010; Mavanji, Billington et al. 2012; Luppi, Cerri et al. 2014). In 
the present study, we found increased sleep/wake fragmentation—particularly wake and 
NREM fragmentation during the dark phase—after both acute and chronic consumption 
of HFD. Conversely, DIO mice acutely consuming RC exhibit normalized bout 
fragmentation during the active phase. We also observed striking differences in the 
number of short wake bouts (≤16 seconds), which were increased and decreased 
following acute consumption of HFD and RC, respectively. Multiple linear regression 
analysis revealed that the dietary condition, but not the animals’ body weight, was 
significantly associated with the number of short wake bouts (Table 3). Thus, acute diet 
switch drove significant, bi-directional changes to wake bout stability independent of 
body weight. Prior studies found less dramatic changes to bout length and number at 
earlier time points (Jenkins, Omori et al. 2006; Guan, Vgontzas et al. 2008). We suspect 
this may be due to technical differences in EEG scoring analysis (e.g., 4-second vs. 10-
second epochs and arbitrary rules for ‘minimal epoch length’, which our study did not 
use). Nonetheless, diet-induced effects on fragmentation are consistent between 
studies, although future work needs to confirm the onset of this phenotype.  
One goal of this study was to disentangle the relative contributions of diet, energy 
balance, and body weight in mediating sleep/wake changes. Genetically obese mice are 
fed a standard chow diet, but are in a state of perpetual weight gain and obesity 
(Laposky, Shelton et al. 2006; Laposky, Bradley et al. 2008). Moreover, they have 
altered gene expression that could directly affect sleep/wake behavior (Franken, Chollet 
et al. 2001). Obesity-susceptible (OS) and obesity-resistant (OR) rats, which are fed the 
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same diet but exhibit divergent weight gain, show dissimilar sleep/wake architecture, 
specifically decreased wakefulness and increased fragmentation in OS rats compared to 
OR rats (Mavanji, Teske et al. 2010). The DIO animal model is generated by feeding 
HFD to non-transgenic mice, which induces weight gain and obesity (Jenkins, Omori et 
al. 2006; Guan, Vgontzas et al. 2008; Luppi, Cerri et al. 2014). Reverting DIO mice back 
to RC stimulates weight loss, which eventually normalizes body weight and sleep/wake 
behavior (Guan, Vgontzas et al. 2008). Our study suggests that excess body weight 
does not fully explain the observed changes to sleep/wake, indicating that other factors 
such as diet and/or energy balance must also contribute.  First, RC → HFD mice were 
significantly less heavy than HFD → HFD mice, but these two groups had statistically 
similar sleep/wake architecture. HFD → RC animals had increased within-animal weight 
change compared to RC → RC, but we found no differences in sleep/wake behavior 
between these groups. Second, although the two diet switch conditions (RC → HFD and 
HFD → RC) had similar average body weight, many aspects of their wake and sleep 
were different. Specifically, RC → HFD mice exhibited increased wake and sleep 
fragmentation during the dark phase and reduced total wakefulness compared to HFD 
→ RC animals. Lastly, our linear regression analysis determined that both body weight 
and dietary condition significantly contribute to modeling wake time. Interestingly, only 
dietary condition was significantly related to wake fragmentation, specifically the number 
of short wake bouts during the dark phase. This suggests that sleep/wake alterations are 
influenced by diet and/or energy balance, which may play a larger role than body weight 
per se.  It is important to note, however, that our study design does not allow us to 
completely separate the relative influences of diet versus energy balance on sleep/wake 
effects. However, the aforementioned study with OS and OR rats suggests that positive 
energy balance and/or increased body weight induces fragmented sleep/wake and EDS, 
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independent of diet (Mavanji, Teske et al. 2010). Taken together, these previous findings 
and our current study suggests that energy balance may be a more important sleep-
altering factor than diet. Nonetheless, future work with different diets (e.g., high-
carbohydrate diets) and different methods to alter energy balance (e.g., access to a 
treadmill) are required to parse apart their relative contributions.    
Sleep/wake behavior is regulated by a two-process system—circadian rhythms 
and sleep homeostasis (Borbely 1982). Previous studies have shown HFD-induced 
alterations to both behavioral and molecular circadian rhythms in mice (Kohsaka, 
Laposky et al. 2007; Mendoza, Pevet et al. 2008; Eckel-Mahan, Patel et al. 2013). 
However, no studies to date have investigated how either prolonged or acute HFD 
affects sleep homeostasis. Increased delta power (1 – 4 Hz) following sleep deprivation 
indicates the depth and intensity of sleep, and is the current gold standard for testing 
sleep homeostasis (Franken, Chollet et al. 2001; Vecsey, Wimmer et al. 2013). Both 
ob/ob and db/db mice have altered sleep homeostasis, evidenced by increased delta 
power following sleep deprivation (Laposky, Shelton et al. 2006; Laposky, Bradley et al. 
2008). The present study, however, indicates that sleep homeostasis is unaffected by 
either acute or chronic dietary changes in C57BL/6 mice. Therefore, the sleep/wake 
changes we observed cannot be explained by dysfunctional sleep homeostasis. 
Our results indicate differential time of day effects regarding total sleep/wake 
time and fragmentation. Chronic HFD increased NREM sleep and decreased 
wakefulness during the beginning of the dark phase, when the activity of mice peaks. 
Further, wake and NREM fragmentation increased during the dark phase. Acute diet 
switch also affected total wake and NREM time (with no effect on REM), but these 
effects were not localized to a particular time of day. However, acute dietary effects on 
sleep/wake bout fragmentation were specific to the dark phase. Taken together, we 
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hypothesize that HFD induces wake bout instability during the active phase, which leads 
to increased total sleep time across the day. Orexin (a.k.a. hypocretin) signaling is 
necessary for wake bout stability, since disruption of this pathway induces narcolepsy 
(Lin, Faraco et al. 1999; Hara, Beuckmann et al. 2001). Previous reports have found that 
HFD reduces prepro-orexin levels (Tanno, Terao et al. 2013) and potentially reduces the 
number of orexin immunopositive neurons in the lateral hypothalamus (Nobunaga, 
Obukuro et al. 2014). Therefore, we predict that orexin signaling partially mediates the 
diet-induced sleep/wake effects. Future work will need to validate these previous 
findings, as well as study the role of altered orexin signaling in mediating the sleep/wake 
effects of HFD.  
There are some inherent limitations with this study design. First, we tracked 
caloric intake throughout the study, but we did not measure energy expenditure and 
locomotor activity. Without information about both intake and expenditure, energy 
balance cannot be directly quantified. We found no differences in caloric intake at any of 
the time points when sleep/wake behavior was measured, although the profound 
changes in weight support our assumptions that energy balance is being affected. One 
possibility is that caloric intake was overestimated for RC-fed conditions since some 
mice will shred this diet, making accurate measurements difficult. On the other hand, 
caloric intake may indeed be similar at these time points, suggesting that changes in 
caloric expenditure drives the energy imbalance and body weight changes. Future 
studies need to measure all aspects of energy balance by directly assessing caloric 
intake, energy expenditure, and locomotor activity. Second, we did not determine if sleep 
and wakefulness are affected earlier than one week after dietary manipulations. Tracking 
sleep/wake alterations during the first week post-diet switch will help elucidate which 
changes are occurring first. Last, there are important differences between the control RC 
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diet and the HFD. The HFD has a much better taste than the RC, which affects 
motivated and hedonic food intake (Lutter and Nestler 2009). Additionally, the HFD is 
much softer and easier to chew, which also may affect motivation to consume food. 
Future studies need to control for the diet content, consistency, and presentation (e.g., 
pellet vs. powder vs. liquid) to ensure that the changes in sleep/wake are generalized to 
energy balance and not the result of these less interesting factors.  
In summary, we have found that short-term changes to diet bi-directionally affect 
energy balance (i.e., weight gain/loss) and sleep/wake architecture. Our results indicate 
that diet and/or energy balance are likely major contributors to the quality of sleep and 
wakefulness. These findings are consistent with obese patients who, after undergoing 
bariatric surgery, report improvements in sleepiness and vigilance despite still being 
quite obese (Dixon, Schachter et al. 2005; Varela, Hinojosa et al. 2007; Holty, Parimi et 
al. 2011). Thus, exploring the mechanisms that regulate diet-induced and/or energy 
balance-induced changes to sleepiness may lead to novel strategies to improve 
sleepiness, vigilance, and/or cognition in both the obese and non-obese population. 
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Figure 2.1: Outline of the experimental paradigm. At Week 0, all mice underwent a 
24-hour baseline sleep recording. The following day, mice were pair-matched by weight 
and randomized to receive either high fat diet (HFD) or continue consuming regular 
chow (RC). At Week 8, 24-hours of undisturbed sleep/wake were recorded. The 
following morning, mice were sleep deprived (SD) from ZT0-6 and recovery sleep was 
recorded (ZT6-12). The next day, mice were randomized to undergo the diet switch or 
remain on their respective diet. One week later (Week 9), 24 hours of undisturbed 
sleep/wake was again recorded, followed by 6 hours of SD and post-SD recovery the 
next day.  
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Figure 2.2: Chronically feeding mice HFD increases body weight and decreases 
total wakefulness in proportion to weight gained. (A) Average body weight at the 
indicated time points. (B) Percent change in body weight from Week 0 at the indicated 
time points. (C) Mice consuming HFD for 8 weeks spent significantly less time awake, 
especially during the beginning of the dark phase (D) HFD-fed mice spent significantly 
more time in NREM sleep, especially during the first 6 hours of the dark phase. (E) 
During the light phase, REM sleep is significantly increased in DIO mice compared to 
RC-fed controls. Correlation plots of mice fed HFD for 8 weeks revealed that increased 
body weight negatively correlates with total wake time (F) and positively correlates with 
total NREM time (G). ΔBody Weight = (Week#BW–Week0BW)/Week0BW; ΔMinutes = Week 
# – Week 0. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.  
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Figure 2.3: Body weight changes before and after acute diet switch. Absolute body 
weight (A) and percent change in body weight (B) throughout the experiment. Note that 
the Week 8 time point is still pre-diet switch, while the Week 9 time point is one week 
after the diet switch has occurred. (C) Body weight at Week 9. All conditions weigh 
significantly less than HFD → HFD animals (p<0.001, p<0.05, and p<0.01). HFD → RC 
mice are of similar weight to RC → RC mice, while RC → HFD animals trended towards 
increased weight over the RC → RC condition (p<0.1). Importantly, the two diet switch 
conditions do not differ in average absolute body weight (p=0.395).  (D) Measuring 
percent change in body weight from Week 0 helps control for interanimal weight 
variability. All conditions are heavier than RC → RC (p<0.05, p<0.05, and p<0.0001), 
and lighter than HFD → HFD (p<0.05 and p<0.05). The two diet switch conditions have 
nearly identical weight change from baseline (p=0.924). ΔBody Weight = (Week#BW–
Week0BW)/Week0BW; a
+, p<0.1 compared to RC → RC; a, p<0.05 compared to RC → 
RC; a’’’, p<0.0001 compared to RC → RC; b, p<0.05 compared to HFD → HFD; b’, 
p<0.01 compared to HFD → HFD. 
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Figure 2.4: The two diet switch conditions (RC → HFD and HFD → RC) have 
different sleep/wake architecture at Week 9, even though they have similar 
weights. (A,B) HFD → RC animals spend significantly more time awake over 24 hours 
than RC → HFD mice. (C,D) Conversely, HFD → RC animals spend significantly less 
time in NREM sleep compared to RC → HFD mice. (E) In the dark phase, wake bout 
distribution is fairly similar between both groups, except RC → HFD animals exhibit 
significantly more short wake bouts (≤16 seconds) than HFD → RC animals. *, p<0.05; 
****, p<0.0001.  
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Figure 2.5: Diet switch bi-directionally affects body weight and sleep/wake 
architecture after one week. (A) One week of HFD significantly increases body weight 
in RC-fed mice, while DIO mice fed RC for one week significantly decreases body 
weight. (B) Caloric intake was similar among all four groups before the diet switch (Week 
8; Day 0) and one week after the diet switch (Week 9; Day 7 post-diet switch). (C,D) 
Acute HFD increases NREM sleep at the expense of wakefulness. Conversely, feeding 
RC to overweight mice enhances wakefulness and decreases NREM sleep. (E,F) Acute 
HFD fragments wakefulness, while reverting DIO mice to RC consolidates wakefulness 
in the dark phase. One week after the diet switch, there is a strong correlation between 
body weight change and wake change (G) and wake to NREM transitions in the dark 
phase (H). ΔBody Weight = (Week9BW–Week8BW)/Week8BW; Δ = Week9 – Week8, *, 
p<0.05; **, p<0.01***, p<0.001; ****, p<0.0001 following Bonferroni correction.   
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Figure 2.6: Acute diet reverses the sleep/wake effects of the chronic diet. 
Regardless of the initial diet (Week 0 → 8), animals that consumed the same diet from 
Week 8 → 9 had similar amounts of wakefulness (A,B) and NREM sleep (C,D). Wake 
and sleep fragmentation were also similar for these comparisons (Table 2). (E,F) REM 
sleep was not statistically different between any of the four dietary conditions. p>0.05 
are not considered significant. 
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Figure 2.7: Sleep homeostasis is similar between all four dietary conditions. 
NREM sleep delta power (1 – 4 Hz) during undisturbed sleep recordings (A,B) and 
following 6-hour sleep deprivation (C,D). Total wake (E), NREM (F), and REM sleep (G) 
during the sleep deprivation (ZT0-6) and recovery period (ZT6-12). There are no 
differences between any dietary condition comparisons, indicating that sleep 
homeostasis in unaffected by dietary changes or diet-induced obesity.  
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Regular Chow (RC) 
(n=13) 
Mean ± SEM 
High Fat Diet (HFD) 
(n=13) 
Mean ± SEM 
Significance 
Wake 
Number of Bouts 
 
24-Hour 297.5 ± 14.5 408.4 ± 19.3 *** 
 
Light 189.9 ± 8.3 220.1 ± 8.5 * 
 
Dark 107.5 ± 8.6 188.3 ± 14.4 **** 
Number of Short Bouts (≤16 seconds) 
 
24-Hour 109.7 ± 12.4 219.55 ± 15.5 **** 
 
Light 70.9 ± 7.6 116.6 ± 7.7 *** 
 
Dark 38.8 ± 5.4 103.0 ± 10.2 **** 
Average Bout Length (seconds) 
 
24-Hour 153.8 ± 8.2 107.4 ± 6.9 *** 
 
Light 81.7 ± 4.3 61.5 ± 3.2 ns 
 
Dark 297.7 ± 28.4 170.1 ± 18.0 **** 
NREM 
Number of Bouts 
 
24-Hour 297.9 ± 14.7 409 ± 19.3 *** 
 
Light 190.3 ± 8.3 220.5 ± 8.55 * 
 
Dark 107.6 ± 8.7 188.5 ± 14.4 **** 
Average Bout Length (seconds) 
 
24-Hour 131.2 ± 7.0 98.6 ± 5.1 *** 
 
Light 134.7 ± 6.7 120.6 ± 6.3 ns 
 
Dark 126.8 ± 8.6 73.2 ± 4.5 **** 
REM 
Number of Bouts 
 
24-Hour 64.6 ± 4.3 84.6 ± 4.7 ** 
 
Light 47.9 ± 3.8 68.8 ± 3.4 **** 
 
Dark 16.7 ± 2.0 15.8 ± 1.9 ns 
Average Bout Length (seconds) 
 
24-Hour 62.2 ± 1.8 56.9 ± 2.0 ns 
 
Light 63.5 ± 1.9 57.9 ± 2.1 ns 
 
Dark 59.9 ± 2.7 51.1 ± 3.2 * 
 
Table 2.1: Sleep/wake fragmentation is increased in DIO mice. Wake, NREM, and 
REM fragmentation are all increased in DIO mice compared to RC-fed controls at Week 
8. Wake and NREM fragmentation is highest during the active phase, while REM 
fragmentation is higher in the resting phase. *, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001; ns, not significant.  
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RC → RC 
(n = 5) 
Mean ± SEM 
RC  → HFD 
(n = 8) 
Mean ± SEM 
HFD → RC 
(n = 7) 
Mean ± SEM 
HFD → HFD 
(n = 6) 
Mean ± SEM 
Significance 
  Wake 
Number of Bouts 
 
24-Hour 313.4 ± 18.4 362.5 ± 21.4 308.4 ± 21.2 390.0 ± 33.9 + 
 
Light 196.8 ± 10.8 205.9 ± 10.9 195.6 ± 10.6 213.5 ± 14.4 ns 
 
Dark 116.6 ± 11.5 156.6 ± 13.1 112.9 ± 13.9
b
 176.5 ± 23.3
a
 * 
Number of Short Bouts (=<16 seconds) 
 
24-Hour 114.8 ± 17.6 190.1 ± 21.4
a 
125.6 ± 16.8
b,§
 208.5 ± 28.4
a
 * 
 
Light 72.0 ± 11.2 103.9 ± 12.4 82.7 ± 10.1 109.5 ± 13.1 ns 
 
Dark 42.8 ± 6.8 86.3 ± 10.3
a
 42.9 ± 7.9
§^,b^
 99.0 ± 16.9
a^
 ** 
Average Bout Length (seconds) 
 
24-Hour 146.6 ± 13.7 117.5 ± 9.3 153.4 ± 13.6
 b,§
 110.8 ± 12.2 * 
 
Light 84.0 ± 6.9 68.4 ± 5.3 82.1 ± 5.1 63.5 ± 3.2 ns 
 
Dark 265.6 ± 48.8 187.7 ± 21.1 302.6 ± 52.4 178.2 ± 32.1 + 
 
NREM 
Number of Bouts 
 
24-Hour 312.4 ± 18.2 362.5 ± 21.5 308.6 ± 20.7 390.2 ± 34.2 + 
 
Light 196.2 ± 10.7 205.9 ± 10.9 196.0 ± 10.4 213.8 ± 14.5 ns 
 
Dark 116.2 ± 11.6 156.6 ± 13.2 112.6 ± 13.7
§
 176.3 ± 23.4
a
 * 
Average Bout Length (seconds) 
 
24-Hour 119.9 ± 6.2 114.4 ± 7.5 121.7 ± 8.0 107.7 ± 9.0 ns 
 
Light 121.7 ± 6.1 127.3 ± 6.7 125.8 ± 6.8 125.0 ± 9.3 ns 
 
Dark 117.4 ± 7.3 99.0 ± 9.8 119.8 ± 14.1 87.6 ± 9.6 + 
 
REM 
Number of Bouts 
 
24-Hour 66.4 ± 6.1 79.3 ± 4.7 66.6 ± 5.3
b,§
 84.0 ± 5.1
a
 * 
 
Light 50.8 ± 4.4 63.5 ± 2.9 48.3 ± 4.3
 b,§
 67.5 ± 5.7
 a
 * 
 
Dark 15.6 ± 2.9 15.8 ± 1.1 18.3 ± 3.1 16.5 ± 2.4 ns 
Average Bout Length (seconds) 
 
24-Hour 64.8 ± 3.0 59.3 ± 2.1 63.4 ± 2.2 56.6 ± 2.1 + 
 
Light 65.1 ± 3.1 58.9 ± 2.9 68.2 ± 3.4
b,§
 56.2 ± 2.3 * 
 
Dark 60.5 ± 5.9 60.9 ± 3.4 54.6 ± 3.9 58.6 ± 4.8 ns 
 
Table 2.2: Wake, NREM, and REM fragmentation at Week 9. Letter superscripts 
indicate uncorrected post-hoc significance when the one-way ANOVA detected a 
significant difference between all four groups. +, p<0.1; *, p<0.05; **, p<0.01; a and a^: 
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p<0.05 and p<0.01 to RC → RC, respectively; b and b^: p<0.05 and p<0.01 to HFD → 
HFD, respectively; § and §^: p<0.05 and p<0.01 to RC → HFD, respectively; ns, not 
significant. 
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 ANOVA 
F-value 
ANOVA 
p-value 
Actual BW [g] 
p-value 
ΔBW [%] 
p-value 
Diet/Energy 
Balance 
p-value 
24 Hours 
Total 
Wakefulness 
7.302 0.0084 0.064 
 
0.088 
16.869 0.00033 
 
0.0017 0.0018 
ΔWake 
2.25 0.1479 0.76 
 
0.070 
3.213 0.0763 
 
0.243 0.053 
 
  
   Dark Period 
Wake Bout 
Number 
2.641 0.1121 0.59 
 
0.046 
2.524 0.1216 
 
0.715 0.045 
Wake → NREM 
Transitions 
2.707 0.1071 0.588 
 
0.044 
2.595 0.1158 
 
0.705 0.043 
Short Wake 
Bouts  
(≤ 16 seconds) 
5.077 0.0253 0.725 
 
0.012 
4.967 0.0268 
 
0.923 0.0085 
 
Table 2.3: Linear regression analysis reveals independent effects of diet/energy 
balance from body weight. Each row in the table represents a unique model, with the 
top line using actual body weight as a covariate and the bottom line using percent 
change in weight from Week 0 as the covariate. The overall fit of the model is calculated 
using an ANOVA. If statistical significance was reached (p<0.05), the relative 
contributions of body weight and dietary condition were considered. Both body weight 
and diet/energy balance independently relate to 24-hour wakefulness, but only 
diet/energy balance are associated with wake fragmentation in the active phase. BW = 
Body Weight; ΔBW = (Week9BW – Week0BW)/Week0BW; ΔWake = Week9Wake – 
Week0Wake; Diet/Energy Balance = Arbitrary covariate depending on experimental 
condition (RC → HFD = 0 and HFD → RC = 1).  
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Figure 2.S1: Caloric intake and sleep/wake metrics at Week 8. Change in total wake 
(A), NREM sleep (B), and REM sleep (C) from Week 0 to Week 9 in mice that did not 
undergo a diet switch. Chronic HFD significantly decreases wakefulness, and trends 
towards increasing both NREM and REM sleep. (D,E) Wake bout distribution at Week 8 
for both RC- and HFD-fed mice. Only short wake bouts (≤16 seconds long) are 
significantly affected, with increased prevalence in HFD mice during both the light and 
dark phases. (F) There were no significant differences of average daily caloric intake at 
Week 0 (when all animals consumed RC) and Week 8. (G) The positive correlation 
between body weight change and total REM time trended towards significance.               
*, p<0.05; ****, p<0.0001. 
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Figure 2.S2: Acute diet switch significantly alters sleep/wake architecture. Total 
wake time (A) and NREM time (B) at Week 9. The Bonferroni correction to the 
significance cutoff (p < 0.025 = 0.05/2) reveals that acute RC  significantly alters total 
wake and NREM time, but acute HFD only has moderate affects. (C,D) NREM 
fragmentation in the dark phase is significantly affected by one week of diet switch. 
Similar to wake architecture, NREM sleep is consolidated following the switch to RC and 
fragmented after one week of HFD. (E) The change in wake bout distribution following 
acute diet switch. Only short wake bouts are significantly affected by the diet switch (F). 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 following Bonferroni correction.  
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ABSTRACT 
 
Diet-induced obese (DIO) mice display profound changes to sleep/wake 
architecture, specifically decreased total wakefulness and increased sleep/wake 
fragmentation.  We identified peroxisome proliferator-activated receptor gamma 
(PPARg) as a molecular target that could potentially mediate obesity-related sleep 
abnormalities. PPARg is activated by free fatty acids and has established roles in 
regulating peripheral circadian rhythms. PPARg was recently detected in the brain, 
and brain PPARg is transcriptionally upregulated in the hypothalamus of DIO animals. 
Furthermore, pan-neuronal PPARg knockout (KO) greatly increases locomotor activity 
in high fat diet (HFD)-fed mice, which indicates that normal sleep/wake architecture 
may be preserved in these DIO animals. Therefore, we hypothesize that central 
PPARg serves as a sensor of energy balance, and is thus required for HFD-induced 
sleep/wake changes. We tested this hypothesis by genetic and pharmacological 
approaches. First, we generated a novel transgenic mouse line lacking PPARg only in 
Nkx2.1+ cells, which are densely expressed throughout the hypothalamus. These 
transgenic KO mice were mildly protected from DIO, but had no discernable 
differences in either sleep/wake behavior or locomotor activity compared to DIO 
littermate controls. Second, we infused the PPARg-specific antagonist GW9662 
directly into the brains of mice and measured changes to behavior. We found chronic 
GW9662 trends toward preventing HFD-induced decreases in activity and 
wakefulness, although neither effect was statistically significant. Further, acute 
intracerebroventricular infusions of GW9662 appeared to worsen DIO sleep/wake 
impairments. In all, these studies do not provide evidence that PPARg has a role in 
regulating sleep/wake behavior in DIO mice.  
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INTRODUCTION 
In the United States, over one-third of adults and nearly one-fifth of children are 
obese (Ogden, Carroll et al. 2014). In addition to the heightened risk for various 
diseases and disorders, obese individuals often suffer from neuropsychological deficits, 
such as decreased alertness and increased drowsiness (Spitznagel, Hawkins et al. 
2015). Compared to non-obese subjects, obese individuals score worse on both 
objective and subjective sleepiness test, even when controlling for sleep disorders such 
as sleep apnea and narcolepsy (Vgontzas, Bixler et al. 1998; Varela, Hinojosa et al. 
2007; Panossian and Veasey 2012). Excessive sleepiness is in itself a major health risk 
to the general population; for example, ‘drowsy driving’ contributes to >300,000 police-
reported car accidents per year (CDC 2011). Further, increased sleepiness in obese 
individuals may even underlie many of their neuropsychological deficits, since 
drowsiness can produce similar cognitive dysfunction in otherwise healthy individuals 
(Alhola and Polo-Kantola 2007; Goel, Rao et al. 2009). Thus, understanding 
mechanisms that underlie obesity-related wake impairments may lead to novel therapies 
to improve vigilance and alertness, potentially improving the quality of life and safety of 
millions of Americans. 
Our lab studies obesity-related sleep abnormalities using the diet-induced obese 
(DIO) mouse model, which is generated by chronically feeding mice a high-fat diet 
(HFD). DIO mice spend an extra 1.5 hours/day asleep at the expense of wakefulness, 
particularly during the dark phase when they are normally most active (Jenkins, Omori et 
al. 2006; Mavanji, Billington et al. 2012); this phenotype closely resembles excessive 
daytime sleepiness observed in humans (Panossian and Veasey 2012; Mokhber, 
Zargham Ravanbakhsh et al. 2016). Further, DIO mice exhibit profound sleep/wake 
instability with greater incidence of short sleep/wake bouts compared to lean controls 
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(Chapter 2, Perron et al). Therefore, our goal is to identify a molecular pathway that may 
mediate HFD-induced changes to sleep architecture and attempt to block or reverse 
these behavioral abnormalities. We defined three key criteria that a candidate transcript 
and/or encoded protein must fulfill: (1) expression in a relevant brain region, defined by 
its capability to both sense nutrients and signal to sleep-regulatory brain regions, (2) 
response to HFD-induced obesity, such as increased expression levels in DIO, and (3) 
necessary for HFD-induced sleep abnormalities.  
The hypothalamus is uniquely situated to receive, integrate, and output signals 
regarding energy status and sleep/wake behavior (Schwartz and Roth 2008; Morton, 
Meek et al. 2014). The hypothalamus surrounds the third ventricle and adjoins the 
median eminence, where circulating hormones and nutrients, such as non-esterified 
long-chain fatty acids (LCFA), can enter the CNS. LCFA can directly affect hypothalamic 
neurons in a variety of ways, including altering cell membrane fluidity, inflammatory tone, 
energy metabolism, and electrochemical properties (McArthur, Atshaves et al. 1999; 
Chari, Lam et al. 2010; Georgiadi and Kersten 2012; Panov, Orynbayeva et al. 2014). 
Further, LCFA are endogenous ligands for peroxisome proliferator activated receptors 
(PPAR), which are nuclear receptors that regulate energy balance and metabolic 
homeostasis (Varga, Czimmerer et al. 2011; Grygiel-Gorniak 2014). One isoform, 
PPAR-gamma (PPARg), is expressed in the hypothalamus, and hypothalamic PPARg is 
transcriptionally upregulated in DIO mice compared to lean controls (Cullingford, Bhakoo 
et al. 1998; Moreno, Farioli-Vecchioli et al. 2004; Sarruf, Yu et al. 2009; Diano, Liu et al. 
2011; Lu, Sarruf et al. 2011; Long, Toda et al. 2014; Cifani, Micioni Di Bonaventura et al. 
2015). Furthermore, administration of PPARg agonists into the 3rd ventricle increases 
food intake while administration of PPARg antagonists decreases food intake (Ryan, Li 
et al. 2011). These studies suggest that hypothalamic PPARg activation promotes 
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positive energy balance. Further, pan-neuronal PPARg knockout (KO) mice are 
metabolically normal when consuming regular chow (RC), but confer resistance to DIO 
and are twice as active compared to wildtype controls when made obese by HFD 
consumption (Lu, Sarruf et al. 2011). This effect is partially mediated by 
proopiomelanocortin (POMC) neurons, since animals lacking PPARg in these neurons 
exhibit a similar, but less dramatic, phenotype (Long, Toda et al. 2014). Since locomotor 
activity and sleep/wake patterns are highly correlated (Pack, Galante et al. 2007), these 
studies suggest that neuronal PPARg KO mice may also spend more time awake. 
However, no study to date has tested the role of PPARg in mediating sleep/wake 
behavior.   
We hypothesize that hypothalamic PPARg senses changes to energy balance 
and mediates HFD-induced sleep/wake changes. We used both genetic and 
pharmacological approaches to test this hypothesis. First, we used polysomnography to 
measure sleep/wake patterns in transgenic mice lacking PPARg in Nkx2.1+ neurons, 
which are densely expressed throughout the hypothalamus (Xu, Tam et al. 2008; Yee, 
Wang et al. 2009; Ring and Zeltser 2010). Second, we surgicated mice with 
intracerebroventricular (ICV) cannula to administer the PPARg antagonist GW9662 
directly into the brain, and tested whether central antagonism of PPARg could prevent or 
restore sleep/wake abnormalities in HFD-fed mice.   Our ultimate goal was to combine 
these two approaches, but we did not find strong evidence that either genetic or 
pharmacological disruption of PPARg affects sleep/wake behavior. 
 
METHODS 
Mice 
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To generate PPARg KO in Nkx2.1+ cells (PPARg xKO), Nkx2.1-Cre male mice 
were obtained from Jackson Labs (008661) and crossed to PPARg flox/flox females 
(004594, Jackson Labs); both of these strains are on a C57BL/6 background. 
Genotyping was performed using the REDExtract-N-Amp kit (XNAT-100RXN, Sigma 
Aldrich, St. Louis, MO) per the manufacturer’s protocol and custom primers (Table S1). 
Select F2 generation animals (homozygous for floxed alleles, hemizygous for Nkx2.1-
Cre) were inbred to generate wildtype controls (Nkx2.1-Cre negative) and mutants 
(Nkx2.1-Cre positive). For pharmacological experiments, we used mice directly obtained 
from Jackson Labs (C57BL/6J; 000664). Male mice (aged 10-12 weeks) were used for 
all experiments. Animals were kept at 23°C on a 12:12 light:dark cycle (with lights-on at 
7 am). The Institutional Animal Care and Use Committee (IUCAC) at the University of 
Pennsylvania approved all experimental protocols prior to the initiation of all studies.  
 
Diets 
 Mice were group housed and maintained on regular chow (RC; 5001, LabDiet, 
St. Louis, MO) until the initiation of all studies.  When indicated by the experimental 
protocol, mice were switched to the hypercaloric high-fat diet (HFD; D12451, Research 
Diets, New Brunswick, NJ). All mice were single housed at least one week prior to all 
behavioral analysis. 
 
Experimental Procedures 
There were three distinct surgical procedures (Table S2): 1) EEG/EMG 
electrodes only, 2) ICV guide cannula + EEG/EMG electrodes, and 3) subcutaneous 
osmotic pumps attached to ICV cannula (sans EEG/EMG electrodes). 
Electroencephalographic/ electromyographic (EEG/EMG) electrodes were constructed 
74 
 
and implanted as previously described. For acute infusions, ICV guide cannula (C313G-
L14/SPC, 22 gauge, cut 2.2 mm below the pedestal, PlasticsOne) were stereotaxically 
implanted into the right lateral ventricle (-0.8 mm anteroposterior and +1.3 mm 
mediolateral from bregma) and affixed with dental cement (Ketac, 3M, St. Paul, MN); 
dummy caps (C313DC/SPC, PlasticsOne) were inserted immediately post-op. ICV 
cannula for chronic infusions were implanted and affixed similarly, with the osmotic 
pump inserted into subcutaneous dorsal area of the mouse. Cannula placement for 
chronic ICV infusions were validated post-mortem.  
 
GW9662 Preparation 
The PPARg-specific antagonist GW9662 (70785, Cayman Chemicals, Ann 
Arbor, MI) was used for both acute infusions (through an ICV guide cannula) and chronic 
infusions (loaded into osmotic pumps). Previous studies have injected between 1-5 μg of 
GW9662 directly into the 3rd ventricle of rodents and found significant hypophagic effects 
(Ryan, Li et al. 2011; Garretson, Teubner et al. 2015). Therefore, we chose to administer 
the high end of this dose (10 mM, or 5.53 μg) because we were targeting the lateral 
ventricle. Further, Ryan et al reported 3 μg/day of ICV GW9662 (infused from 
subcutaneous osmotic pumps) does not affect body weight, but does reduce 
hypothalamic PPARg activity (Ryan, Li et al. 2011); therefore, we used the same dose 
and administration route for chronic studies.   
For acute infusions, 1 mg of pure GW9662 was dissolved in 180.7 μL of 100% 
DMSO (D8418, Sigma Aldrich, St. Louis, MO) and gently mixed until fully dissolved. 
Next, 180.7 μL of sterile saline was added (final concentration of 2.765 μg/μL), and <1 
μL of sterile 1 N HCl was used to bring pH to 7.5. 50% DMSO (pH = 7.5) was used as 
vehicle. Solutions were made fresh prior to every infusion. For chronic infusions, mini 
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osmotic pumps (1002, Azlet, Cupertino, CA) were filled with GW9662 (0.5 μg/μL) or 
vehicle (33% DMSO, 67% sterile DI water). Pumps were then attached to silicone tubing 
(CT24SR, PlasticsOne, Roanoke, VA) which were push fit to ICV cannula (3300P/SP, 
cut 2.2 mm below pedestal, PlasticsOne). The pump-tubing-cannula apparatus was 
checked for complete absence of bubbles, and stored in sterile saline at room 
temperature overnight prior to surgery.  
 
Homecage Locomotor Activity 
 Animals were single housed with low bedding and no nestlet at least one week 
prior to data collection of locomotor activity (Opto-M4, Columbus Instruments, 
Columbus, OH). Beam break data was collected for both x- and y-axes and output into 
10 second bins. Locomotor activity is reported as the aggregate number of beams 
broken within the indicated time frame. Locomotor-estimated wakefulness is calculated 
using the ’40-second’ algorithm, which considers 0 beams broken in at least four 
consecutive 10-second epochs as ‘sleep’, and everything else as ‘wake’; this has >90% 
agreement with EEG-recorded sleep (Pack, Galante et al. 2007). All data was analyzed 
in MATLAB (Natick, MA). 
 
EEG Signal Acquisition and Analysis 
Animals were allowed one week of post-operative recovery, attached to 
recording cables, and then given an additional week of acclimation prior to EEG/EMG 
signal acquisition. Signals were amplified, digitized, and filtered as previously described 
(see Chapter 2). Polysomnographic signals were segmented into 4-second epochs and 
manually scored as wake, NREM, or REM by a blinded, experienced investigator in 
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SleepSign for Animals (Kissei Contec Co., Nagano, JAP). Total time in each behavioral 
state and sleep/wake fragmentation was calculated using MATLAB. 
 
Acute ICV Infusions 
Polyethylene tubing (C313CT, PlasticsOne) was push-fit onto an internal guide 
cannula (28 gauge, C313I/SPC) on one end and a 23-gauge needle on the other 
(305193, BD Falcon, Franklin Lakes, NJ); the needle was sealed with Parafilm (PM998, 
Fischer Scientific, Waltham, MA). The apparatus was filled with mineral oil and 
assembled to a 10 μL Luer tip syringe (80001, Hamilton Syringes, Reno, NV). There 
were no bubbles in the apparatus prior to infusion. The infusion rate was set to 1 μL/min 
and a total volume of 2 μL was infused. Animals were detached from recording hardware 
(with tether cables still attached), lightly restrained, and had dummy inserts removed and 
internal cannula inserted (without any anesthetic). Following infusions, the internal 
cannula was left in place for at least 1 minute before removal and replacement with the 
dummy cap. Animals were reattached to polysomnography hardware and sleep/wake 
was immediately recorded. Animals were infused two at one time, taking 5-10 minutes in 
total for each infusion. Prior to any infusion, all animals were handed 3-5 times (5-10 
minutes each time) to allow acclimation to investigators. Prior to GW9662 or vehicle 
infusion, cannula placement was verified in vivo using angiotensin II (1 μL of 20 ng/μL, 
H-1705, Bachem, Bubendorf, SUI) dissolved in sterile saline. All animals in the study 
robustly drank water (>3 mL) immediately following the angiotensin infusion.  
 
RT-qPCR 
 Purified hypothalamic mRNA was obtained as previously described (Panossian, 
Fenik et al. 2011; Zhang, Zhu et al. 2014). Briefly, animals were deeply anesthetized 
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using pentobarbital between ZT11-12, and perfused with ice-cold phosphate-buffered 
saline (PBS) solution with RNAse inhibitor (N8080119, ThermoFisher). Brains were 
removed and the hypothalamus was excised on a chilled brain block. This tissue was 
then digested in Trizol (15596026, Fisher Scientific) and chloroform (366927, Sigma 
Aldrich) and precipitated in isopropanol (I9030, Sigma Aldrich). Purified mRNA was 
converted to cDNA, and Taqman real-time qPCR (SDS 7500 Real Time PCR System, 
Fischer Scientific) was used to quantify transcript expression. Custom primer-probes 
were designed for PPARg (NCBI Reference: NM_011146.3), PPAR-alpha (PPARa; 
NCBI Reference: NM_011144.6), PPAR-beta/delta (PPARbd; NCBI Reference: 
NM_011145.3), and Lpl (NM_008509.2), and validated prior to use; 18S was used as 
housekeeping (Table S1). All genes were reliably expressed in hypothalamic tissue (80 
ng reactions) with average Ct values ranging from 28-31 (not shown).  
 
Immunohistochemistry 
 The immunohistochemistry (IHC) protocol is similar to previously described 
(Zhang, Zhu et al. 2014). Animals were deeply anesthetized and transcardially perfused 
with ice-cold 4% paraformaldehyde (PF; pH = 7.5). Brains were left in 4% PF overnight, 
and then switched to 30% sucrose the following day. A cryostat was used to coronally 
section the brains (50 μm) and free-floating sections were placed into blocking buffer 
(4% normal donkey serum and 0.4% Triton-X in 1x PBS) overnight. The following day, 
anti-PPARg (1:100, 07-466, EMD Millipore, Billerica, MA) and anti-NeuN (1:1000, 
MAB377, EMD Millipore) was diluted in blocking buffer. Brain slices were incubated in 
primary antibody at 4°C on a shaker for 3 days. The primary was then washed off thrice 
with 1X PBS, and the secondary antibodies (A21203 and A21206, Invitrogen, Carlsbad, 
CA) were applied (1:500 in 50% blocking buffer:50% 1X PBS) for 1 hour. After the 
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second wash, DAPI (1:20,000) was applied for 5 minutes, and then the brain slices were 
washed three times more. Brains were then mounted onto microscope slides with 
Fluoromount G (17984-25, EMS, Hatfield, PA) and imaged on an epifluorescent 
microscope (DM5500B, Leica Microsystems, Wetzlar, GER).  
 
Western Blotting 
 Western blotting was conducted as previously described (Panossian, Fenik et al. 
2011; Zhang, Zhu et al. 2014). Briefly, hypothalamic extracts were homogenized on ice 
in a protease-containing lysis buffer. Protein concentrations were quantified using a 
Pierce BCA assay (23225, Fisher Scientific), and 20 μg of protein was run on a 10% 
SDS-PAGE gel (4561033EDU, Biorad, Hercules, CA). Gels were wet transferred to 
polyvinylidene difluoride membranes and immunoblotted against PPARg (1:50 dilution, 
07-466, EMD Millipore) and beta-tubulin (1:1000 dilution, SC-8035, Santa Cruz Biotech, 
Dallas, TX). Bands were detecting using the Odyssey Imaging System (Li-Cor, Lincoln, 
NE).  
 
Statistics 
 All statistical analysis and graph generation was conducted in PRISM (GraphPad 
Software, La Jolla, CA). Simple comparisons between two groups were conducted by a 
Student’s t-test. Comparisons between three or more groups were conducted by a one-
way analysis of variance (ANOVA) with Holm-Sidak post hoc corrections. Comparisons 
between conditions that spanned multiple time points were conducted by a two-way 
repeated-measures ANOVA, with ‘time’ as the within-subjects variable and 
‘drug/genotype’ as the between-subjects variable. Significance was achieved at p<0.05 
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(denoted by one or more asterisks), although trends towards significance were reported 
when appropriate. 
 
RESULTS 
Multiple reports have detected PPARg expression in the hypothalamus using 
IHC, in situ hybridization, and/or RT-qPCR approaches (Cullingford, Bhakoo et al. 1998; 
Moreno, Farioli-Vecchioli et al. 2004; Sarruf, Yu et al. 2009; Diano, Liu et al. 2011; 
Garretson, Teubner et al. 2015). Therefore, we wanted to confirm these findings by 
detecting both PPARg transcript and protein in hypothalamic tissue. First, we used RT-
qPCR to measure levels of hypothalamic PPARg. We used hypothalamic tissue from a 
previous experiment that measured transcriptional homeostasis in response to acute 
sleep deprivation (3 hours) and sleep restriction (8 hours per day for 3 days) compared 
to rested controls (Zhang, Zhu et al. 2014). Since extending wakefulness is associated 
with hyperphagia and positive energy balance, we predicted that PPARg expression and 
its downstream target lipoprotein lipase (Lpl) would be increased in sleep deprived and 
restricted animals. While we did not detect significant differences across waking 
conditions (Figure 1AB: p>0.05 for both), this experiment confirmed that PPARg and Lpl 
transcript were present in hypothalamic tissue. Next, we attempted to quantify PPARg 
protein levels in the hypothalamus. IHC against PPARg revealed diffuse staining 
throughout the ventral hypothalamus without strong localization to either neurons (NeuN) 
or nuclei (DAPI) (Figure1C-F).  We then used the same anti-PPARg antibody to probe 
for protein expression via western blotting (Figure 1G). Liver tissue yielded three 
identifiable bands including bands at 58 kDA, the predicted molecular weight for PPARg. 
We also detected a single band in hypothalamic tissue, but did not observe a band at 58 
kDa. Taken together, we were able to detect PPARg transcript in hypothalamic tissue, 
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but the only protein signal detected was potentially off-target, evidenced by the presence 
of non-specific bands and non-nuclear signal.  
Previous studies have used Cre/LoxP technology to restrict PPARg KO to either 
all neurons or a subtype of hypothalamic neurons (Lu, Sarruf et al. 2011; Long, Toda et 
al. 2014); both strains are metabolically normal on RC, but are mildly protected from 
HFD-induced obesity and exhibit a hyperlocomotive phenotype.  Therefore, we 
hypothesized that PPARg xKO (generated by crossing Nkx2.1-Cre mice with PPARg 
floxed mice) would be similar to controls when consuming RC, but would not exhibit 
stereotypical HFD-induced hypersomnolence. Indeed, we found no body weight or 
caloric intake differences between mutant (MUT; PPARg xKO) mice and wildtype (WT) 
controls at Week 0, when all animals consumed RC (Figure 2AB: p>0.05 for both). 
Following 8 weeks of HFD, controls weighed significantly more than MUT mice, although 
this effect was absent when normalizing to baseline weight (Figure 2A). Caloric intake 
was similar between transgenic and control strains at Week 8 (Figure 2B). Further, 
sleep/wake behavior was similar between HFD-fed control and PPARg xKO mice, 
specifically total wake time and total NREM time during the dark phase, as well as wake 
bout number and distribution of wake bout lengths (Figure 2C-F: p>0.05 for all 
comparisons). Next, we determined if PPARg xKO mice would be hyperactive on HFD 
despite the lack of sleep/wake differences. We found no body weight or caloric intake 
differences between MUT and WT animals on either RC or HFD (Figure 3AB: p>0.05 for 
both). Furthermore, we did not find any locomotor or locomotor-estimated wake 
differences at either Week 0 (on RC, not shown) or after four weeks of HFD (Figure 
3CD: p>0.05 for both). Last, we took hypothalamic and hindbrain punches from the mice 
placed in locomotor boxes and probed for PPARg, PPARa, PPARbd, and Lpl 
expression. We found that hypothalamic PPARg was higher in MUT mice compared to 
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WT, with no expression differences in the hindbrain (Figure S1A). Gene expression 
levels of Lpl and other PPAR isoforms were similar between genotypes in both brain 
regions (Figure S1B-D), although PPARbd was significantly higher in the hindbrain of 
MUT mice (Figure S1D). These results suggest that our genetic cross was ineffective at 
reducing hypothalamic PPARg. Taken together, our results suggest that PPARg xKO 
mice do not show differences in body weight, caloric intake, sleep/wake behavior, or 
locomotor activity, which is likely because PPARg xKO mice have normal (or elevated) 
PPARg expression levels. 
While experiments with PPARg xKO mice were ongoing, we also tested whether 
acute or chronic inhibition of PPARg activity would affect HFD-induced sleep changes. 
First, we tested how pharmacological PPARg inhibition (using GW9662) would affect 
locomotor-estimated wakefulness during initiation of HFD consumption. We used a low 
dose of GW9662 that has previously been shown to not affect body weight, but does 
decrease Lpl transcript levels (Ryan, Li et al. 2011). Indeed, we found neither body 
weight nor caloric intake was affected by GW9662 administration, but Lpl levels were 
similar to RC-fed controls (Figure 4A-C). Further, we found locomotor activity was similar 
between all conditions, but GW9662 trended towards rescuing HFD-induced decreases 
in activity (Figure 4D: p=0.5150). We estimated total wake time from this locomotor data, 
using the 40-second algorithm of inactivity to estimate sleep states. While overall 
significance was not achieved (Figure 4E: p=0.0607), our data suggests HFD decreases 
total wake time which is partially rescued by GW9662. Thus, continuous infusion of 
GW9662 normalizes hypothalamic Lpl levels and trends towards rescuing HFD-induced 
locomotor and locomotor-estimated wakefulness decreases.  
We also tested whether a single ICV infusion of GW9662 could acutely rescue 
wake impairments in HFD-fed mice. Animals were surgicated for ICV guide cannula and 
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EEG/EMG recording electrodes and then fed HFD for 6 weeks. Sleep/wake behavior 
during the dark period was recorded following gentle handling (no infusion, ZT11.5). 
Three days later, we quantified sleep/wake behavior following a single infusion of either 
GW9662 or vehicle, then repeated the infusion protocol (each animal received the same 
treatment again) the following week. We found that GW9662 trended towards reducing 
body weight and caloric intake compared to VEH infusions, although this effect was not 
statistically significant (Figure 5AB: p>0.05 for both). Furthermore, GW9662 had no 
effect on total wake, NREM, or REM time (Figure C: p>0.05 for all). However, GW9662 
did significantly increase both the number of wake and NREM bouts (Figure 5D: p<0.05 
for both) and trended towards reducing NREM bout length (Figure 5E: p = 0.0695), 
suggesting a worsened fragmentation phenotype. There was no effect on distribution of 
wake bouts, suggesting a stronger influence on sleep bout architecture (Figure 5F: 
p>0.05 for all comparisons). However, we also compared the effects of the infusion 
protocol on sleep/wake behavior by comparing to the no infusion time point. We found 
that infusions (whether VEH or GW9662) robustly reduced body weight (p<0.001), 
caloric intake (p<0.001), and total wake time (p<0.01) while also increasing the number 
of wake bouts (p<0.0001) compared to gentle handling (Figure S2). Therefore, acute 
GW9662-mediated PPARg antagonism moderately increases sleep/wake fragmentation 
in HFD-fed animals, but this effect is minor compared to the profound effects induced by 
the vehicle solution (50% DMSO, pH = 7.5).  
 
DISCUSSION 
 Using both pharmacological and transgenic approaches, we tested whether 
central PPARg is necessary for the stereotyped increase in sleep time and sleep/wake 
fragmentation induced by HFD-consumption. While disrupting PPARg signaling 
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moderately reduced caloric intake and body weight, we did not find strong evidence that 
this manipulation rescues or prevents stereotyped sleep/wake abnormalities observed in 
HFD-fed mice; in fact, most metrics trended towards a worsened phenotype. Further, we 
were unable to detect a reliable, strong signal for PPARg protein within the 
hypothalamus, which may explain these minor behavioral effects. 
Multiple studies have reported PPARg expression in brain tissue, but the 
experiments within do not replicate many of these findings. Classically studied in 
peripheral cells such as adipocytes and hepatocytes, PPARg has long been known to 
play a crucial role in adipogenesis, metabolism, and insulin sensitization (Spiegelman, 
Hu et al. 1997; Varga, Czimmerer et al. 2011; Grygiel-Gorniak 2014). Indeed, 
thiazolidinediones (TZDs) are potent PPARg agonists that are FDA-approved to treat 
type 2 diabetes (Hauner 2002). While these drugs are effective at restoring insulin 
sensitivity, one notable side effect is weight gain. Although some of this excess weight 
can be attributed to edema, food intake and adiposity is increased following oral 
treatment with TZDs (Emilsson, O'Dowd et al. 2000).  Furthermore, adipose PPARg 
levels are elevated in obese people (Vidal-Puig, Jimenez-Linan et al. 1996; Vidal-Puig, 
Considine et al. 1997), suggesting a potential maladaptive response that may perpetuate 
positive energy balance. Recently, PPARg mRNA and protein was detected throughout 
the brain, with enrichment in hypothalamic neurons (Moreno, Farioli-Vecchioli et al. 
2004; Sarruf, Yu et al. 2009). Further, two studies report increased PPARg mRNA in the 
hypothalamus of DIO animals (Diano, Liu et al. 2011; Cifani, Micioni Di Bonaventura et 
al. 2015), suggesting a similar maladaptive response in the brain. In the present study, 
we also detected hypothalamic PPARg transcript by RT-qPCR. However, unbiased gene 
expression assays, such as RNA-sequencing, detects PPARg transcript at extremely 
low levels relative to other genes (~10 reads per >18 million) (Zhang, Chen et al. 2014, 
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Chapter 4, Perron et al.). Therefore, hypothalamic PPARg may be theoretically 
detectable with RT-qPCR or in situ hybridization, but with very low absolute expression. 
This idea is supported by our western blot results, which did not show a band at the 
predicted size for PPARg protein (58 kDa) in hypothalamic tissue. Further, western 
blotting did detect a band at the wrong size (44 kDA), indicating a potential off-target 
effect that may explain the diffuse, non-nuclear staining observed with IHC. 
Nonetheless, it is still unclear why some reports have found strong nuclear PPARg 
immunostaining in brain tissue (Sarruf, Yu et al. 2009). Since the primary antibody used 
was the same, these differences likely result from dissimilarities in tissue collection 
and/or preparation. Thus, PPARg transcript and protein may be detectable by 
biochemical techniques, but the absolute expression levels may not be robust.  
In addition to its detection, central PPARg was shown to be physiologically 
relevant to maintain body weight and energy homeostasis. HFD-fed mice lacking PPARg 
in all neurons (Synapsin I-Cre) or in POMC-expressing neurons are hyperactive 
compared to littermate controls (Lu, Sarruf et al. 2011; Long, Toda et al. 2014), 
indicating that HFD-induced hypersomnolence may be absent in these animals. 
However, our present studies found that PPARg xKO mice (theoretically lacking PPARg 
in Nkx2.1-expressing cells) were metabolically and behaviorally normal on both RC and 
HFD. While the lack of phenotype was unexpected, there are some possible 
explanations. First, Nkx2.1 is not expressed in all neurons, with enrichment in the 
forebrain and hypothalamus (Xu, Tam et al. 2008; Yee, Wang et al. 2009; Ring and 
Zeltser 2010). Therefore, it is possible that the remaining PPARg-positive neurons were 
capable of mediating HFD-induced metabolic and behavioral changes. However, this is 
unlikely since Nkx2.1 is densely expressed throughout the hypothalamus including 
>75% of POMC neurons (Yee, Wang et al. 2009). Second, the previous studies 
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maintained mice on HFD for much longer (16 weeks), and some metabolic differences 
(such as body weight differences) did not present until 8 weeks on HFD or later (Diano, 
Liu et al. 2011; Lu, Sarruf et al. 2011). In the current study, PPARg xKO mice were 
maintained on HFD for 8 weeks or less when tested for sleep and locomotor behavior. 
Therefore, it is possible that the role of central PPARg does not become clear until very 
long exposure to HFD, or in older animals (regardless of weeks on HFD). However, this 
also appears unlikely since the profound hyperlocomotive phenotype in pan-neuronal 
PPARg KO mice was observed following 6 weeks on HFD, even when body weight was 
similar between mouse strains (Lu, Sarruf et al. 2011). Third, it is possible that issues 
with this novel transgenic mouse strain did not yield a functional knockdown of 
hypothalamic PPARg. Indeed, our RT-qPCR results did not detect PPARg 
downregulation in the hypothalamus (instead showing significant upregulation; Figure 
S1. Taken together, it is unclear why we did not observe strong metabolic or sleep/wake 
differences between PPARg xKO mice and littermate controls, but these negative results 
further the notion that central PPARg may only play a minor role in mediating HFD-
induced behavioral changes.  
Pharmacological activation or inhibition of central PPARg activity has been 
shown to induce striking behavioral changes. Specifically, central or peripheral 
administered PPARg agonists stimulate hyperphagia and weight gain in a brain PPARg-
dependent manner (Lu, Sarruf et al. 2011; Ryan, Li et al. 2011; Garretson, Teubner et al. 
2015). The present studies used similar approaches, but we did not find significant 
effects on weight change or caloric consumption. One likely reason could be related to 
the location of the infusions. Ryan et al found HFD consumption was reduced in rats 
administered GW9662 into the 3rd ventricle (2011), whereas our studies infused 
GW9662 into the lateral ventricles. We purposefully used a higher dose (5 μg compared 
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to 1 μg) because of this anatomical difference, but it is possible that the drug did not 
reach the hypothalamus or other relevant brain site.  This could be determined by 
punching hypothalamic tissue and quantifying PPARg genes (such as Lpl). Indeed, 
chronic ICV infusion of GW9662 reduced hypothalamic Lpl levels, but it is unknown 
whether Lpl was affected after acute PPARg antagonism. Second, GW9662 is a 
lipophilic compound that has low solubility in water or saline. Therefore, it must be 
diluted in solutions containing at least 33% DMSO, which has many deleterious effects 
on its own. This is clearly observed in Figure S2, where these infusions caused 
pronounced decreases in food intake and body weight and worsened wake impairments 
compared to no infusion controls. Thus, a strong insult such as DMSO may mask the 
mild to moderate effects of central PPARg on metabolic and sleep phenotypes. Further, 
it is unclear how stable GW9662 is in solution, both related to its ability to stay in solution 
and to stay bioactive at 37°C. Taken together, pharmacological approaches are powerful 
tools to study the importance of a single protein in mediating a specific behavior, but 
solubility limitations of GW9662 required the use of a high-DMSO containing solvent, 
which had stronger metabolic and sleep effects than GW9662 alone. 
As detailed extensively, these studies are limited in a number of ways. First, 
without a reliable method to quantify PPARg, we could not definitively test how PPARg 
expression or activity was affected by metabolic or sleep challenges. Further, while we 
showed transcript levels of all PPAR isoforms and Lpl were either unchanged our 
upregulated in PPARg xKO mice (Figure S1), we were unable to quantify protein 
expression and thus could not validate the efficiency of PPARg KO in our novel 
transgenic mouse line. In hindsight, initiating these sleep/wake experiments with an 
established mouse line (such as the pan-neuronal PPARg KO) would have been better. 
Second, while we observed a promising trend of chronic GW9662 rescuing HFD-induced 
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hypersomnolence (Figure 4), this was based off of locomotor data, not EEG. Not only 
was raw activity statistically similar between all three conditions (p = 0.5150), but 
emerging evidence has found that the locomotor-based algorithm to estimate 
wakefulness is not reliable for HFD-fed mice (Chapter 4, Perron et al.). Third, despite 
making GW9662 solutions immediately prior to acute infusions, particulate formation 
was evident within minutes. Therefore, the actual administered dose may be below 5 μg. 
This highlights the necessity to quantify central and hypothalamic Lpl expression, as 
previously mentioned.  
Altogether, the current studies do not provide strong evidence for PPARg 
involvement mediating HFD-induced sleep alterations. While some of these reasons 
may be technical in nature, the lack of robust PPARg protein signal in hypothalamic 
tissue suggests that this protein may only have mild to moderate effects on metabolic (or 
other) behaviors. While it is still of great importance to understand the molecular 
underpinnings linking metabolism and sleep, central PPARg appears to not play a strong 
role in modulating sleep in response to changes in diet and energy balance.  
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Figure 3.1: Hypothalamic expression of PPARg. RT-qPCR of hypothalamic tissue for 
PPARg (A) and the downstream gene Lpl (B) shows no difference between rested 
animals, 3 hours of sleep deprivation (SD, ZT8-11), and 3 days of sleep restriction (SR, 
ZT3-11 with undisturbed sleep otherwise). Nonetheless, this approach detected both 
PPARg and Lpl transcript in the hypothalamus (average Ct values ranging from 28-31, 
not shown). Immunohistochemistry was used to detect PPARg (C), neurons (D), and cell 
nuclei (E) in coronal brain slices. While diffuse PPARg expression is detected throughout 
the ventral hypothalamus, it does not co-localize with DAPI (F) as expected, suggesting 
non-specific binding. (G) Western blotting of hypothalamic and liver tissue shows 
multiple bands using the PPARg antibody, but only a clear band for liver tissue at the 
predicted molecular weight (58 kDA); beta-tubulin (~50 kDA) was used as 
housekeeping.  
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Figure 3.2: PPARg xKO mice exhibit normal sleep architecture. (A) Body weight is 
similar between wildtype (WT) and PPARg xKO mutants (MUT) while consuming RC 
during Week 0. However, MUT mice are moderately protected from HFD-induced weight 
gain by Week 8, although this effect is absent when normalizing to Week 0 body weight. 
(B) 24-hour caloric intake is similar between WT and MUT groups at both Week 0 and 
Week 8, with trends similar to body weight. Neither total wake time (C) nor total NREM 
time (D) during the dark phase (ZT 12- 24) is different between WT and MUT mice, 
although mutants are trending towards a hypersomnolent phenotype. (E,F) Bout 
architecture during the dark phase is similar between PPARg xKO and control mice. WT: 
n = 8, MUT: n = 7. *p<0.05. 
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Figure 3.3: PPARg xKO mice exhibit normal locomotor activity. (A) Body weight is 
similar between wildtype (WT) and PPARg xKO (MUT) mice on both RC (Week 0) and 
the first four weeks on HFD. (B) Caloric intake is statistically similar on both RC and 
HFD. Further, there are no behavioral differences between these mice at Week 0 (not 
shown) or following 4 weeks on HFD, specifically related to locomotor activity (C) and 
activity-estimated wake time (D). WT: n = 9, MUT: n = 9.  
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Figure 3.4: Chronic PPARg antagonism trends towards preventing locomotor-
estimated wake decreases. Mice were implanted with subcutaneous osmotic pumps 
attached to ICV cannula and then fed either RC or HFD for 14 days (RC-GW9662 
condition was not tested).  The low-dose of continuous GW9662 did not affect body 
weight (A) or caloric intake (B) compared to HFD-VEH condition. However, hypothalamic 
Lpl levels were normalized in HFD-GW9662 compared to HFD-VEH (C). On the final day 
of activity monitoring (Day 14), locomotor activity was similar between all three groups 
during the dark period (D), although HFD-VEH trended towards reduced activity 
compared to the other two conditions. (E) Activity-estimated wake time during the dark 
period trended towards a reduction in HFD-VEH compared to both RC-VEH and HFD-
GW9662. RC-VEH: n = 6, HFD-VEH: n = 7, HFD-GW9662: n = 7. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 for indicated comparisons or to RC-VEH when not indicated.  
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Figure 3.5: Acute GW9662 moderately increases sleep fragmentation, with no 
effect on total sleep/wake times. ICV administered GW9662 (between ZT11-12) 
slightly decreased body weight (A) and caloric intake (B), although neither of these 
effects were statistically significant. (C) Total time spent in each behavioral state 
following the infusion was similar between vehicle and GW9662. However, GW9662-
infused animals exhibited greater sleep/wake fragmentation, with wake and NREM bout 
numbers significantly elevated (D) and NREM bout lengths trending towards a significant 
decrease (E). (F) Wake bout distribution was similar between VEH and GW9662. VEH: n 
= 8, GW9662: n = 12. +p<0.1, *p<0.05. 
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Figure 3.S1: PPARg xKO mice do not show expected decreases in PPARg and Lpl 
transcript levels. Hypothalamic and hindbrain punches were obtained from PPARg 
xKO mice and littermate controls which were run in locomotor boxes; RT-qPCR was 
used to assess gene expression. (A) Hypothalamic PPARg was upregulated in the 
hypothalamus, which is the opposite of the expected result; hindbrain PPARg was 
unaffected. (B) Lpl, a downstream PPARg target, showed no transcript changes in either 
brain region. (C) PPARa transcript levels were similar in both the hypothalamus and 
hindbrain. (D) PPARbd mRNA was similar in the hypothalamus, with a significant 
increase in MUT mice compared to controls. n = 9, MUT: n = 9. *p<0.05.   
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Figure 3.S2: ICV infusions of either vehicle or GW9662 greatly influence energy 
balance and sleep architecture. No infusion controls were handled at ZT11.5, while 
Infusions 1 and 2 were identical. Infusions of either vehicle or GW9662 profoundly 
decreased body weight (A), caloric intake (B), and total wake time (C) while increasing 
number of wake bouts (D). VEH: n = 4, GW9662: n = 6. **p<0.01, ***p<0.001, 
****p<0.0001.  
  
95 
 
Primer Description Primer Sequence (5’ → 3’) 
For Genotyping 
 Nkx2.1-Cre Transgene FOR CTCTGGTGGCTGCCTAAAAC 
 Nkx2.1-Cre Transgene REV CGGTTATTCAACTTGCACCA 
 
Internal positive control for 
Nkx2.1-Cre FOR 
CTAGGCCACAGAATTGAAAGATCT 
 
Internal positive control for 
Nkx2.1-Cre REV 
GTAGGTGGAAATTCTAGCATCATCC 
 PPARg flox FOR TGTAATGGAAGGGCAAAAGG 
 PPARg flox REV TGGCTTCCAGTGCATAAGTT 
For RT-qPCR 
 PPARg FOR ATGACCAAGTGACTCTGCTCAAGTA 
 PPARg REV GAGGAACTCCCTGGTCATGAAT 
 PPARg Probe CATCTACACGATGCTGGCCTCCCTG 
 PPARa FOR TGAGAACAGGAATCTAAACCCATCT 
 PPARa REV GGTCTTGGGAGTCAGCCATATA 
 PPARa Probe CCACCAGGCACCACTCTGTCCT 
 PPARbd FOR TTCGAGTTTGCTGTCAAGTTCAAT 
 PPARbd REV TGGTGTCCTGGATGGCTTCTA 
 PPARbd Probe ACCTGGCGCTCTTCATCGCGG 
 Lpl FOR CAGTCTCAAATATTAAACGGTGGCTAA 
 Lpl REV GGGAGCAAATGATTCCTTCTTAAG 
 Lpl Probe TGGCCCATAGCAGGTCTTCCAGCA 
 18S FOR GTAAGTGCGGGCCATAAGCTT 
 18S REV AGTCAAGTTCGACCGTCTTCTCA 
 18S Probe ACACCGCCCGTCGCTACTACCGA 
 
Table 3.S1: Primers used for genotyping and RT-qPCR experiments.   
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Table 3.S2: Summary of various surgical procedures for included experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Behavioral Study Surgical Procedure 
Transgenic PPARg xKO mice  
 Locomotor Activity None 
 Sleep Recordings EEG/EMG 
Pharmacological PPARg Antagonism  
 Chronic (Locomotor Activity) Subcutaneous osmotic pump +  ICV cannula 
 Acute (Sleep Recordings) EEG/EMG + ICV guide cannula 
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ABSTRACT 
 Associated with numerous metabolic and behavioral abnormalities, obesity is 
classified by metrics reliant on body weight (such as body mass index). However, 
overnutrition is the common cause of obesity, and may independently contribute to these 
obesity-related abnormalities.  The goal of this study is to isolate ‘diet/energy balance’ 
effects independent from ‘body weight’ effects on various metabolic and behavioral 
parameters using the Diet Switch feeding paradigm in mice. We found spontaneous 
activity patterns are negatively correlated with body weight (p<0.0001) with no relation to 
diet/energy balance (p=0.63). Furthermore, both body weight and diet/energy balance 
predict circulating glucose and insulin levels, while body weight alone predicts plasma 
leptin and thyroxine (T4) levels. These measurements were complemented by unbiased 
gene expression analysis of the nutrient-sensing circumventricular hypothalamus. 
Remarkably, only two genes responded to diet/energy balance (neuropeptide y [npy] 
and agouti-related peptide [agrp]), while others were related only to body weight. 
Furthermore, linear regression models revealed that npy and agrp showed similar 
modifiability by diet/energy balance and body weight compared to 
electroencephalographic-measured wake time. Collectively, these results demonstrate 
that acute changes to diet/energy balance should be considered when assessing 
metabolic health, thereby highlighting the shortcomings of metrics which solely rely on 
body mass. Additionally, we identify clinically obtainable metrics that are affected by 
diet/energy balance independent of body weight, which may be better indicators of 
metabolic health. 
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INTRODUCTION 
Obesity and overweightness are conditions of excessive fat or body weight, 
typically quantified by the body mass index (BMI: weight / height2) in humans. Currently, 
over 70% of American adults are overweight (BMI > 25 kg/m2) with roughly half of those 
people considered obese (BMI > 30 kg/m2) (Ogden, Carroll et al. 2014). Obesity is a risk 
factor for numerous morbidities, including hypertension, type II diabetes, neurological 
disorders (such as depression), and sleep disorders (such as sleep apnea) (Pi-Sunyer 
2009; Berenson and Bogalusa Heart Study 2012; Panossian and Veasey 2012). 
Therefore, there is great incentive to determine the links between obesity and 
physiological dysregulation.  
Excess body weight per se is not the only predictor of molecular, metabolic, and 
behavioral abnormalities. Some studies have tracked obese individuals shortly after 
bariatric surgery (<4 weeks), when weight loss has been initiated but these people are 
still considered obese (BMI > 30 kg/m2). These patients exhibit reductions in 
hypertension, normalization of many blood metabolite levels, and significant 
improvements in subjective sleepiness and alertness prior to significant weight loss 
(Varela, Hinojosa et al. 2007; Kashyap, Gatmaitan et al. 2010; Narath, Mautner et al. 
2016). Second, moderate diet-induced weight loss in humans improves cardiometabolic 
health outcomes (Berk, Mulder et al. 2016; Joris, Plat et al. 2017). Third, studies with 
diet-induced obese (DIO) mice following weight loss show similar effects to humans. DIO 
mice switched to a leptogenic diet show normalized glucose tolerance and insulin 
sensitivity, even though they weigh significantly more than lean controls (Agardh and 
Ahren 2012). Furthermore, our previous work using a diet switch feeding paradigm found 
that mice gaining weight on high-fat diet (HFD) exhibit increased total sleep time and 
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sleep/wake fragmentation compared to overweight mice losing weight due to regular 
chow consumption, despite these two groups of mice having nearly identical body weight 
(Chapter 2, Perron et al.). Using linear regression modeling, we demonstrated that body 
weight and diet/energy balance independently influence sleep/wake architecture 
(Chapter 2, Perron et al.). Collectively, these studies demonstrate that diet/energy 
balance could also influence certain obesity-related physiological abnormalities.  
These studies highlight underexplored areas of research, specifically related to 
obesity-related pathogenesis and its reversibility. First, how are metabolic parameters 
affected by initial consumption of HFD, and do these parameters normalize in obese 
animals following weight loss? Second, what is the relative contribution of diet/energy 
balance vs body mass in mediating these changes? Third, can we build hypothesis-
generating models assessing changes in gene expression in relevant brain regions, 
biomarkers in the blood, and spontaneous sleep/wake and locomotor activity and isolate 
their relationship to diet/energy balance and body weight? The present study is focused 
on addressing these broad questions. 
Following initial weight gain induced by high-fat diet consumption, many 
peripheral organs release hormones (e.g., insulin and leptin) which signal to the central 
nervous system (CNS) to reduce caloric intake (Blouet and Schwartz 2010; Grill and 
Hayes 2012). One of the critical brain areas responsible for sensing these circulating 
hormones is the ventral hypothalamus, which contains the arcuate nucleus (ARC), 
ventromedial nucleus (VMN), and paraventricular nucleus (PVN).  These heterogeneous 
populations of neurons directly sense circulating nutrients and hormones because they 
adjoin the 3rd ventricle, thus allowing entry of these hormones into the CNS (Gao and 
Horvath 2008; Blouet and Schwartz 2010; Coll and Yeo 2013). These circumventricular 
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hypothalamic (CVH) nuclei are defined both anatomically and by the neuropeptides they 
express, many of which have roles in energy balance (Leibowitz and Wortley 2004). For 
example, the ARC contains two primary neuronal populations: orexigenic neurons, co-
expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP); and anorexigenic 
neurons, co-expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-
regulated transcript (CARTPT). Importantly, many CVH nuclei, including the ARC, send 
projections to both intra- and extra-hypothalamic brain areas important for regulating 
behavior, including locomotor activity and sleep and wakefulness (Saper, Chou et al. 
2001; Szymusiak and McGinty 2008). Furthermore, CVH neurons express functional 
hormone receptors, including for insulin and leptin, and their activation alters the 
electrochemical properties of these neurons, thereby affecting the synthesis and release 
of neuropeptides (Leibowitz and Wortley 2004; Diano, Liu et al. 2011; Coll and Yeo 
2013). Taken together, CVH contain a heterogeneous population of neurons and 
neuropeptides which work in concert to regulate complex behaviors such as food intake, 
energy expenditure, and sleep/wake. However, it is unclear how the input signals to the 
CVH, the CVH itself, and downstream behaviors are relatively influenced by changes in 
diet/energy balance and body weight.  
We hypothesize that the unique relationships of both diet/energy balance and 
body mass to blood hormones, CVH gene expression, and metabolic and sleep 
phenotypes will help reveal novel relationships between these parameters. To test this, 
we used the aforementioned Diet Switch (DS) feeding paradigm to generate four groups 
of animals which either differed by energetic status (with similar absolute weight) or 
differed by absolute body weight (with relatively neutral energetic balance; see Figure 1). 
In addition to recording locomotor activity and measuring plasma leptin, insulin, and 
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glucose levels, we performed RNA-sequencing on CVH punches to analyze unbiased 
gene expression patterns of these animals and tracked metabolic phenotypes using 
comprehensive lab animal monitoring systems (CLAMS). We used linear regression and 
response surface modeling to isolate the effects of diet/energy balance from body mass, 
finding that some metrics are affected primarily by body weight while others are highly 
modulated by both diet/energy balance and body weight.  
METHODS 
Animals 
Male C57BL/6J mice (12-14 weeks of age) were used for all experiments. The 
Institutional Animal Care and Use Committee (IUCAC) at the University of Pennsylvania 
approved all experimental procedures prior to initiation of these studies. Mice were 
housed at 23°C on a 12:12 h light:dark cycle, with lights-on at 7:00am. Light intensity 
was 100-150 lux during lights ON (Zeitgeber [ZT] 0-12), and 0 lux during lights OFF (ZT 
12-24).  
 
Diet Switch Protocol 
Upon arrival to our facility, mice were weighed (Week 0), ear tagged, and group-
housed while consuming either regular chow (RC; 5001, Lab Diet, St. Louis, MO) or 
high-fat diet (HFD; D12451, Research Diets, New Brunswick, NJ). After 8-10 weeks, 
mice were randomized to either continue consuming their respective diet (RC NoDS or 
HFD NoDS) or switched to the alternate diet (RC → HFD or HFD → RC). All data is 
generated from three cohorts of animals. The first cohort (80 animals) was tested in 
homecage locomotor boxes and used for RNA-sequencing (referred to as ‘RNA-seq 
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mice’, although only a subset of mice were sequenced). Nine mice never completed the 
protocol (due to fight wounds or dehydration by malfunctioning sipper tubes) and one 
mouse lost ~10% body mass in the ‘positive energy balance’ group (RC → HFD); 
therefore, 70 mice were used in total. The group sizes were: RC NoDS, n = 16; RC → 
HFD, n = 21; HFD → RC, n = 19; HFD NoDS, n = 14.  The second cohort (24 animals) 
was placed into CLAMS boxes (referred to as ‘CLAMS mice’); there were n=6 per 
condition. Data for the third cohort of mice was from a previously published manuscript 
observing electroencephalogram (EEG)-recorded sleep behavior (referred to as ‘EEG 
mice’); experimental methods can be found in (Chapter 2, Perron et al.).  
Mice were acclimated to individual housing 7-10 days prior to the Diet Switch 
(DS). For RNA-seq mice, animals underwent 3 days of continuous locomotor monitoring 
before randomization to DS or diet maintenance (no DS, or NoDS). Locomotor activity 
was recorded continuously; food intake and body weight were measured daily between 
ZT2-3. On day 7, mice were sleep deprived from ZT3-6 using novel objects, and 
sacrificed between ZT6-7. This acute sleep deprivation controlled for differences in 
behavioral state, since HFD-fed mice sleep significantly more than RC-fed mice 
(Mavanji, Billington et al. 2012), allowing us to discover genes that may be upstream of 
sleep/wake changes. CLAMS mice underwent a similar protocol, with some exceptions. 
Mice were loaded into CLAMS and remained on their respective diet for >48 hours. They 
were then removed from CLAMS, weighed, and randomized to diet switch or diet 
maintenance. They remained in CLAMS for 4 full days following the DS (the experiment 
could not be extended to 7 days because of technical limitations). CLAMS mice were 
removed from their cages between ZT6-7, weighed, and sacrificed.  
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Homecage locomotor activity and sleep/wake estimation 
Spontaneous activity patterns were recorded using infrared beam splitting 
locomotor boxes (Omnitech Electronics, Columbus, OH). The number of beams broken 
in both x- and y-planes was exported into 10 second bins, which was used to quantify 
activity and estimate sleep/wake architecture as previously described (Pack, Galante et 
al. 2007). Briefly, 40-seconds or longer of inactivity (0 beams broken) is defined as 
‘sleep’ while everything else is defined as ‘wake’; this algorithm has >90% agreement 
with EEG-recorded sleep in healthy, lean mice (Pack, Galante et al. 2007). These 
calculations were performed in MATLAB. 
 
CLAMS 
Oxymax Comprehensive Lab Animal Monitoring System, or CLAMS (Columbus 
Instruments, Columbus, OH) was used to determine various metabolic phenotypes, 
including food intake, locomotor activity, VO2, VCO2, respiratory exchange ratio (RER; 
VCO2/VO2), and heat burned. RER quantifies the source of burned calories, equaling 0.7 
if lipids are burned exclusively, 1.0 if carbohydrates are burned exclusively, and 0.85 if 
an even mix of both is burned (Speakman 2013). Data is binned into light phase, dark 
phase, or total (summation of light and dark for caloric intake and locomotor activity; 
average of light and dark for all other parameters).  
 
Blood and Brain Collection 
Immediately after sacrifice, blood was transferred to heparin-containing 
microtainers (365965, Fisher Scientific, Waltham, MA) and spun at room temperature for 
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10 min at 10,000 rpm. The supernatant was pipetted to clean Eppendorf tubes and 
stored at -80°C. Brains were immediately dissected and flash frozen in dry ice-cold 
isopentane (2-mehtylbutane, Fisher Scientific). Whole brains were stored at -80°C until 
further use. 
 
CVH mRNA isolation 
Whole brains were mounted and sectioned using a cryostat. Beginning at -1.3 
mm anteroposterior of bregma, three 400 µm sections were transferred to a cold RNAse-
free microscope slide. One punch (1.2 mm diameter) of the ventral hypothalamus 
(enriched with ARC, VMN, and PVN nuclei, but not the lateral hypothalamus [LH]) per 
section was transferred to an RNAse-free 2.0 mL Eppendorf tube. The RNeasy mini 
prep (74104, Qiagen, Frederick, MA) was used to isolate mRNA and the eluted mRNA 
product was DNAse treated (2224G1, AM1931, Fisher Scientific) per the manufacturers’ 
protocol. Concentration of purified mRNA was measured using the Nanodop v1.0 (Fisher 
Scientific). To ensure accuracy of punches, we measured gene expression of two ARC 
genes (agrp and pomc) and one LH gene (hypocretin/orexin, or hcrt). Punches that did 
not have 5-fold enrichment of average agrp and pomc compared to hcrt were omitted 
from RNA-seq and future RT-qPCR validation studies. Of 70 brains sectioned, 8 
punches did not meet these quality standards; these ‘enrichment scores’ are shown in 
Table S1.   
 
RNA-sequencing  
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To reduce technical and biological variability, two mRNA samples were pooled 
equally (300 ng mRNA total). We constructed cDNA libraries using the TruSeq Stranded 
mRNA kit (RS-122-2101, Illumnia, San Diego, CA) following the manufacturer’s protocol 
for polyA enrichment. Each sample was quality checked for concentration, molarity, and 
length distribution using the Qubit (3.0, ThermoFisher), BioAnalyzer (2100, Agilent, 
Santa Clara, CA), and Kapa (KK4873, Kapa Biosystems, Wilmington, MA), respectively. 
Three samples did not meet quality control standards (one each from RC NoDS, HFD → 
RC, and HFD NoDS conditions) and were not loaded onto the sequencer. The remaining 
21 samples were equimolarly pooled and run thrice on the HiSeq 4000 system (Illumina, 
~350 million reads per run, 100 bp read, single end). To merge fastq and BAM files from 
the three runs, we used Picard Tools (v2.7.1, http://broadinstitute.github.io/picard/). 
Alignment of fastq files to the mouse reference genome (mm9 build) was conducted with 
STAR (v2.5.1b) using gene models from Ensembl v67 genome annotation (Flicek, 
Amode et al. 2012; Dobin, Davis et al. 2013). Over 95% of reads were aligned to the 
genome for each sample (not shown). To normalize the data, we used 
the Pipeline of RNA-Seq Transformations, or PORT (v0.8.2a-beta), which is based off 
the manuscript: (Li and Tibshirani 2013).  Briefly, PORT recognizes potential 
confounding factors (e.g., ribosomal RNA and mitochondrial DNA) and omits these 
reads from the normalization process. Importantly, our samples had normal ranges and 
distributions of both ribosomal RNA (2.28 – 6.05%) and mitochondrial DNA (0.5 – 1.8%; 
Table S1). Next, PORT identifies the input sample with the fewest number of gene-
mapping reads and randomly re-samples each of the other datasets down to this 
minimum read count. This re-sampling approach accounts for batch effects and 
differences in sequencing depth between the samples, and allows for direct comparison 
between samples (Li and Tibshirani 2013). All samples were re-sampled to 20.98 million 
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reads; the original number of reads per sample is shown in Table S1. All data generated 
and analyzed are available in the Gene Expression Omnibus repository (GSE104709; 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE104709).   
To discover differentially expressed genes, we used two unique approaches. 
First, we used LimmaVoom package (v3.5, https://bioconductor.org/packages/limma), 
which is a linear regression modeling approach originally designed for microarrays and 
now adapted for RNA-seq. Second, we used the microarray analysis of variance, or 
MAANOVA package (v3.5, http://www.bioconductor.org/packages/release/bioc/html/ 
maanova.html), which was also originally designed for microarray analysis. For the 
latter, we added one read to all samples (to omit zeros) and log2 transformed data to 
normally distribute the expression values. Differentially expressed genes were 
considered significant at a false discovery rate (FDR, or q-value) < 0.15. 
 
GSEA 
We used gene set enrichment analysis (GSEA, v3.0) to discover differences in 
enriched pathways between diet switch conditions (Subramanian, Tamayo et al. 2005). 
This approach considers the entire matrix of gene expression data, ranks the genes 
based off the magnitude of differential expression, and identifies coherent expression 
patterns against pre-defined lists for established biochemical pathways.  We input a 
filtered list of genes (99.5% of the greatest expressed genes, 12368 genes total). 
However, GSEA is designed for human gene data sets, so all mouse gene symbols 
were converted to human gene symbols using the Mouse Genome Informatics database 
from the JAX labs website (HOM_MouseHumanSequence.rpt); 1351 genes did not have 
human homologs and were omitted from GSEA. Therefore, a gene expression data for 
108 
 
11,017 genes were input into GSEA and tested against the Hallmark Gene Set (v6.0, 
MSigDB) using ‘gene_set’ permutations (1000 total). We tested both raw and log2 
transformed data, and used a family-wise error rate (FWER) cut-off of p<0.05.  Both raw 
and log2-transformed data returned the same top 5 significantly enriched pathways 
(Table S3). 
 
RT-qPCR 
Purified mRNA was converted to cDNA using the High-Capacity RNA-to-cDNA 
kit (4387406, ThermoFisher). RT-qPCR was performed with pre-mixed Taqman 
primer/probes (4331182, ThermoFisher; see Table S2) and Taqman master mix 
(4369016, ThermoFisher) using 4 ng cDNA per well (10 µL reactions). 384-well plates 
were robotically loaded using the Biomek 3000 (Beckman Coulter, Indianapolis, IN) and 
analyzed using the 7900HT Fast Real-Time PCR System (Fisher Scientific). Each gene 
of interest was normalized to the geometric mean of three housekeeping genes (18s, 
rplp0, and actb); the Ct values of these housekeeping genes did not differ between 
dietary conditions (not shown). Statistical tests and linear modeling were conducted 
using ∆∆Ct values (normalized to RC NoDS), and data are presented as percent change 
from RC NoDS (Hatori, Vollmers et al. 2012).  
 
Blood Biomarkers 
Plasma was thawed on ice, with no more than 2 freeze-thaw cycles prior to all 
measurements. Glucose was measured using the OneTouch Ultra Mini (LifeScan, 
Wayne, PA). Leptin and insulin were measured using the Luminex multiplex kit 
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(MMHMAG-44K-03, EMD Millipore). The thyroid hormones T3 and T4 were also 
measured using the Luminex multiplex kit (RTHYMAG-30K-02, EMD Millipore), and TSH 
was quantified with ELISA (EKU07683, Biomatik, Wilmington, DE).  
 
Statistical Methods 
Linear regression modeling and response surface modeling (RSM) were 
performed in STATA, Version 14 (College Station, TX). All other statistical analyses and 
figures were conducted in PRISM (GraphPad, La Jolla, CA). Analyses compared 
continuous outcome measures of sleep-wake, blood metrics, and gene expression data 
across conditions and examined the associations with body weight and Δbody weight 
(both independently and jointly) within the relevant phenotyped samples of mice. Mean 
comparisons across conditions were performed using a one-way analysis of variance 
(ANOVA) with Holm-Sidak’s post-hoc correction to observe individual group differences. 
When data was stratified across multiple time points, we used a repeated-measure two-
way ANOVA with ‘time’ as the within-subjects variable and ‘diet’ as the between-subjects 
variable. To examine the individual and joint associations of body weight (Post-DS, in 
grams) and/or diet/energy balance (Δbody weight; percent weight change from Pre-DS 
to Post-DS), we utilized linear regression models. Individual associations were examined 
by fitting separate linear regression models for body weight and Δbody weight. To test 
whether each variable had an independent effect (e.g., if body weight is associated 
when controlling for diet/energy balance or vice versa), a joint linear regression model 
was fit, including both body weight and Δbody weight. Primary results from linear 
regression model are presented as model estimated beta-coefficients (β) and standard 
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errors, representing the expected change in outcome for a 1 unit increase in predictor 
(e.g., 1 gram for body weight, or 1% for Δbody weight). In addition, to provide 
comparable estimates between predictors, we calculated standardized β estimates, 
equal to the expected change in outcome for a 1 standard deviation increase in the 
predictor. We also calculated standardized β estimates for both predictor and outcomes 
(Stdxy), equal to the expected Z-score change in outcome for a 1 standard deviation 
increase in the predictor. Statistical significance in these analyses was based on the β-
coefficient of interest, testing the null hypothesis of no association (e.g., H0: β = 0 vs. HA: 
β ≠ 0). The results of all linear modeling analyses are shown in Tables 2-4. Significance 
was achieved at p<0.05, although trends towards significance (p<0.10) were reported 
where appropriate.  
We performed RSM to explore simultaneous linear and non-linear (interaction 
and quadratic) effects of body weight and Δbody weight on dependent variables of 
interest (Marcus, Keenan et al. 2017). The data was fit to the following complex 
regression model: 
E(Y) = β0 + β1∙X1 + β2∙[X1
2] + β3∙X2 + β4∙[X2
2] + β5∙[X1∙X2] + β6∙[X1
2∙X2] + β7∙[X2
2∙X1] 
where X1 = standardized body weight, X2 = standardized Δbody weight, and Y = 
outcome of interest. The relative impact of X1, X2, interactions, and quadratic terms can 
be evaluated through multiple degree-of-freedom tests examining whether the set of 
related β-coefficients are equal to 0. For example, the overall effect of body weight (X1) 
is assessed by testing the null hypothesis H0: β1 = β2 = β5 = β6 = β7 = 0. The 
simultaneous effect of body weight and acute weight changes on the outcome can be 
visualized utilizing a three-dimensional plot of the predicted values of the outcome (in the 
z-axis) across observed ranges of both body weight and Δbody weight. While models 
are fit using all data, these graphs are restricted to the 5th – 95th percentile ranges of the 
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two predictors; however, given less information in the extremes of these ranges, edges 
of the plots should be interpreted more cautiously and models require large numbers of 
samples with robust differences in the output variable (e.g., glucose and insulin metrics 
from RNA-seq mice).  
 
RESULTS 
Diet Switch (DS) to separate diet/energy balance from body mass 
The DS feeding paradigm generates four groups of mice which greatly differ from 
one another by body weight and/or energetic statuses (Figure 1). Specifically, RC ‘No 
Diet Switch’ [NoDS] mice remain lean while HFD NoDS mice develop obesity, but both 
groups’ weight remains stable the final week of the study (although HFD NoDS animals 
trend towards a significant increase; Figure S2: p<0.1). Conversely, the two DS 
conditions are in divergent energetic status, with RC → HFD mice gaining 12.5% body 
mass and HFD → RC losing 15.3% body mass in one week on average (Figure 1B and 
S2D). Importantly, these two groups are similar in regards to absolute body weight one 
week Post-DS (Figure S2C: p=0.17). When modeling all four groups, there is no linear 
relationship between body weight and one-week weight changes (R2 = 8.8x10-5, p = 
0.9387, line not shown). Therefore, the variability achieved across these four dietary 
conditions allows us to build linear models analyzing between-group comparisons for 
each output measurement. 
Locomotor Activity 
 Our previous work found that RC → HFD mice exhibited profound 
hypersomnolence compared to HFD → RC mice, even though these two groups had 
similar body weight at the time of the recording (Chapter 2, Perron et al.). Therefore, we 
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wanted to test if locomotor activity would track similarly and whether locomotor-
estimated wakefulness would match with our EEG-measured sleep experiments. First, 
we analyzed Pre-DS locomotor activity comparing RC vs HFD. We found a significant 
decrease in HFD-induced locomotor activity during the beginning of the dark phase 
(Figure 2A), which appears to correlate with the hypersomnolence phenotype observed 
in DIO mice. However, when total wakefulness was estimated from this locomotor data 
(using the ’40-second’ cut-off threshold), these robust differences disappeared (Figure 
S3C). We attempted to estimate wakefulness using different inactivity cut-off thresholds 
to model sleep (20-seconds, 30-seconds, and 50-seconds), but none of these estimates 
agreed with EEG-measured data (Figure S3). Therefore, we did not use locomotor-
estimated sleep/wake metrics for any future analysis.  
 One week Post-DS, locomotor activity was similar between all groups except 
HFD NoDS which was significantly less active than RC NoDS (p<0.01), RC → HFD 
(p<0.001), and HFD → RC (p<0.01) conditions (Figure 2BC). Further, we found a 
significant negative relationship between locomotor activity and body weight (Figure 2D: 
p<0.0001) but not with ∆body weight (Figure 2E: p=0.6228). This effect was driven by 
activity differences in the dark period; activity patterns during the light period were not 
associated with either body weight or energy balance (Table 2). 
 
CVH Gene Expression 
Unbiased gene expression of the CVH was performed using RNA-seq. There 
were 21517 unique genes aligned, but of this entire gene list, many genes had very low 
expression. Therefore, we compiled a filtered list of aligned genes composed of the 
aggregate 99.5% most expressed genes (representing 57.5% of the total gene list); the 
filtered list contained 12368 genes. We analyzed both the full gene expression set and 
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the filtered list. Initially, we directly compared the two DS conditions (RC → HFD vs HFD 
→ RC) to discover differentially expressed genes (DEG).  However, no genes were 
found significantly different between these two groups (FDR>0.15, not shown). Next, we 
reasoned that any relevant DEGs related to metabolic or behavioral abnormalities seen 
in obesity should be present in RC NoDS vs HFD NoDS comparisons. When comparing 
these two groups, we found a short list of DEGs, many of which were common between 
LimmaVoom and MAANOVA analyses (Table 1: FDR < 0.15). Interestingly, four of these 
DEGs encode neuropeptides with roles in regulating and responding to changes in 
energy balance. Specifically, thyrotropin-releasing hormone (trh) initiates the 
hypothalamus-pituitary-thyroid (HPT) axis, and exogenous administration can decrease 
food intake (Steward, Horan et al. 2003); trh has controversial effects on sleep and 
wakefulness (Chihara, Kato et al. 1977; Buckley, Tormey et al. 1979). Neuropeptide y 
(npy), agouti-related peptide (agrp), and cocaine- and amphetamine regulated transcript 
(cartpt) are enriched in the ARC with well-known roles in food intake (Leibowitz and 
Wortley 2004). Specifically, npy/agrp-expressing neurons promote food intake, while 
carpt neurons (which are co-expressed with proopiomelanocortin [pomc]) inhibit food 
intake.   
To ensure the validity of these results, we performed RT-qPCR on tissue both 
used for RNA-seq and from animals that were not sequenced (Figure 3 and Figure S4). 
We found similar relationships for most genes compared to the RNA-seq results. 
Specifically, agrp and npy were decreased in both RC → HFD and HFD NoDS groups 
compared to both RC NoDS and HFD → RC groups (Figure 3A,B,E,F,I,J). Further, linear 
regression modeling found both agrp and npy levels were negatively associated with 
both body weight and Δbody weight (Table 2). Cartpt was increased primarily in HFD 
NoDS, but not other conditions (Figure 3C,G,K), and was significantly related to body 
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weight, but not diet/energy balance (Table 2). Similarly, trh was increased in HFD NoDS, 
but the diet switch conditions revealed intermediate expression levels (Figure 3D,H,L). 
Indeed, hypothalamic trh levels were positively correlated with body weight, but not 
diet/energy balance (Table 2). We also found that sbno2, serpina3n, and c4b were 
strongly associated with body weight but not energy balance (Figure S4; Table 2). 
Finally, we also measured pomc and hcrt levels, which were not detected by RNA-seq 
as significantly different between RC NoDS and HFD NoDS. We found no mean 
differences between any conditions nor any association with either weight metric for both 
pomc and hcrt (Figure S4; Table 2). Altogether, RNA-sequencing discovered a short list 
of DEGs which were validated in both sequenced and non-sequenced tissue. Most of 
these genes were related to body weight (cartpt, trh, sbno2, serpina3n, c4b) while others 
were related to both diet/energy balance and body weight (agrp, npy).  
Since no genes were differentially expressed between DS conditions, we used 
Gene Set Enrichment Analysis (GSEA) to discover pathways that may significantly differ 
between RC → HFD and HFD → RC groups. We tested the filtered gene list (12368 
genes, 99.5% most expressed) against the Hallmark Molecular Signatures Database, 
which contains 50 gene sets for common biochemical processes. Although there were a 
few enriched pathways (FWER < 0.05), ‘Oxidative Phosphorylation’ showed strongly 
significant differences, with enrichment in HFD → RC compared to RC → HFD (Table 
S3: p<0.0001).   
 
Blood Biomarkers 
 Obesity is the greatest risk factor for type II diabetes, which is characterized by 
hyperglycemia and hyperinsulinemia (Pi-Sunyer 2009). Therefore, we wanted to test 
whether body mass, diet/energy balance, or both contributed to elevated glucose and 
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insulin levels. Glucose levels were significantly elevated in both HFD-consuming groups 
(RC → HFD and HFD NoDS) compared to both RC-consuming groups (HFD → RC and 
RC NoDS; Figure 4). Furthermore, glucose was positively associated with both body 
weight (Figure 4D: p<0.0003) and Δbody weight (Figure 4G: p<0.0001). Insulin showed 
a similar pattern to glucose, although the relationships were not as strong. Specifically, 
insulin levels were highest in HFD NoDS mice, intermediate in RC → HFD mice, and 
lowest in both groups of mice consuming RC (Figure 4B). Further, insulin was strongly 
associated with body weight (Figure 4E: p<0.0001), but only trended towards a positive 
association with Δbody weight (Figure 4H: p<0.0504). However, a joint linear regression 
model that contains both body weight and Δbody weight metrics found significant, 
independent effects of each factor when controlling for the other (Table 2: p<0.0001 for 
body weight, p=0.0031 for Δbody weight).  
 Leptin is synthesized and released from adipocytes, and circulating levels are 
strongly correlated with body weight (Benoit, Clegg et al. 2004; Al Maskari and Alnaqdy 
2006). Indeed, we found RC NoDS had the lowest leptin levels, HFD NoDS had the 
highest levels, and both DS groups had intermediate levels (Figure 4C). Linear modeling 
confirmed that leptin is highly correlated with absolute body weight (Figure 4F: p = 
0.0001) with no relation to Δbody weight (Figure 4I: p=0.2864). Therefore, our findings 
confirm that leptin is a good biomarker to track body mass or adiposity, but not 
diet/energy balance.  
 Having found a significant positive relationship between trh and body weight, we 
wondered whether circulating thyroid factors would exhibit a similar relationship. 
Therefore, we also measured thyroid-stimulating hormone (TSH), triiodothyronine (T3), 
and thyroxine (T4). Due to an unknown reason, TSH levels were highly variable between 
animals and thus limited interpretation of the results (Figure S5A: p=0.9658). Further, 
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59% of samples could not measure plasma T3 above the detection threshold (not 
shown). However, T4 levels were robustly detected in all samples, and while statistically 
similar across all groups (p=0.2046), T4 negatively trended in relation to body weight 
(p=0.0530) but not Δbody weight (p=0.929; Figure S5). Therefore, circulating T4 
decreases as body weight increases (with no relation to diet/energy balance), although 
the exact relation to thyroid hormones and body weight metrics is still unclear. 
 
Metabolic parameters from CLAMS 
Metabolic chambers, such as CLAMS, are valuable tools to detect and quantify 
differences in metabolic processes, such as caloric intake, locomotor behavior, and 
energy expenditure. Therefore, we tested how these parameters were affected by the 
DS feeding paradigm. RC- and HFD-fed mice were placed into CLAMS for 48 hours 
while consuming their respective diet to establish baseline parameters. Then all animals 
were removed, weighed, and randomized to diet switch or diet maintenance; mice were 
sacrificed four days later. CLAMS mice had normal weight response to the diets (Figure 
S6A-F). However, locomotor activity was abnormal in CLAMS, with no observed 
differences during either Pre-DS (Figure S6G: p = 0.1495) or Post-DS (Figure S6H: p = 
0.9150).  
Nonetheless, we found interesting calorimetric differences following the DS. 
Specifically, RER was initially elevated in RC-fed animals compared to HFD-fed animals, 
indicating that RC-fed animals preferentially burned more carbohydrates than fatty acids 
compared to HFD-fed animals (Figure 5A). Immediately following the DS, RER dropped 
drastically in HFD → RC animals, indicating fatty acids were the primary source of 
energy. Conversely, RER in RC → HFD animals was unaffected after the first day, but 
similar to HFD NoDS thereafter (Figure 5C). RER was strongly associated with 
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diet/energy balance (Figure 5G: p=0.0002) but not with body weight (Figure 5E: p = 
0.1380), although the relation to body weight is stronger during the dark period (Table 3: 
p=0.0772). However, it is interesting to note that their relationship trended in opposite 
directions; increased body weight was associated with decreased RER, while acute 
weight gain was associated with increased RER.  VO2, VCO2, and caloric intake all 
followed similar trends to RER (Figure S7A-C, Table 3). Furthermore, CLAMS measures 
the heat produced by the animals, which is an indicator of calories burned (i.e., energy 
expenditure). Prior to the DS, heat is increased in HFD-fed animals compared to RC-fed 
controls (Figure 5B). However, within 24 hours Post-DS, RC → HFD mice trended 
towards increased heat production and HFD → RC mice trended towards reduced heat, 
although these mean effects were not significant (Figure 5D). Heat demonstrated a 
strong relationship to body weight (Figure 5F: p<0.0001), but not Δbody weight     
(Figure 5H: p=0.1286). Therefore, distinct calorimetric measurements have different 
relationships with body weight and energy balance, with heat relating to the former and 
RER (i.e., fuel source) relating to the latter. 
Next, we attempted to bridge our findings with the RNA-seq experiment to 
determine if CLAMS mice had similar CVH gene expression and blood profiles. With the 
exception of npy, we did not detect any significant gene expression differences across 
any of the four groups using RT-qPCR (Figure S8). Further, glucose and insulin levels 
(which were robustly different in RNA-seq mice) were similar between all dietary 
conditions in CLAMS mice (Figure S9AB). Leptin was significantly higher in HFD NoDS 
vs RC NoDS conditions, although this effect was greatly attenuated compared to RNA-
seq animals (Figure S9C). Last, we found no differences in the thyroid-related hormones 
TSH or T4 (Figure S9DE). Along with the abnormal locomotor data, these results 
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indicate that CLAMS housing devices per se may impact numerous metabolic output 
measures. 
 
RSM to visualize the interaction of body weight and energy balance 
 While one goal of these studies was to separate the effects of body mass from 
diet/energy balance, one limitation to our current analysis approach is that it prevents us 
from visualizing how these metrics interact. For example, even in circumstances when 
both input metrics significantly relate to an output metric (e.g., glucose and insulin), it is 
unclear whether body weight and diet/energy balance have additive or synergistic 
effects. To better understand how these metrics could interact, we used a powerful 
technique—response surface modeling (RSM)—to visualize blood glucose and insulin 
levels from RNA-seq mice (Figure 6AB). The approach works by simultaneously 
visualizing how two input variables (x1 = body weight and x2 = Δbody weight) interact to 
affect a single output measure (on the z-axis) by first fitting the data to quadratic model. 
Next, a matrix of physiologically relevant x1 and x2 values (5
th – 95th percentile of actual 
values) are input into the model, and the output is plotted in the 3-D space. The colors 
correspond to the magnitude of the modeled output variable, from lowest values (deep 
blue) to highest values (deep red).  
Both RSM for glucose and insulin showed significant relations to both body 
weight and Δbody weight, without any interaction or quadratic effects (Figure 6C). 
However, the shape and distributions of the fit curve were strikingly different from one 
another. For glucose, acute weight gain alone increases levels to near maximum values, 
while excess body weight alone reaches an intermediate level; when both are increased 
concurrently, there is a steady rise to maximum glycemic levels (Figure 6A). Conversely, 
insulin levels are only mildly increased by either acute weight gain or obesity alone, but 
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when both are increased concurrently, insulin levels rise steeply (Figure 6B). Therefore, 
both glucose and insulin were shown to be related to both body weight and diet/energy 
balance by linear 2-D models (Table 2), but RSM can reveal unique features of their 
interaction. Specifically, body weight and Δbody weight have strong independent effects 
and weak synergistic effects on glucose levels, while insulin is weakly affected by each 
input variable alone and greatly increased by their synergistic association. 
 
Relation of blood metrics, CVH gene expression, and metabolic and sleep/wake 
phenotypes 
 These studies were motivated, in part, by our previous finding that EEG-
measured sleep/wake metrics were independently affected by both body weight and 
diet/energy balance (Chapter 2, Perron et al.). Since the mechanisms that regulate DIO-
associated sleep abnormalities are unclear, we attempted to relate the measured 
metrics herein with our sleep/wake results (termed ‘EEG mice’). Briefly, for each 
individual metric, we fit a joint model (containing both body weight and Δbody weight) 
and isolated the individual effect of each predictor. This yields two β-values (or slope of 
the linear fit) that describes the relationship of each input variable (body weight or Δbody 
weight) to the output variable. Furthermore, both the x and y distributions (mean ± 
standard deviation) can be normalized to Z-scores. This yields a standardized score 
along both axes (Stdxy) that can now be interpreted as the magnitude increase (in 
standard deviations) of the output variable given a 1 standard deviation increase in the 
predictor variable. Since there are two predictor variables (body weight and Δbody 
weight), two Stdxy values are calculated for each metric and can be directly compared to 
one another; these values are shown in Tables 2-4. Note that not all of these calculated 
values are statistically significant, but larger Stdxy values tend to show greater 
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significance. Finally, we plotted these values on a scatter plot (body weight [Stdxy], 
Δbody weight [Stdxy]) to observe how these different metrics relate to one another 
(Figure 7). 
 We found five primary clusters by visual inspection. First, some metrics clustered 
in the first quadrant, relating to values that were positively associated with both 
increased body weight and acute weight gain; this included glucose and insulin levels, 
heat produced, NREM sleep time, and wake fragmentation (short wake bout numbers 
[SWBN] during the dark period). A second cluster was positively correlated with 
increased body weight, but without a significant relation to diet/energy balance; this 
included leptin levels and CVH gene expression of cartpt, trh, serpina3n, c4b, and 
sbno2. Third, a cluster of presented in the third quadrant, indicating negative correlation 
with both increased body weight and acute weight gain; this contained total wake time 
and the ARC genes npy and agrp. Fourth, a cluster was negatively associated with 
increased body weight, but no relation to diet/energy balance; this included plasma T4 
levels and activity metrics from both RNA-seq and CLAMS mice. Last, a fifth cluster was 
found in the second quadrant, indicating decreasing values as body weight increases but 
increasing values during acute weight gain; all of these values were related to VO2, 
VCO2, and RER (which is a ratio of VCO2 and VO2). Altogether, this approach allows 
visualization of correlated metabolic parameters which helps to inform which peripheral 
and central processes may regulate specific metabolic and sleep phenotypes.  
 
DISCUSSION 
Obesity is characterized by excessive body weight, but caused by chronic weight 
gain (usually due to overnutrition and unhealthy diets). Using the DS feeding paradigm, 
we were able to isolate the individual effects of body weight and acute weight changes 
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on various metabolic and behavioral outcomes. We found that many of these variables 
were highly modified by changes to diet/energy balance independent of body weight, 
thus highlighting how body weight alone is an insufficient snapshot of metabolic health. 
Furthermore, our results reveal novel associations between blood biomarkers, neural 
gene expression, and spontaneous activity and sleep/wake behavior, thus offering new 
insights into the genesis of metabolic and behavioral abnormalities in obesity. 
 DIO animals are both profoundly hypoactive and hypersomnolent, spending an 
extra 1-2 hours asleep per day compared to lean controls (Mavanji, Billington et al. 
2012). Spontaneous activity and sleep/wake patterns are highly correlated, since 
inactivity is a requirement for sleep. Indeed, our lab has developed an algorithm to 
estimate sleep/wake behavior from homecage locomotor activity, which has >90% 
correlation with EEG-measured sleep/wake (Pack, Galante et al. 2007). However, this 
algorithm failed to recapitulate known hypersomnolence phenotypes in HFD-induced 
obese mice (Figure S3). We believe this is likely due to two reasons. First, obese mice 
are physically wider than lean mice, so less movement is required from an obese mouse 
to break an infrared beam. The ‘wake-estimating’ algorithm relies on four consecutive 
10-second epochs with 0 beams broken (’40-second’ rule) to behaviorally categorize the 
animal as ‘asleep’ (Pack, Galante et al. 2007). Therefore, occasional beam breaks 
during a stretch of relative quiescence will categorize that animal as awake and thus 
underestimate sleep time. Obese mice exhibit increased sleep/wake fragmentation 
compared to lean controls, which may indicate sleep apnea in these obese animals 
(Duffy and Czeisler 2009; Mavanji, Billington et al. 2012; Davis and O'Donnell 2013). 
Either way, physically wider animals that also awaken more often may trick this activity-
based algorithm. Other approaches, such as video tracking, may provide a more reliable 
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signal to estimate sleep/wake behavior (Fisher, Godinho et al. 2012). Second, our linear 
regression models revealed that locomotor activity and sleep/wake behavior have 
different relationships with body weight and diet/energy balance (Figure 7). Specifically, 
wakefulness is negatively associated with both increased body weight and acute weight 
gain (NREM sleep has the opposite association; Table 4). Locomotor patterns are 
negatively associated with increased body weight, but do not have a significant relation 
to Δbody weight (Table 2). With these relationships now known, it is not surprising that 
sleep/wake cannot be estimated from spontaneous activity in metabolically abnormal 
mice. Therefore, these studies reveal that activity patterns and sleep/wake behavior can 
be decoupled under conditions of metabolic dyshomeostasis. However, future work that 
measures these behaviors simultaneously (e.g., telemetry-based EEG recordings with 
video tracking) will be required to confirm these differences.  
 The present studies used RNA-seq to discover genes located within the CVH 
which would relate to body weight, diet/energy balance, or both. This approach has the 
advantage of quantifying all mRNA transcripts in the tissue sample, potentially revealing 
novel associations with genes that would otherwise not be tested. Indeed, we found 
strong differential expression of trh, which was positively correlated with body weight but 
with no relation to diet/energy balance (Table 2). Not only can trh act as a 
neuromodulatory peptide (increasing activity of wake-promoting orexinergic neurons), 
but trh can initiate the HPT axis by causing pituitary release of TSH (Storch and Weitz 
2009; Silver, Balsam et al. 2011).  Although our results measuring circulating TSH and 
T3 were inconclusive, T4 was trended towards a negative association with body weight 
with no relation to diet/energy balance (Figure S4). Other studies have found elevated 
TSH in obesity, which are reduced following weight loss (Kok, Roelfsema et al. 2005). 
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Therefore, the relationship between thyroid functioning and body weight and diet/energy 
balance remains unclear, although these preliminary results indicate the HPT axis may 
be related to body weight independent of diet/energy balance. Furthermore, RNA-seq 
analysis revealed upregulation of serpina3n, sbno2, and c4b in HFD NoDS; these genes 
are all positively correlated with body weight without relation to acute weight changes 
(Table 2). C4b is a member of the complement pathway, which is part of the innate 
immune system in the CNS (Veerhuis, Nielsen et al. 2011). Sbno2 is a pro-inflammatory 
factor in the CNS expressed predominately in astrocytes (Grill, Syme et al. 2015). 
Serpina3n is a marker for astrogliosis, and is increased in hypothalamus of DIO mice 
(Zamanian, Xu et al. 2012; Guillemot-Legris, Mutemberezi et al. 2016). Hypothalamic 
inflammation is a known consequence of obesity (Ellacott, Morton et al. 2010; Eckel-
Mahan, Patel et al. 2013), but these results suggest that these pro-inflammatory 
pathways are associated with increased body weight independent of diet/energy 
balance. However, future work measuring gene and protein expression of various pro-
inflammatory markers will be required to fully support this claim. Finally, we ran RNA-seq 
results through GSEA to discover biochemical pathways that may differ between DS 
groups. Although this approach is prone to false-positives, ‘Oxidative Phosphorylation’ 
was identified as significantly enriched in HFD → RC animals compared to RC → HFD 
(Table S3: p<0.0001). This indicates that weight loss may be associated with greater 
ATP production via oxidative phosphorylation than weight gain animals independent of 
body weight (RC → HFD and HFD → RC animals were similarly weighted; Figure S1). 
This may be due to differences in mitochondrial biogenesis, morphology, or functioning 
(which are altered in obesity) (Johnson and Wardle 2014), although future work will need 
to measure mitochondrial functioning directly following the DS paradigm. Taken 
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together, RNA-seq is a powerful hypothesis-generating tool that enables the investigator 
to measure all transcripts in a given tissue sample.  
 RNA-seq, however, does have limitations, especially when measuring 
heterogeneous tissues such as the brain. Like other gene expression assays 
(microarrays and RT-qPCR), RNA-seq is most powerful with homogenous samples 
(Conesa, Madrigal et al. 2016). The CVH, however, contains many neural cell types 
(e.g., neurons, astrocytes, microglia), distinct neuronal nuclei (e.g., ARC, PVN, and 
VMN), and the ARC alone contains as many as 50 transcriptionally-distinct cell types 
(Campbell, Macosko et al. 2017).  Thus, assessing gene expression changes in CVH 
punches may dilute relevant ‘signal’ with the ‘noise’ of other cell types. Indeed, RNA-seq 
of purified pomc+ and agrp+ ARC neurons from lean, ad lib-fed mice found hundreds of 
DEG (Henry, Sugino et al. 2015). However, this purification process requires 3+ hours of 
cell manipulation before cell lysis and RNA extraction, which may have unintended 
effects on expression profiles. Nonetheless, our approach did identify genes with robust 
expression differences, which was confirmed using RT-qPCR of tissue samples from an 
independent animal cohort. 
 In our previous work with EEG mice, we used a simplified linear regression 
model to isolate body weight and diet/energy balance effects. Specifically, we compared 
the two DS groups directly (without incorporating RC NoDS and HFD NoDS into the 
models) and used a binary indicator (RC → HFD = 0 and HFD → RC = 1) to parse apart 
the group differences. Using this approach, we found wake time was significantly related 
to both body weight and diet/energy balance, while wake fragmentation was only 
associated with diet/energy balance (Duffy and Czeisler 2009). However, this approach 
is limited for two reasons. First, the model does not include data from RC NoDS and 
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HFD NoDS groups, which provide valuable information about the upper and lower limits 
of sleep/wake metrics. Second, the model will have difficulty determining body weight 
associations because body weight was similar between RC → HFD and HFD → RC 
conditions. Therefore, the previous modeling approach is best suited to determine 
whether or not diet/energy balance is independent from body weight, but it cannot 
appropriately compare the magnitude of these relative effects.  In the current report, we 
fit linear trends to both raw body weight and Δbody weight (percent change in body 
weight from Pre-DS to Post-DS) using all four dietary conditions. This approach is 
superior for multiple reasons. First, the data is ‘spread’ across a large range for both 
body weight (min / median / max :: 26.5 / 33.8 / 50.7; in grams) and Δbody weight (-20.5 
/ 1.70 / 22.0; in %), which strengthens the interpretability of linear modeling results. 
Second, the animals with the most extreme differences in body weight (RC NoDS and 
HFD NoDS) have the smallest changes in Δbody weight, and vice versa for the DS 
groups (Figure 1).  Third, this approach uses real data for all input and output metrics, as 
opposed to the arbitrary binary values, thus capturing interanimal variability associated 
with RC and HFD consumption.  Last, this approach includes data from all four groups 
instead of just the two DS conditions, allowing for estimation of effects associated with 
body weight. Indeed, when we re-modeled data from EEG mice, we found some 
different trends, specifically a stronger influence of body weight than previously realized. 
The main drawback from this approach is that it assumes most diet-induced metabolic 
effects are due to weight gain/loss; however, we believe this assumption is valid for two 
reasons. First, when feeding all animals HFD, obesity resistant rodents do not show 
stereotypical metabolic and behavioral abnormalities compared to obesity prone rodents 
(Mavanji, Teske et al. 2010; Grissom, Herdt et al. 2015; Antunes, Elkfury et al. 2016), 
suggesting HFD-induced weight changes are required to induce these 
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pathophysiological conditions. Second, the Δbody weight metric used herein has 80% 
correlation with binary indicators (HFD-consuming animals = 1 and RC-consuming 
animals = 0; not shown), suggesting that the majority of diet-associated effects can be 
explained by Δbody weight. Nonetheless, pure diet effects (due to differences in 
macronutrient composition, for example) may not be captured by our DS feeding 
paradigm.  In order to disassociate ‘diet’ from ‘energy balance’, future work could repeat 
the DS with different hypercaloric diets varying by carbohydrate, fat, and protein content 
and/or use novel approaches to affect acute weight changes (e.g., access to a running 
wheel). 
Collectively, our results demonstrate that diet/energy balance can greatly affect 
many metabolic processes and behavioral outcomes independent of body weight.  This 
work reinforces the shortcomings of BMI, which classifies obesity based on body mass 
irrespective of recent changes to diet or weight. This is especially relevant for patients, 
doctors, and insurance companies who continue to track metabolic health with BMI, 
despite its unreliability (Tomiyama, Hunger et al. 2016). Although BMI is still a useful 
metric, we propose that measuring changes to body weight or BMI over time may 
provide a better snapshot of metabolic health (Huang, Ramsey et al. 2011). 
Furthermore, our results allow us to predict which metrics are consequences, rather than 
causes, of obesity. Specifically, a metric that only correlates with body weight, but not 
diet/energy balance, cannot contribute to the genesis of obesity-related abnormalities. 
For example, leptin is elevated in obese animals in proportion to adiposity, but does not 
cause obesity; in fact, leptin replacement may help promote weight loss for certain 
obese patients (Eckel-Mahan and Sassone-Corsi 2013). Furthermore, these correlations 
allow predictions for which metrics may be biologically related (e.g., npy, agrp, and total 
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wake time), although causal experiments controlling for body weight will be needed to 
confirm such associations.  Finally, this DS feeding paradigm could easily be amended 
for humans, which may prove useful to determine clinically relevant indicators of 
metabolic health.  In all, these studies provide the framework to identify better metrics to 
differentiate between metabolically healthy and unhealthy individuals, which may lead to 
novel therapeutic strategies for obese patients. 
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Figure 4.1: Diet Switch (DS) feeding paradigm isolates ‘diet/energy balance’ and 
‘body weight’.  (A) Mice consume either RC or HFD for 8-10 weeks (Pre-DS), then are 
randomized to either continue consuming their respective diet (RC NoDS and HFD 
NoDS) or switched to the alternate diet (RC → HFD and HFD → RC). All mice were 
sacrificed one week after the DS, with the exception of CLAMS mice which were 
sacrificed 4 days Post-DS. (B) Scatter plot of absolute body weight (in grams) vs Δbody 
weight (percent change in body weight from Pre- to Post-DS, a proxy for energy 
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balance). Both DS groups have similar body weight, but divergent energetic status. 
Conversely, both NoDS controls are in neutral energy balance but HFD NoDS mice 
weigh significantly more than RC NoDS animals. Therefore, there is no correlation 
between body weight and energy balance for these mice (R2 = 8.771x10-5, p = 0.9387). 
Scatter plot displays weight data from RNA-seq mice. 
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Figure 4.2: Spontaneous locomotor activity is related to body weight, but not 
Δbody weight. (A) Locomotor activity is significantly reduced in DIO mice, especially 
during the beginning of the dark period. (B) One week Post-DS, locomotor activity is 
similar between all conditions, except HFD NoDS is significantly less active than all other 
groups; these mean differences are presented in (C). Locomotor activity is negatively 
correlated with body weight (p<0.0001) but has no relation to energy balance 
(p=0.6228). *p<0.05, ***p<0.001, ****p<0.0001; a: p<0.05 compared to RC NoDS; b: 
p<0.05, b’’: p<0.001 compared to HFD NoDS. One significant outlier from RC NoDS 
condition was removed from analysis (>2.0 standard deviations above the mean of all 
animals combined). Body weight and food intake were measured daily between 9-10 am 
(ZT2-3), so locomotor data is omitted during the ZT2-4 time window. 
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Figure 4.3: RNA-seq results of CVH-expressed neuropeptides and RT-qPCR 
confirmation in both sequenced and non-sequenced tissue. (A-D) Normalized read 
counts of agrp, npy, cartpt, and trh expression in CVH punches obtained from RNA-seq 
analysis. (E-H) RT-qPCR of mRNA purified from CVH punches which included samples 
used for RNA-seq analysis. (I-L) RT-qPCR of CVH mRNA from samples which were not 
sequenced.  All three approaches yielded similar results. Further analysis of these 
expression differences (e.g., linear regression) was performed on RT-qPCR results from 
sequenced tissue (data shown in E-H). agrp: Agouti-related peptide; npy: Neuropeptide 
y; carpt: Cocaine- and amphetamine regulated transcript; trh: Thyrotropin-releasing 
hormone. *p<0.05, **p<0.01, ****p<0.0001; a+: p<0.1, a: p<0.05, a’: p<0.01, a’’: p<0.001, 
a’’’: p<0.0001 compared to RC NoDS; b+: p<0.1, b: p<0.05, b’: p<0.01, b’’: p<0.001, b’’’: 
p<0.0001 compared to HFD NoDS. Sample sizes: (E-H) [RC NoDS: n = 13; RC → HFD: 
n = 18; HFD → RC: n = 11; HFD NoDS: n = 7]; (I-L) [RC NoDS: n = 5; RC → HFD: n = 8; 
HFD → RC: n = 6; HFD NoDS: n = 3]. 
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Figure 4.4: Blood biomarkers from RNA-seq mice. (A) Glucose is significantly higher 
in both groups consuming HFD compared to both groups consuming RC. (B) Insulin is 
highest in HFD NoDS animals, lowest in RC NoDS and HFD → RC animals, and 
intermediate in RC → HFD mice. (C) Leptin is highest in HFD NoDS, lowest in RC 
NoDS, and similar between both DS groups (RC → HFD and HFD → RC). Linear 
modeling shows that glucose is positively associated with both body weight (D) and 
energy balance (G). Insulin is also strongly related to body weight (E), but less strongly 
related to energy balance (H). Leptin strongly correlates with body weight (F) with no 
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relation to energy balance (I). ****p<0.0001; a+: p<0.1, a: p<0.05, a’: p<0.01, a’’: 
p<0.001, a’’’: p<0.0001 compared to RC NoDS; b+: p<0.1, b: p<0.05, b’: p<0.01, b’’: 
p<0.001, b’’’: p<0.0001 compared to HFD NoDS. Sample sizes for glucose: [RC NoDS: 
n = 16; RC → HFD: n = 21; HFD → RC: n = 19; HFD NoDS: n = 14]. Sample sizes for 
insulin and leptin: [RC NoDS: n = 13; RC → HFD: n = 17; HFD → RC: n = 12; HFD 
NoDS: n = 13].  
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Figure 4.5: Metabolic parameters from CLAMS mice. (A) Respiratory exchange ratio 
(RER) is decreased in HFD-fed animals Pre-DS. Following the DS, RER decreases 
dramatically in HFD → RC animals, while RER in RC → HFD trends towards a decrease 
(Panel C). (B) Heat produced from animals (a metric of energy expenditure) is increased 
in HFD-fed animals Pre-DS. After the DS, heat production changes quickly, with all 
groups exhibiting similar heat profiles except for HFD NoDS compared to RC NoDS and 
HFD → RC (Panel D). Linear modeling shows that RER has a weak (non-significant) 
negative association with body weight (E) but is positively correlated with energy 
balance (G). Heat has a strong positive association with body weight (F) but only a weak 
(non-significant) association with energy balance (H). ***p<0.001; a: p<0.05, a’’’: 
p<0.0001 compared to RC NoDS; b: p<0.05 compared to HFD NoDS. 
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Figure 4.6: RSM plots visualize how body weight and Δbody weight interact to 
affect glucose and insulin levels. RSM plots fit the x1 variable (body weight), x2 
variable (Δbody weight), and output variable (z-axis, either glucose [A] or insulin [B]) to a 
quadratic equation (see methods). (C) For both glucose and insulin, body weight and 
Δbody weight were both significant terms in the model (confirmed in Table S3), without 
significant interaction or quadratic terms. The arbitrary colors correspond to low values 
(blue) to high values (red). Glucose levels are sharply increased by Δbody weight and 
body weight alone; as these values increase concurrently, glucose is only moderately 
increased (A). Insulin levels are mildly affected (albeit significantly) by either body weight 
or acute weight changes alone, but as these values rise concurrently, insulin levels are 
massively increased. Note that the edges of these cubes are approximations, often with 
insufficient data. For example in (A), the downward ‘arc’ shape along the front-left cube 
face corresponds to simultaneous ‘negative energy balance’ and ‘obesity’, which does 
not exist in our data set. Therefore, one must take caution when interpreting the 
extremes of RSM plots, although the modeled data is restricted to the 5th – 95th 
percentile to mitigate these issues.   
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Figure 4.7: Plotting standardized β coefficients to relate blood biomarkers, CVH 
gene expression, and behavioral data. For every reported metric, we calculated β 
coefficients that were standardized for both the predictor (body weight or Δbody weight) 
and the outcome. For each metric, there are two standardized scores (Stdxy for body 
weight and Stdxy for Δbody weight). These two standardized scores (reported in Table 
S3, S4, and S5) are scatter plot against one another. The shape of the data point 
corresponds to origin of the data (Ο for RNA-seq mice,  for CLAMS mice, and Δ for 
EEG mice). This approach reveals five distinct clusters: 1) positive correlation with both 
increased body weight and weight gain [glucose, insulin, NREM time, SWBN, heat]; 2) 
positive correlation with increased body weight, but no relation to Δbody weight [leptin, 
cartpt, trh, serpina3n, sbno2, c4b]; 3) negative correlation with both increased body 
weight and weight gain [Wake time, npy, agrp]; 4) negative correlation with increased 
body weight and no correlation to Δbody weight [locomotor activity and T4]; and 5) 
negative correlation with increased body weight and positive correlation with weight gain 
[VO2, VCO2,and RER]. Note that the shaded regions indicating significance are 
approximations, and linear regression tables (S3, S4, and S5) should be consulted for 
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exact significance values. REM: Rapid Eye Movement sleep; NREM: Non-REM sleep; 
SWBN: Short wake bout number (<16 seconds in duration); Cartpt: Cocaine- and 
amphetamine regulated transcript; Serpina3n: Serine (or cysteine) peptidase inhibitor 
clade A member 3N; Sbno2: Strawberry notch homolog 2; Trh: Thyrotropin-releasing 
hormone; C4b: Complement component 4b; Agrp: Agouti-related peptide; Npy: 
Neuropeptide y; T4: Thyroxine; VO2: Volume of VO2 inhaled; VCO2: Volume of VCO2 
exhaled; RER: Respiratory exchange ratio. 
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Statistical 
Approach 
No Filter 
      Data Filtering 
Common Filter 
MAANOVA 
 Trh  
 Npy 
q = 0.0238 
q = 0.0753 
 Trh 
 Npy 
 Cartpt 
 Sbno2 
 Serpina3n 
 C4b 
q < 1x10-6 
q = 0.0076 
q = 0.0555 
q = 0.0555 
q = 0.0807 
q = 0.0918 
Trh 
Npy 
LimmaVoom 
 Trh  
 Npy  
 Cartpt 
 Serpina3n  
 Agrp  
 Sbno2 
q = 1.54x10-5 
q = 6.43 x10-5 
q = 0.002 
q = 0.0036 
q = 0.0073 
q = 0.121 
 Trh 
 Npy 
 Cartpt 
 Serpina3n 
 Agrp 
 Sbno2 
q = 1.76x10-5 
q = 7.39x10-5 
q = 0.002 
q = 0.0036 
q = 0.0072 
q = 0.105 
Trh 
Npy 
Cartpt 
Serpina3n 
Agrp 
Sbno2 
Common 
Trh 
Npy  
  
Trh 
Npy 
Cartpt 
Serpina3n 
Sbno2 
Trh 
Npy 
 
Table 4.1: Differentially expressed genes (DEG) of RNA-seq results between RC 
NoDS and HFD NoDS groups. Genes with false discovery rate (q-value) < 0.15. Cartpt: 
Cocaine- and amphetamine regulated transcript; Serpina3n: Serine (or cysteine) 
peptidase inhibitor clade A member 3N; Sbno2: Strawberry notch homolog 2; Trh: 
Thyrotropin-releasing hormone; C4b: Complement component 4b; Agrp: Agouti-related 
peptide; Npy: Neuropeptide 
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Table 4.2: Linear regression modeling results for all metrics in RNA-Seq mice. 
Note that CVH gene expression values are modeled using RT-qPCR results from 
sequenced tissue. Individual Models: estimates from individual regression models 
containing only the indicated factor (body weight or Δbody weight). Joint Models: 
estimates from joint regression model containing both factors. β (SEM): β-estimate and 
standard deviation indicates expected change in outcome for a 1 unit increase in 
predictor. Std β: Standardized β-estimate indicating the expected change in outcome for 
a 1 standard deviation increase in predictor. Stdxy: Standardized β-estimate along both 
axes, indicating the standard deviation change for the y-variable given a 1 standard 
deviation increase in the predictor. Shading indicates significance at p<0.05.  
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Table 4.3: Linear regression modeling results for all metrics in CLAMS mice. 
Individual Models: estimates from individual regression models containing only the 
indicated factor (body weight or Δbody weight). Joint Models: estimates from joint 
regression model containing both factors. β (SEM): β-estimate and standard deviation 
indicates expected change in outcome for a 1 unit increase in predictor. Std β: 
Standardized β-estimate indicating the expected change in outcome for a 1 standard 
deviation increase in predictor. Stdxy: Standardized β-estimate along both axes, 
indicating the standard deviation change for the y-variable given a 1 standard deviation 
increase in the predictor. RER: Respiratory Exchange Ratio; VCO2: Volume CO2 
exhaled; VO2: Volume O2 inhaled. Shading indicates significance at p<0.05.  
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Table 4.4: Linear regression modeling results for EEG mice. Individual Models: 
estimates from individual regression models containing only the indicated factor (body 
weight or Δbody weight). Joint Models: estimates from joint regression model containing 
both factors. β (SEM): β-estimate and standard deviation indicates expected change in 
outcome for a 1 unit increase in predictor. Std β: Standardized β-estimate indicating the 
expected change in outcome for a 1 standard deviation increase in predictor. Stdxy: 
Standardized β-estimate along both axes, indicating the standard deviation change for 
the y-variable given a 1 standard deviation increase in the predictor. REM: Rapid Eye 
Movement sleep; NREM: Non-REM sleep; WBN: Wake Bout Number; SWBN: Short 
WBN (<16 seconds in length). Shading indicates significance at p<0.05. 
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Figure 4.S1: CVH punch enrichment values displayed as the ratio of ARC genes 
over hcrt expression. After purifying mRNA from CVH punches, RT-qPCR was run for 
agrp, pomc, and hcrt. The hcrt Ct value was subtracted from the geometric mean of the 
Ct values of putative ARC genes (agrp and pomc). This Delta Ct (DCt) value was 
converted to a linear scale (2-DCt) to calculate the enrichment value. Samples with 
enrichment scores less than 5 were omitted from future analysis (~10% of samples did 
not meet this standard). This value was statistically greater in RC NoDS samples used 
for RNA-seq (A), but was statistically similar across all groups for RT-qPCR studies with 
sequenced samples (B), non-sequenced samples (C), and CLAMS mice (D). a+: p<0.1, 
a: p<0.05, a’: p<0.01 compared to RC NoDS. 
  
143 
 
 
Figure 4.S2: Body weight effects for RNA-seq mice induced by the DS feeding 
paradigm. (A) Raw body weight and (B) percent change in body weight from Week 0 
throughout the DS protocol. (C) Percent change in body weight from Pre-DS to Post-DS 
throughout the DS protocol. (D) Raw body and (E) percent change in body weight from 
Week 0 one week after the DS protocol. The values shown in (D) were used as the 
‘body weight’ metrics for all linear modeling analysis. (F) Percent change in body weight 
at one week Post-DS compared to Pre-DS, which is a proxy for energetic status of the 
animal. These values were used as the ‘Δbody weight’ metrics for all linear modeling 
analysis. ****p<0.0001; a+: p<0.1, a: p<0.05, a’: p<0.01, a’’:p<0.001, a’’’:p<0.0001 
compared to RC NoDS; b+: p<0.1, b: p<0.05, b’: p<0.01, b’’: p<0.001, b’’’: p<0.0001 
compared to HFD NoDS. 
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Figure 4.S3: Sleep and wakefulness cannot be estimated from locomotor activity 
in DIO mice. DIO mice sleep ~1-2 hours more per day and exhibit increased sleep/wake 
fragmentation compared to lean animals. Figure 2A shows that DIO mice are hypoactive 
compared to lean mice during the dark period, when these sleep effects are most 
pronounced.  An activity-based algorithm to estimate wake differences has been 
developed and validated in lean mice; this ’40-second’ rule agrees >90% with 
simultaneous EEG-recordings.  We find that this algorithm does not recapitulate 
stereotypical sleep/wake abnormalities observed in DIO mice (C,G). Further, alternate 
algorithms using 20, 30, or 50 seconds of inactivity as a cut-off threshold for sleep shows 
similar inadequacies (A,E for 20 seconds; B,F for 30 seconds; D, H for 50 seconds).  
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Figure 4.S4: RNA-seq results and RT-qPCR confirmation of remaining genes. (A-E) 
Normalized read counts of sbno2, serpina3n, c4b, pomc, and hcrt expression in CVH 
punches obtained from RNA-seq analysis. (F-J) RT-qPCR of mRNA purified from CVH 
punches which included samples used for RNA-seq analysis. (I-L) RT-qPCR of CVH 
mRNA from samples which were not used for RNA-seq. All three approaches yielded 
similar results. Further analysis of these expression differences (e.g., linear regression) 
was performed on RT-qPCR results from sequenced tissue (data shown in F-J). Sbno2: 
Strawberry notch homolog 2; Serpina3n: Serine (or cysteine) peptidase inhibitor clade A 
member 3N; C4b: Complement component 4b; Pomc: Proopiomelanocortin; Hcrt: 
Hypocretin (aka orexin). a+: p<0.1, a: p<0.05, a’: p<0.01, a’’:p<0.001, a’’’:p<0.0001 
compared to RC NoDS; b+: p<0.1, b: p<0.05, b’: p<0.01, b’’: p<0.001, b’’’: p<0.0001 
compared to HFD NoDS. Sample sizes for (F-J) graphs: [RC NoDS: n = 13; RC → HFD: 
n = 18; HFD → RC: n = 11; HFD NoDS: n = 7]. Samples sized for (K-O) graphs: [RC 
NoDS: n = 5; RC → HFD: n = 8; HFD → RC: n = 6; HFD NoDS: n = 3]. 
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Figure 4.S5: Thyroid related blood biomarkers from RNA-seq mice.  (A) Thyroid-
stimulating hormone (TSH) showed highly variable expression levels across samples, 
contributing to non-significant group effects (p=0.9658). (B) Thyroxine (T4) levels were 
not robustly different between dietary conditions. However, T4 trended towards a 
negative relationship with body weight (C) with no relationship to Δbody weight (D). 
Triiodothyronine (T3) levels were also measured, but most samples were below 
detection threshold and not quantifiable (not shown).   
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Figure 4.S6:  Body weight and locomotor effects induced by DS feeding paradigm 
in CLAMS mice. (A) Raw body weight and (B) percent change in body weight from 
Week 0 throughout the DS protocol. (D) Raw body and (E) percent change in body 
weight from Week 0 four days after the DS protocol. The values shown in (D) were used 
as the ‘body weight’ metrics for linear modeling analysis. (C,F) Percent change in body 
weight from Pre-DS to Post-DS. (F) These values (percent change in body weight four 
days Post-DS compared to Pre-DS) shown in (F) were used as the ‘Δbody weight 
metrics for linear modeling analysis. ****p<0.0001; a+: p<0.1, a: p<0.05, a’: p<0.01, a’’: 
p<0.001, a’’’: p<0.0001 compared to RC NoDS; b+: p<0.1, b: p<0.05, b’: p<0.01, b’’: 
p<0.001, b’’’: p<0.0001 compared to HFD NoDS. 
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Figure 4.S7: VO2, VCO2, and caloric intake in CLAMS mice. (A) Volume of O2 inhaled 
[VO2] was similar between all four groups initially, but following the DS, was increased in 
RC → HFD animals and decreased in HFD → RC animals. These changes persisted 
until the conclusion of the study (Day 4 Post-DS; Panel D).  (B) Volume of CO2 exhaled 
[VCO2] was initially increased in RC-fed animals compared to HFD-fed animals. 
Immediately after the DS, RC → HFD mice exhibited an acute increase above RC NoDS 
levels. Conversely, VCO2 dropped immediately Post-DS in HFD → RC mice and stayed 
lower throughout. These changes persisted until the conclusion of the study (Day 4 Post-
DS; Panel E).  (C) Caloric intake was greatly reduced in HFD → RC mice, which 
presumably drove the substantial weight loss in these animals. Caloric intake was 
acutely increased in RC → HFD animals, but did not significantly differ from NoDS 
controls four days Post-DS (Panel F). **p<0.01; ****p<0.0001; a+: p<0.1, a: p<0.05, a’: 
p<0.01, a’’: p<0.001, a’’’: p<0.0001 compared to RC NoDS; b: p<0.05, b’: p<0.01, b’’: 
p<0.001, b’’’: p<0.0001 compared to HFD NoDS. 
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Figure 4.S8: RT-qPCR of CVH punches from CLAMS mice.  CVH tissue was 
punched from brains from CLAMS mice, and RT-qPCR was used to quantify gene 
expression.  With the exception of decreased npy expression in RC → HFD animals (B), 
there were no significant expression differences for any other genes. a+: p<0.1, a: 
p<0.05 compared to RC NoDS. Agrp: Agouti-related peptide; Npy: Neuropeptide y; 
Cartpt: Cocaine- and amphetamine regulated transcript; Trh: Thyrotropin-releasing 
hormone. Sbno2: Strawberry notch homolog 2; Serpina3n: Serine (or cysteine) 
peptidase inhibitor clade A member 3N; C4b: Complement component 4b; Pomc: 
Proopiomelanocortin; Hcrt: Hypocretin (aka orexin). 
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Figure 4.S9: Blood biomarkers in CLAMS mice. (A) Glucose and (B) insulin levels 
were similar between all four groups of mice, although insulin levels trended towards an 
increase in RC → HFD mice compared to RC NoDS controls. (C) Leptin levels were 
moderately increased in HFD-fed animals compared to RC NoDS. There were no group 
differences for either (D) thyroid-stimulating hormone (TSH) or (E) thyroxine (T4). a+: 
p<0.1, a’: p<0.01 compared to RC NoDS. 
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Sample ID 
Total Reads 
[#] 
Ribosomal RNA Mitochondrial DNA 
Unique 
Reads [#] 
Unique 
Reads [%] 
Unique 
Reads [#] 
Unique 
Reads [%] 
RC NoDS.01 39,976,549 914,784 2.28 719,521 1.80 
RC NoDS.02 35,798,997 1,186,847 3.31 568,321 1.60 
RC NoDS.03 47,083,916 1,553,233 3.29 650,136 1.40 
RC NoDS.05 40,940,308 1,230,467 3.00 390,894 0.90 
RC NoDS.06 45,770,168 1,615,528 3.52 388,202 0.80 
RC-HFD.07 38,781,692 906,187 2.33 547,978 1.40 
RC-HFD.08 42,003,016 1,865,562 4.44 615,024 1.50 
RC-HFD.09 51,745,981 1,463,758 2.82 647,418 1.20 
RC-HFD.10 49,316,975 2,876,939 5.83 606,875 1.20 
RC-HFD.11 58,975,589 2,097,050 3.55 599,556 1.00 
RC-HFD.12 45,443,568 2,086,999 4.59 523,198 1.10 
HFD-RC.13 20,984,913 656,285 3.12 224,815 1.10 
HFD-RC.14 53,072,720 1,640,727 3.09 568,618 1.10 
HFD-RC.15 59,752,128 2,292,245 3.83 760,391 1.30 
HFD-RC.16 61,245,611 2,386,657 3.89 839,802 1.40 
HFD-RC.17 52,892,796 1,436,217 2.71 669,739 1.30 
HFD NoDS.19 55,625,859 2,514,734 4.52 499,525 0.90 
HFD NoDS.20 44,776,843 2,706,141 6.04 219,408 0.50 
HFD NoDS.21 55,935,831 3,387,002 6.05 752,085 1.30 
HFD NoDS.23 48,446,179 1,979,114 4.08 605,161 1.20 
HFD NoDS.24 47,731,405 1,289,909 2.70 583,758 1.20 
MINIMUM 20,984,913 656,285 2.28 219,408 0.50 
MAXIMUM 61,245,611 3,387,002 6.05 839,802 1.80 
 
Table 4.S1: RNA-seq total read counts and contamination from ribosomal RNA 
and mitochondrial DNA.  All samples were re-sampled to the minimum read depth 
(20.98 million). 
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Gene Name NCBI Reference Sequence Catalog Number 
Npy NM_023456.2 Mm01410146_m1 
Agrp NM_007427.3 Mm00475829_g1 
Cartpt NM_013732.7 Mm04210469_m1 
Pomc NM_008895.4 Mm00435874_m1 
Trh NM_009426.3 Mm01182425_g1 
Hcrt NM_010410.2 Mm01964030_s1 
Serpina3n NM_009252.2 Mm00776439_m1 
Sbno2 NM_183426.1 Mm00839231_m1 
C4b NM_009780.2 Mm00437893_g1 
Rn18s NR_003278.3 Mm03928990_g1 
ACTB NM_007393.5 Mm00607939_s1 
RPLP0 NM_007475.5 Mm00725448_s1 
 
Table 4.S2: Gene name, NCBI reference sequence, and catalog number of Taqman 
Primer/Probes used for RT-qPCR experiments. Agrp: Agouti-related peptide; Npy: 
Neuropeptide y; Cartpt: Cocaine- and amphetamine regulated transcript; Trh: 
Thyrotropin-releasing hormone; Sbno2: Strawberry notch homolog 2; Serpina3n: Serine 
(or cysteine) peptidase inhibitor clade A member 3N; C4b: Complement component 4b; 
Pomc: Proopiomelanocortin; Hcrt: Hypocretin (aka orexin). 
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GSEA Pathway 
Name 
Log2-
Transformed 
Raw values 
General 
Description 
FDR 
q-value 
FWER 
p-value 
FDR 
q-value 
FWER 
p-value 
Oxidative 
Phosphorylation 
<0.0001 <0.0001 <0.0001 <0.0001 
Mitochondrial 
process to 
aerobically generate 
ATP 
Coagulation 0.026 0.002 0.003 0.004 
Generally involved in 
clotting blood 
following injury, 
‘coagulation’ may 
suggest changes to 
brain vasculature in 
circumventricular 
regions 
KRAS Signaling 
Up 
0.007 0.014 0.013 0.031 
KRAS is an 
oncogene that 
regulates protein 
dynamics and 
glucose homeostasis 
Adipogenesis 0.011 0.028 0.028 0.078 
The formation of 
mature adipocytes, 
which store fatty 
acids. This complex 
process is crucially 
regulated by PPARg 
Xenobiotic 
Metabolism 
0.023 0.071 0.006 0.01 
Process to break 
down and dispose of 
foreign substances, 
such as drugs or 
food additives 
 
Table 4.S3: Results from Gene Set Enrichment Analysis (GSEA).  Using filtered 
RNA-seq results, GSEA shows significantly enriched pathways in HFD -→ RC animals 
compared to RC -→ HFD. Using both raw and log2-transformed data, we found the 
same five enriched pathways at an FWER < 0.05. FDR: False discovery rate; FWER: 
Family wise error rate; PPARg: Peroxisome proliferator-activated receptor gamma. 
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CHAPTER 5 
GENERAL DISCUSSION 
 
 
The function of sleep is one of the greatest biological mysteries and is the topic 
of many research efforts (Krueger and Obal 1993; Benington 2000; Born and Fehm 
2000; Tononi and Cirelli 2006; Diekelmann and Born 2010; Krueger, Frank et al. 2016). 
One strategy to address this experimentally is to determine factors that influence the 
duration, timing, or quality of sleep. Indeed, a critical factor necessary to maintain normal 
sleep/wake cycles is circadian rhythms, which are internal clocks that have evolved to 
track the earth’s rotation on its axis thereby estimating light and dark cycles (Paranjpe 
and Sharma 2005). Functional circadian rhythms help animals define rest periods (to 
conserve energy and/or avoid predation) and active periods (to scavenge for food and/or 
attempt mating). In particular, sleep and eating behavior are mutually exclusive, since 
wakefulness is necessary for food-seeking and food intake. Thus from an evolutionary 
perspective, an animal that can properly track both sleep and caloric need will confer an 
advantage to maximize energy resources required for alertness and food scavenging. In 
other words, an animal that sleeps when it should be scavenging, or an animal that 
scavenges when it should be sleeping, will have difficulty surviving in the wild. However, 
in our current society, highly nutritive food is readily available and >70% of the U.S. 
population is overweight or obese (Ogden, Carroll et al. 2014). Furthermore, many 
people report being excessively sleepy during the day, regardless of how much sleep 
they get on average (CDC 2011). Therefore, the evolutionarily-conserved sleep-
metabolism link, which helps motivate hungry animals to stay awake and find food, may 
also contribute to excessive sleepiness in our overweight modern-day society.  
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The relationship between sleep and metabolism extends beyond epidemiological 
evidence and Darwinian musings, and is backed up by solid empirical research. 
Specifically, sleep deprivation or restriction increases circulating hunger hormones 
(ghrelin) and induces hyperphagia, especially of calorically-dense fatty foods (Taheri, Lin 
et al. 2004; Greer, Goldstein et al. 2013; Spaeth, Dinges et al. 2013). Furthermore, 
artificial light sources shift circadian rhythms and keep people awake longer, thus 
allowing a greater opportunity to consume food (Duffy and Czeisler 2009). Conversely, 
metabolic challenges can profoundly affect sleep and wakefulness. Caloric restriction 
increases wakefulness and reduces sleepiness in both rodents and humans, while 
overnutrition has the opposite effect (Danguir and Nicolaidis 1979; Danguir 1987). 
Compared to lean people, obese humans demonstrate increased sleepiness via both 
objective and subjective measures, even when controlling for obesity-related sleep 
abnormalities such as sleep apnea (Vgontzas, Bixler et al. 1998; Varela, Hinojosa et al. 
2007; Panossian and Veasey 2012).  This sleepiness phenotype is recapitulated in 
numerous animal models of obesity, including diet-induced obese (DIO) mice (Mavanji, 
Billington et al. 2012). The DIO mouse is a good model of human obesity for multiple 
reasons. First, similar to most humans, obesity is driven by overnutrition rather than 
genetic deficiencies. Second, DIO mice recapitulate many metabolic and behavioral 
abnormalities observed in obese humans, such as type II diabetes and 
hypersomnolence. Third, many of these abnormalities can be reversed by weight loss, 
which can be achieved by replacing the obesogenic high-fat diet (HFD) with a 
normocaloric regular chow (RC) diet (Guan, Vgontzas et al. 2008; Agardh and Ahren 
2012). The benefits of weight loss translates to humans; bariatric surgery or caloric 
restriction alone reduces type II diabetes symptoms and improves neurocognitive scores 
such as sleepiness (Barnosky, Hoddy et al. 2014; Berk, Mulder et al. 2016; Joris, Plat et 
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al. 2017). However, these observations raised questions about the relative influence of 
diet, energy balance, and body weight on the pathogenesis and reversibility of these 
metabolic and behavioral abnormalities. 
The studies contained herewithin were motivated by the following question: what 
contributes to excessive sleepiness in DIO animals? In Chapter 2, I introduce the novel 
Diet Switch (DS) feeding paradigm and demonstrate that diet/energy balance and body 
weight independently affect sleep/wake behavior. In Chapter 3, I manipulate central 
PPARg signaling via pharmacological and genetic approaches and measure their effect 
on sleep architecture; these PPARg-targeting interventions had mild effects on sleep 
behavior, but focused my attention on hypothalamic integration of metabolism and sleep. 
In Chapter 4, I again use the DS feeding protocol, but instead measure various 
molecular (blood biomarkers and hypothalamic gene expression) and behavioral 
(locomotor and metabolic) outcomes. Using refined statistical modeling approaches, I 
determine the relative influence of body weight and diet/energy balance on these 
parameters, and relate these findings to the results from Chapter 2. In the remainder of 
this chapter, I will summarize key findings, speculate on their implications, and discuss 
future avenues of research to expand on this current body of work.   
 
Diet Switch (DS): A novel approach to separate effects of diet/energy balance and 
body weight 
 Latin for “to eat away,” obesity is caused by chronic positive energy balance, but 
is actually classified based on absolute weight or body mass index (BMI; weight / 
height2). However, BMI is generally considered a poor indicator of cardiometabolic 
health, and the reasons underlying metabolically healthy vs metabolically unhealthy 
obesity is unclear (Munoz-Garach, Cornejo-Pareja et al. 2016; Tomiyama, Hunger et al. 
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2016; Sharma and Campbell-Scherer 2017). One possibility could relate to differences in 
diet and/or energy balance that may influence physiological processes independent from 
body weight. To this end, we developed the DS feeding paradigm to isolate diet/energy 
balance effects from body weight effects. 
 
Previous approaches to isolate diet, energy balance, and body weight 
Previous studies have attempted to parse apart diet, energy balance, and obesity 
effects, but these approaches have their limitations. One common approach uses DIO 
susceptible (OS) and resistant (OR) rodents to parse apart diet effects from body weight 
effects (Chang, Graham et al. 1990; Choi, McGregor et al. 2016). However, these types of 
studies are technically tedious and may introduce unrecognized bias. First, one 
approach is to put a large number of mice (typically n > 100) on HFD and stratify animals 
as OS or OR depending on their relative weight to the group population (Xia, Duan et al. 
2015; Choi, McGregor et al. 2016). However, this approach does not use most animals in 
the study, making it inefficient and not cost effective. Further, this approach is unrealistic for 
studies that require survival surgeries (e.g., EEG/EMG electrodes for sleep monitoring) prior 
to initiation of HFD. Second, another approach is to use specific rodent strains inbred for 
their OS and OR phenotype. Indeed, one study reported that OS rats gain more weight 
and exhibit classical obesity-related sleep/wake abnormalities compared to OR rats, 
even though these groups consume the same HFD (Mavanji, Teske et al. 2010).  
However, the unknown genetic or epigenetic modifications that drive the OS and OR 
phenotype may confound the experimental results. Another common approach is pair-
feeding to parse apart diet effects from total caloric intake (i.e., energy balance). This 
approach generally uses three (or more) groups of animals: ad lib RC-fed, ad lib HFD-
fed, and the pair-fed condition which is provided HFD that is calorically matched to RC-
158 
 
fed controls (Ellacott, Morton et al. 2010).  Pair-feeding helps to control for differences in 
caloric intake, but restricted feeding paradigms induce food anticipatory behavior that 
greatly affect locomotor and sleep/wake activity (Storch and Weitz 2009; Silver, Balsam 
et al. 2011). Therefore, this approach is not ideal to study spontaneous behavioral 
patterns induced by HFD or DIO. Last, some studies acutely provide HFD (1-3 days) to 
disassociate diet from obesity (Eckel-Mahan, Patel et al. 2013). However, this approach 
can still induce significant weight gain and positive energy balance compared to RC-fed 
controls. 
 
DS feeding paradigm: Strengths over alternate methods 
Compared to other approaches, the DS feeding paradigm offers unique 
advantages to isolate body weight effects from other diet-related factors. First, the DS 
uses age- and gender-matched isogenic mice, which are the best possible within-
experiment controls.  Second, the DS is simple to perform, robustly induces weight 
changes, and only requires moderate sample sizes. Third, inclusion of non-DS controls 
(RC NoDS and HFD NoDS) allows investigators to determine the physiological range of 
output variables and compare results to established literature. Fourth, the DS approach 
allows for within-animal measurements of certain variables (Pre- to Post-DS), thus 
quantifying acute changes to these variables while also enhancing statistical power. 
Last, DS yields a rich data set which can be modeled in a variety of ways. In Chapter 4, 
I show that body weight and energy balance has independent effects on a variety of 
metabolic and behavior factors using linear regression modeling. Furthermore, this 
approach allows us to compare metrics across experiments (from different animals), 
although within-animal comparisons would undoubtedly be preferred. Last, I chose two 
robust and related signals—glucose and insulin—and used response surface modeling 
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(RSM) to demonstrate how energy balance and body weight interact to affect their 
circulating levels. Linear modeling revealed both glucose and insulin are independently 
affected by both body weight and energy balance. However, RSM showed that glucose 
is strongly affected by each factor independently (with mild synergistic effects) while 
insulin levels are only elevated substantially when both body weight and ∆body weight 
rise together (Figure 4.7). To my best knowledge, this is the first study to show how 
glucose and insulin levels are dynamically and differentially affected during diet-induced 
weight gain. Taken together, the DS feeding paradigm is a novel approach to 
disentangle diet/energy balance effects from body weight, revealing a deeper 
understanding of sleep, metabolism, and obesity.   
 
DS feeding paradigm: Limitations and potential improvements 
 Although the DS approach is superior in some regards, it does have some clear 
shortcomings. First, dietary interventions are used to drive changes to energy balance. 
Therefore, it is difficult to disassociate diet effects from energy balance. This could be 
most troublesome if a measured output is truly related to diet independent of energetic 
changes. For example, isocaloric diets differing in macronutrient composition may have 
divergent effects on certain metabolites or behaviors, even if subsequent weight gain is 
similar. Therefore, direct comparisons of different calorie-dense diets varying only in 
macronutrient composition would help determine relative diet vs energy balance effects. 
Furthermore, energy balance could be modified via alternate approaches, such as 
access to a running wheel or treadmill. If the amount of spontaneous exercise is 
sufficient, two groups could both consume similar amounts of the same HFD but be in 
dissimilar energy balance. Second, the RC and HFD used in our studies differ 
considerably in palatability and texture, raising the possibility that motivation or ability to 
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consume food could be impacted by acute DS. Texture can be controlled for by 
shredding or powderizing the diets, although this will make quantification of caloric intake 
difficult. Controlling for palatability is a greater challenge, and is a concern for many 
scientists studying the rewarding properties of food (Johnson and Wardle 2014). 
Regardless of the underlying motivational reasons, acute DS induces robust changes to 
energy balance, which was of primary importance to my studies. Third, the DS paradigm 
induces dynamic and dramatic weight changes, which may interfere with certain 
behavioral protocols. For example, food deprivation is used to motivate animals for some 
behavioral tasks and to reduce variability in glucose and insulin measurements 
(Grissom, Herdt et al. 2015; Antunes, Elkfury et al. 2016). By placing all mice into 
negative energy balance, food deprivation may interfere with the DS protocol and 
generate mice of unusual body weights and energetic status. Taken together, the DS 
feeding paradigm may not be appropriate for all types of obesity research, especially 
when related to diet-specific or motivational effects.  
 
Insights and Interpretations from DS Experiments 
Normal sleep homeostasis in DS mice 
Despite the well-known effect of DIO on sleep/wake behavior, there has not been 
any published literature testing whether sleep homeostasis was intact in DIO mice. 
Previous studies have shown that genetically obese animals (ob/ob and db/db mice) 
respond normally to sleep deprivation (SD) with increased NREM delta power and 
typical delta power discharge (Laposky, Shelton et al. 2006; Laposky, Bradley et al. 
2008). However, these animals display abnormal baseline NREM delta power, indicating 
circadian misalignment of sleep pressure. In Chapter 2, I report that baseline NREM 
delta power, post-SD delta power, and post-SD sleep/wake times are all normal across 
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the DS conditions (Figure 2.7). Therefore, these results implicate dysregulated circadian 
processes underlying sleep/wake differences in DS animals. Indeed, profound 
impairments to behavioral and circadian rhythms are well-described (Kohsaka, Laposky 
et al. 2007; Huang, Ramsey et al. 2011; Eckel-Mahan and Sassone-Corsi 2013). One 
striking characteristic of HFD-fed animals is increased food intake during the resting 
period (mistiming of caloric intake). Furthermore, time-restricted feeding (only allowing 
HFD-fed mice the opportunity to eat during the dark period) can protect against DIO and 
keep molecular circadian rhythms intact, even though 24-hour caloric intake is similar to 
HFD-fed ad lib controls (Hatori, Vollmers et al. 2012).  Taken together, I believe that 
sustained HFD intake across the day significantly contributes to altering behavioral and 
molecular circadian rhythms, thus driving the observed sleep/wake behavioral 
phenotypes. Future work could test how DS mice behave in free running conditions (total 
darkness) to quantify induction and rescuing of behavioral circadian rhythms.  
 
Locomotor activity and sleep/wake behavior are decoupled following DS  
 Locomotor activity is highly correlated with sleep/wake behavior for the simple 
reason that spontaneous, voluntary movement can only be achieved while awake. This 
association is valuable to the sleep research field because locomotor-based 
approximations of wake time are much quicker and more efficient than EEG-based sleep 
measurements (Pack, Galante et al. 2007). In fact, two of the studies described in this 
dissertation (Chapter 3 and the Appendix) were motivated by observing locomotor 
differences in HFD-fed transgenic animals (Lu, Sarruf et al. 2011; Ramadori, Fujikawa et 
al. 2011). However, in both cases, sleep/wake differences were not observed in our 
hands (although other methodological differences may also have contributed to the lack 
of phenotype, as described in their respective discussion sections). Nonetheless, this 
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highlights how sleep researchers use locomotor data to motivate future studies. In 
Chapter 4, we ran a large cohort of mice in locomotor boxes during the DS protocol and 
compared those results to EEG-measured sleep/wake from Chapter 2. We found that 
EEG-measured wakefulness was negatively associated with both body weight and 
positive energy balance, but locomotor activity was negatively associated with body 
weight only (with no relation to energy balance). These locomotor associations were 
primarily driven by the HFD-consuming animals. Specifically, HFD NoDS mice were 
hypoactive compared to all other groups; therefore, they primarily drove the negative 
association with body weight. On the other hand, RC → HFD mice had significantly 
greater activity compared to HFD NoDS animals (even though these two groups exhibit 
similar sleep/wake behavior; Figure 2.6). Therefore, RC → HFD mice have normal 
activity patterns but are hypersomnolent (compared to RC NoDS controls). In the 
discussion of Chapter 4, we postulate potential technical and biological reasons for why 
a locomotor-based algorithm to estimate wakefulness could fail. Here, I will expand on 
why and how locomotor activity and wakefulness could be dissimilar. 
 There are two plausible scenarios in which wake and activity patterns could 
decouple in metabolically abnormal mice. First, animals that move while asleep would 
represent one form of wake-activity decoupling (e.g., REM behavior disorder, or RBD). 
Sleep movement disorders would present as increased activity (thus overestimating 
wake time using locomotor-based algorithms) although sleep times may be normal. One 
recent study developed an animal model for RBD, which exhibited abnormal sleep 
architecture, but locomotor activity was not measured (Brooks and Peever 2011). 
However, this is unlikely to relate to DS mice because it would imply HFD induces profound 
parasomnias, which only occur in ~0.5% of the general population (Markov, Jaffe et al. 
2006). Instead, animals that tire easier following normal amount of activity could explain 
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this disassociation. Indeed, obesity is associated with decreased endurance and increased 
fatigue (Mehta 2015). Thus, increased fatigue in DIO animals may contribute to greater sleep 
times following similar activity patterns. Furthermore, this would make an interesting 
prediction about fatigue. Specifically, body weight is related to physical fatigue (i.e., reduced 
physical stamina), but body weight and energy balance are both related to mental fatigue 
(i.e., drowsiness). Following initial HFD consumption, mice attempt to keep their weight down 
by increasing energy expenditure (Figure 4.5). However, I postulate that this increased 
energy expenditure following acute HFD/positive energy balance also has the consequence 
of tiring the animal, which manifests as hypersomnolence. Furthermore, RC → HFD animals 
may begin to consume food throughout the day, thus acutely increasing activity (while 
eating) but engaging in the behavioral satiety sequence shortly thereafter (which 
includes resting) (Ishii, Blundell et al. 2003). Conversely, animals losing weight (HFD → 
RC) show similar wake and activity patterns to RC NoDS animals, suggesting that the 
mechanisms that induce hypersomnolence may be separate from the mechanisms that 
rescue it. This is supported, in part, by studies with exogenous administration of 
hormones, such as leptin. One study found leptin can increase NREM sleep in fed 
animals, but this effect is absent in fasted animals (Sinton, Fitch et al. 1999). One 
interpretation of these results is that other circulating hormones (e.g., ghrelin) mask the 
effects of exogenous leptin. Furthermore, sleep/wake studies with exogenous ghrelin 
have yielded controversial results (Tolle, Bassant et al. 2002; Weikel, Wichniak et al. 
2003; Szentirmai 2012), raising the possibility that many metabolites and hormones 
interact to affect behavior during negative energy balance. Taken together, it is possible 
that hypersomnolence observed in RC → HFD animals is a result of fatigue following 
activity, while the normalization of activity patterns in HFD → RC is due to separate 
processes related to weight loss.  
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Positive energy balance and increased body weight encode different information 
 This collection of work clearly demonstrates that diet/energy balance and body 
weight can have separate effects on many metabolic and behavioral factors. This raises two 
interesting questions. First, what is the benefit of having separate ‘body weight’ and ‘energy 
balance’ signals, each capable of sending and/or encoding information? Evolutionarily 
speaking, one could imagine certain situations in the wild where energy balance is dissimilar 
to body weight. For example, a mal-nourished animal that has recently feasted would greatly 
benefit from rest to aide digestion. This post-prandial signal (colloquially known as the ‘food 
coma’) would help this animal conserve its energetic resources. Conversely, a well-
nourished but hungry animal would be actively engaged in food-seeking behavior. However, 
unsuccessful hunts or scavenging is common in the wild, but as long as stored energy 
sources are sufficient, the animal would benefit from returning home, resting, and resume 
food-seeking tomorrow. Therefore, these hypothetical situations highlight circumstances in 
which unique body weight and energy balance signals would be evolutionarily beneficial.  
Second, if separate signals are so important, why do certain hormones and genes correlate 
with both body weight and energy balance? Maintaining sufficient nutritive status is of utmost 
importance to any animal, and striking the balance between the risk of food-seeking and the 
safety/comfort of rest is critical to survival. Therefore, the presence of redundant signals 
capable of signaling to multiple CNS regions confers the advantage of ensuring an animal 
has proper motivation to seek food when needed. Furthermore, this allows the ‘gain’ of the 
signal to be easily manipulated. For example, the initiation of negative energy balance may 
induce the release of some orexigenic signals, but mal-nutrition would augment the release 
of those same signals plus many more. Thus, some signals may respond to both diet/energy 
balance and body weight independently, but their relative circulating levels may depend on 
how those factors interact. Indeed, our results with RSM for glucose and insulin provide one 
such example, where both factors are related to body weight and energy balance, but their 
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dynamic regulation is strikingly different (Figure 4.6). Conversely, in obesity, many of these 
circulating satiation signals (e.g., insulin and leptin) are elevated for extended periods which 
eventually results in hormone resistance (or a lack of effect on effector cells). It is unknown 
whether hormone resistance is a cause or consequence of obesity and/or positive energy 
balance; this is remains an active debate in the metabolism field (Myers, Leibel et al. 2010). 
Our work suggests that insulin levels are not a consequence of either positive energy 
balance or obesity alone (based on RSM; Figure 4.6) and that leptin levels are not a 
consequence of positive energy balance (Figure 4.4). However, future work will need to 
directly measure insulin and leptin resistance following the diet switch (via molecular and 
behavioral responses to exogenous administration of these hormones). Determining the 
relative contribution of positive energy balance and body weight on hormone resistance 
would be an important step in understanding the pathogenesis and best treatments for 
obesity. 
 
Unanswered questions and future directions 
Do male and female mice respond similarly to DS? 
All of the studies were conducted using male mice, but female mice are generally 
more resistant to HFD-induced weight gain. Therefore, it would be interesting to see if 
the acute dietary effects on weight and sleep/wake behavior persist in female mice. 
Females are often excluded from diet studies because of potential confounds of the 
estrous cycle (Ellacott, Morton et al. 2010). However, previous research has found that 
C57BL/6 females exhibit similar sleep/wake architecture across the estrous cycle, 
making this less of a concern for this particular behavior (Koehl, Battle et al. 2003).  
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Would younger DIO mice be more resistant to the benefits of RC-induced weight 
loss? 
Childhood obesity is another component of the obesity epidemic and is itself a 
significant risk factor for morbid obesity in adulthood (Biro and Wien 2010; Sahoo, 
Sahoo et al. 2015). Furthermore, there is evidence that HFD exposure immediately post-
weaning can cause greater neurogenesis and cognitive deficits than HFD-fed adults 
(Boitard, Etchamendy et al. 2012). Therefore, it is possible that HFD-exposed juvenile 
mice may exhibit even greater metabolic and behavioral issues, which may be more 
resistant to RC-induced weight loss. Future work repeating the DS feeding paradigm 
with young (3 week old) mice would allow comparison to my current results (with 10-12 
week old mice).  
 
How quickly to metabolic and behavioral abnormalities present? How quickly are 
they rescued? 
The DS experiments with CLAMS demonstrated that certain metabolic 
parameters changed immediately (caloric intake, heat production, and RER in HFD → 
RC animals) while others did not onset until a fully day later (RER in RC → HFD 
animals; Figures 4.5 and 4.S7). Therefore, it would be interesting to know how soon 
after the DS blood biomarkers, hypothalamic gene expression, and sleep/wake behavior 
differed. Furthermore, adding these one-day DS groups would potentially yield two novel 
conditions (obese + negative energy balance; lean + positive energy balance), which 
may improve our linear regression and response surface models.  
 
How are other obesity-related pathways affected following DS?  
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As previously mentioned, obesity is associated with many negative health 
consequences, including cardiovascular diseases and increased cancer risk (Pi-Sunyer 
2009; Berenson and Bogalusa Heart Study 2012). Therefore, future work could expand 
output metrics to include cardiac health and oncogene pathways to determine the 
relative influence of energy balance and body weight on these comorbidities.  
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ABSTRACT 
Sleep disorders and wake impairments are commonplace in modern-day society. 
In addition, >70% of the U.S. population suffers from a metabolic disorder (such as 
obesity). Thus, discovering molecular links between these processes is the subject of 
much investigation. Previous studies have shown SIRT1 (a NAD+ dependent 
deacetylase) is critically important for both metabolic homeostasis and normal 
sleep/wake behavior. Lean SIRT1 null mice are hypersomnolent with increased sleep 
drive, similar to obese animals. However, it is unclear in which brain area SIRT1 is 
required to induce these sleep effects. A recent study reported SIRT1 knockout (KO) 
restricted to SF1+ neurons (located in the ventromedial hypothalamus) affects how 
animals respond to metabolic challenges. Specifically, SF1-SIRT1 KO animals do not 
respond to leptin (which has been shown to increase NREM sleep) and are hyperactive 
compared to wildtype controls. Therefore, we hypothesize that SF1-SIRT1 KO mice 
would behave abnormally following metabolic and leptin challenges, specifically related 
to sleep/wake behavior. We developed an acute diet switch regimen to observe within-
animal responses to both fasting and high-fat diet (HFD). While we found no genotype 
differences, acute dietary manipulations profoundly affected sleep architecture. Leptin 
injections moderately decreased caloric intake in both genotypes, but had no effect on 
any sleep/wake metrics. Furthermore, we observed augmented NREM time and 
sleep/wake fragmentation following 8 weeks of HFD. Taken together, our results confirm 
that both acute and chronic dietary challenges can influence sleep/wake architecture 
independent of SIRT1 in SF1+ neurons.  
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INTRODUCTION 
Sleep and metabolism are greatly intertwined, since manipulation of one process 
affects  the other (Sharma and Kavuru 2010). Therefore, it is challenging to isolate the 
molecular underpinnings linking these processes, but identifying these key molecular 
players may reveal new therapies to treat both metabolic and sleep disorders. One 
pivotal player with roles in both sleep and metabolic regulation is a family of NAD+-
dependent deacetlyases called sirtuins (Panossian, Fenik et al. 2011; Li 2013; Chang 
and Guarente 2014). In particular, the SIRT1 isoform is ubiquitously expressed in 
neurons, including wake-promoting neurons, and has been implicated in mitochondrial 
biogenesis, anti-oxidant defense, and autophagy, thus highlighting its importance in 
metabolic health. Importantly, previous work from our lab has shown germline knockout 
of SIRT1 robustly decreases wakefulness and increases both NREM and REM sleep 
(Panossian, Fenik et al. 2011). While this study proves the necessity of SIRT1 for normal 
sleep/wake rhythms, it is unclear which neuronal populations drive the SIRT1-mediated 
sleep changes. Further, metabolic challenges (such as fasting or hypercaloric diets) 
modulate SIRT1 levels, suggesting that mice lacking functional SIRT1 may behave 
differently under these conditions (Schug and Li 2011).  
Previous research has shown central SIRT1 is both capable of responding to 
changes in energetic status and necessary for normal metabolic homeostasis (Martin, 
Mattson et al. 2006; Ramadori, Lee et al. 2008; Schug and Li 2011). Hypothalamic 
SIRT1 mRNA, protein levels, and enzymatic activity all increase during fasting (Kanfi, 
Peshti et al. 2008). However, in ob/ob mice, SIRT1 mRNA levels are increased, but 
enzymatic activity is reduced, likely due to reduced NAD+ levels (Ramadori, Lee et al. 
2008). Further, pharmacological SIRT1 inhibition (with EX-527) decreases food intake 
and consequently lowers body weight (Dietrich, Antunes et al. 2010). Additionally, 
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central EX-527 blocks the effects of intraperitoneal (i.p.) ghrelin, which normally 
increases food intake and NPY/AgRP neuronal activity (Dietrich, Antunes et al. 2010). 
Conversely, transgenic mice overexpressing SIRT1 in all tissues are resistant to diet 
induced obesity (DIO) (Pfluger, Herranz et al. 2008). Taken together, SIRT1 is 
necessary for animals to properly adapt to metabolic challenges. However, it is unclear 
in which brain regions SIRT1 is required, and how SIRT1 deficiency affects sleep and 
wakefulness under metabolic stressors.  
Steroidogenic factor 1 (SF1) neurons are located in the ventromedial 
hypothalamus (VMH) and are important for sexual reproduction and energy homeostasis 
(Val, Lefrancois-Martinez et al. 2003; Kim, Zhao et al. 2011). These glutamatergic 
neurons express functional leptin receptors (LepR) and project to neurons in the arcuate 
nucleus (Dhillon, Zigman et al. 2006). Indeed, i.p. leptin causes ~80% of SF1 neurons to 
depolarize and increase firing rate, which is completely blocked in mice lacking LepR in 
SF1+ neurons (Dhillon, Zigman et al. 2006). In addition, SF1-Cre/LepR-flox mice have 
increased susceptibility to DIO (Dhillon, Zigman et al. 2006). These studies suggest that 
SF1+ neurons are downstream of leptin signaling. SF1-SIRT1 knockout (KO) mice do 
not become hypophagic in response to i.p. leptin, suggesting that SIRT1 within these 
SF1+ neurons is required for proper leptin signaling (Ramadori, Fujikawa et al. 2011). 
Furthermore, SF1-SIRT1 KO mice also weigh more on HFD, quickly develop leptin 
resistance, and have blunted activity patterns (Ramadori, Fujikawa et al. 2011). Since 
locomotor activity has high correlation with wake patterns (Pack, Galante et al. 2007), 
we hypothesize that these mice will also exhibit similar sleep changes seen in global 
SIRT1 KO mice, especially following dietary challenges. Additionally, i.p. leptin has been 
shown change sleep architecture (Sinton, Fitch et al. 1999). Therefore, we also predict 
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that exogenous leptin will induce sleep/wake changes in wildtype mice, but not SF1-
SIRT1 KO animals. 
The following experiments investigate metabolic and sleep/wake behavior in 
SF1-SIRT1 KO mice during acute dietary manipulations, chronic HFD, and exogenous 
leptin administration. Our results do not show strong genotype effects; instead, our 
results highlight the profound effects of metabolic challenges on sleep/wake behavior. 
 
METHODS 
Mice 
 Transgenic mice heterozygous for SF1-Cre recombinase and homozygous for 
SIRT1-flox/flox were generously gifted from the lab of Roberto Coppari (UT 
Southwestern, Dallas, TX). Their generation and characterization are detailed here: 
(Ramadori, Fujikawa et al. 2011). All experiments were performed with male, virgin mice 
aged 3-5 months under normal lighting conditions (12:12 L:D, 7am lights on). Four 
separate cohorts of mice were used for: 1) blood glucose measurements [Fig 2D]; 2) 
acute dietary changes [Fig 1, Fig 2A-C, Fig 3]; 3) leptin injections [Fig 4]; and, 4) chronic 
HFD [Fig 5]. All experiments were approved by the Institutional Animal Care and Use 
Committee (IUCAC) at the University of Pennsylvania.  
 
EEG/EMG for sleep/wake measurement 
 Recording electrodes for both electroencephalography (EEG) and 
electromyography (EMG) were constructed and implanted, as previously described 
(Panossian, Fenik et al. 2011; Zhu, Fenik et al. 2015). After one week of recovery, mice 
were tethered to recording cables and allowed one week of acclimation before any 
experimental protocol began. Signals were acquired and analyzed using SleepSign for 
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Animals (Kissei Comtec). Sleep/wake architecture was quantified by segmenting 
recordings into 4-second epochs, which were scored manually as wake, NREM, or REM 
sleep by an experienced investigator. MATLAB was used to calculate total times in each 
state and sleep/wake fragmentation metrics. For the murine multiple sleep latency test 
(MMSLT), the investigator entered the recording suite at ZT12 (7pm, lights off) and 
began sleep depriving all animals from 7:00p – 7:10p. At 7:10p, the investigator left mice 
undisturbed and watched EEG waveforms in real-time, looking for a minimum of 15 
consecutive seconds of NREM (slow wave) sleep. When observed, the investigator 
logged the sleep latency (in MM:SS). If the animal did not fall asleep within 20 minutes, 
the maximum latency time (20:00) was recorded. At 7:30p, the 10 minutes of sleep 
deprivation followed by 20 minutes of permitted sleep was repeated. This was recurred 
four times total (at 7:00p, 7:30p, 8:00p, and 8:30p). The average sleep latency per 
animal per dietary condition is reported.  
 
Dietary Protocols 
All mice were maintained on regular chow (RC, Purina 5001) unless noted 
otherwise. When indicated, mice were given a hypercaloric, high-fat diet (HFD, 
Research Diets, D12451). To test acute dietary changes, we used the protocol shown in 
Fig 1. All reported sleep/wake metrics are in reference to the first RC condition (Week 1), 
unless noted otherwise. To test chronic HFD, all mice were switched to HFD for 8 weeks 
following the baseline (Week 0) recording. HFD was given fresh bi-weekly. 
 
Blood glucose 
Glycemia was measured using the OneTouch Ultra blood glucose monitors 
(LifeScan Inc). Unanesthesized mice had ~0.5 mm of their distal tail cut with a clean 
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blade; the first drop of blood was not used. Blood glucose was tested between 9:00-
9:30am and 11:00-11:30am. For fasted mice, all food was removed at 5:00pm the 
previous day.  
 
Leptin Injections 
Recombinant mouse leptin (UCLA Medical Center) was diluted in sterile saline to 
a working concentration of 0.6 μg/uL. Injection dose was 3 mg/kg (100-150 uL i.p. per 
mouse per injection) (Ramadori, Fujikawa et al. 2011). Food intake was measured 
directly before the injection (ZT11.5) and exactly 24-hours later. Reported sleep/wake 
patterns are only for the dark period following the injection (ZT12-24). All animals 
received both a leptin and saline injection with counterbalanced controls. 
 
Statistics 
PRISM was used to generate graphs and calculate statistics. Briefly, 2x2 
repeated measures analysis of variance (RM-ANOVA) were used for most analysis, with 
‘diet’ as the within-animal factor and ‘genotype’ as the between animal factor. Holm-
Sidak post-hoc corrections were applied, when appropriate. After observing limited 
genotype effects, the overall significance of ‘diet’ (by pooling genotypes) were reported 
instead. For chronic HFD (when only control mice were analyzed), a RM-one way 
ANOVA with Holm-Sidak post-hoc correction was used. Significance was achieved at 
p<0.05, although exact p-values are reported when appropriate.  
 
RESULTS 
SIRT1 is critically important for proper sleep/wake behavior (Panossian, Fenik et 
al. 2011); however, it is unclear in which brain area SIRT1 is required. Previous work 
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demonstrated SF1-SIRT1 KO mice exhibit abnormal behavioral (locomotor) rhythms in 
response to both dietary and leptin challenges (Ramadori, Fujikawa et al. 2011). 
Therefore, we tested how both SF1-SIRT1 KO (MUTANT) and littermate control 
(CONTROL) mice responded to different dietary challenges (Figure 1). Briefly, after a 
baseline recording (when all mice consumed RC), mice were randomized to one of two 
groups: 1) Group 1, which were first given HFD for 1 week [positive energy balance]; or 
2) Group 2, which remained on RC throughout the week but were fasted on the final day 
[negative energy balance].  After one week restitution to RC, the dietary challenge was 
switched for each mouse. For all relevant metrics, ‘RC’ refers to the baseline day (Week 
1), ‘HFD’ refers to the final day after 1 week of HFD (Week 2 for Group 1, Week 4 for 
Group 2), and ‘FR’ or ‘Fasted’ refers to complete removal of food during the 24-hour 
recording (Week 4 for Group 1, Week 2 for Group 2).  
We found that the dietary condition had significant influence on body weight, with 
HFD increasing and FR moderately decreasing weight; there was no genotype effect on 
weight (Figure 2A). Further, Groups 1 and 2 had different trajectories of weight gain/loss, 
as expected, but there was no significant difference in their terminal weight (Figure 2B). 
Caloric intake was similar between RC and HFD conditions, both significantly greater 
than the 0 kcal consumed during fasting (Figure 2C).  Finally, in a separate cohort of 
animals, we tested blood glucose levels during ad libitum RC-feeding and fasting 
conditions (Figure 2D). We found fasted animals had reduced glucose levels, but there 
were no genotype differences. 
 
Sleep/wake behavior in SF1-SIRT1 KO mice 
We used EEG-recordings to measure both undisturbed, 24-hour sleep/wake 
architecture and the MMSLT. While we did not find any genotype differences, we found 
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acute dietary manipulations had profound effects on sleep behavior and sleepiness. 
Specifically, HFD decreased wake (Figure 3A: p=0.0628) and FR increased wake 
(p<0.05). HFD increased NREM by ~50 minutes, although this only trended towards 
significance (Figure 3B: p=0.1628); REM was significantly increased (Figure 3C: 
p<0.05). Fasting significantly decreased NREM (p<0.05), with no effect on REM. Dietary 
conditions also had profound effects on sleep/wake fragmentation, with FR consolidating 
and HFD fragmenting bouts (Figure 3DE). Finally, HFD-feeding caused a significant 
reduction in sleep latency, indicating a higher drive to sleep (Figure 3F: p<0.01). Fasted 
mice trended towards a longer sleep latency, which would indicate a lower sleep drive. 
Taken together, SF1-SIRT1 KO mice had indistinguishable sleep/wake architecture 
compared to controls, but dietary interventions induced major behavioral changes.  
 
Leptin injections did not affect sleep/wake behavior in either mouse strains 
Exogenous leptin can moderately increase NREM sleep in rats (Sinton, Fitch et 
al. 1999), and previous work with SF1-SIRT1 KO mice demonstrated a blunted response 
to leptin injections (Ramadori, Fujikawa et al. 2011). We wanted to test whether leptin 
would differentially induce sleep/wake changes between wildtype and SF1-SIRT1 KO 
mice. Mice surgicated with EEG electrodes received both a leptin and saline injection 
counterbalanced one week apart. While leptin induced a near significant reduction in 
caloric intake (Figure 4A: p=0.0514), there were no genotype differences.  Further, leptin 
did not change any aspects of sleep/wake architecture during the dark period (Figure 
4B-F). However, SF1-SIRT1 KO mice had significantly less REM sleep than controls, 
which was not affected by leptin administration (Figure 4D: p<0.05). Taken together, 
leptin moderately reduced food intake and had no effect on sleep architecture in both 
wildtype and mutant mice. 
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Chronic HFD profoundly alters sleep/wake architecture  
Last, we put a separate cohort of wildtype and mutant mice into chronic positive 
energy balance (HFD for 8 weeks). However, the cohorts were small (control, n=4; 
mutant, n=3) and we observed substantial variability in mutants. Specifically, one mutant 
gained much more weight than any other animal (Figure 5A), and a different mouse 
exhibited a large increase in wakefulness unlike any other (Figure 5B). Since we had not 
observed any major genotype effects thus far, we instead analyzed the within-animal 
effects of obesity-induced sleep changes in control mice only (Figure 5C-F). We found 
control mice fed HFD for 8 weeks weighed significantly more (Figure 5C, p<0.05), spent 
more time in NREM and less time awake (Figure 5D, p<0.0001 for both), and exhibited 
increased sleep/wake fragmentation (Figure 5EF, p<0.05 for both bout number and bout 
length). While this comparison lacks proper controls (i.e., RC-fed mice for 8 weeks), this 
experiment provides evidence that 8 weeks of HFD induces significant sleep/wake 
changes in our hands, in accordance with previous literature (Mavanji, Billington et al. 
2012).  
 
DISCUSSION 
Based on previous literature showing, we predicted that SF1-SIRT1 KO mice 
would recapitulate the sleep/wake phenotype observed in SIRT1 null mice. Further, we 
expected leptin to increase NREM sleep in control, but not SF1-SIRT1 KO, mice. 
Instead, we found no major genotype effects with either acute or chronic dietary 
interventions, nor any sleep-modifying effect of exogenous leptin administration.  
There are many potential reasons why we did not observe phenotypic differences 
between SF1-SIRT1 KO and control mice. First, SIRT1 is only one member of the sirtuin 
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family in mammals, with 6 others sirtuins (SIRT2-7) present in neural tissues (Braidy, 
Poljak et al. 2015). While their functions are not all similar (e.g., SIRT1, 6, and 7 are 
nuclear, while SIRT3, 4, and 5 are mitochondrial), we cannot rule out compensatory 
mechanisms (Michishita, Park et al. 2005). Second, we obtained the SF1-SIRT1 KO 
strain from the Coppari lab, which characterized the localization and efficiency of SIRT1 
KO in SF1+ neurons in their original publication (Ramadori, Fujikawa et al. 2011). 
Although we did not confirm the knockout ourselves, we have no strong reason to 
believe that SF1-SIRT1 expression returned in our mice (e.g., we did not experience 
genotyping issues). Alternatively, Ramadori et al used SIRT1 flox/flox mice lacking SF1-
Cre as controls (2011). Some reports have found that the Cre recombinase enzyme 
alone can interfere with normal cell functioning (Pomplun, Florian et al. 2007), raising the 
possibility that their observed effects were partially mediated by Cre and not SIRT1 
excision. In support of this, our current studies used both SIRT1 flox/flox (Cre-negative) 
and Cre-positive (SIRT1 +/+) animals and could not recapitulate many of their results. A 
final possibility is that the SIRT1 contained in other (non-SF1+) neurons provides 
sufficient support to maintain normal sleep/wake behavior. Altogether, given the 
insufficient biochemical data, we cannot differentiate between these three explanations. 
Nonetheless, our results provide evidence that SF1-SIRT1 KO mice behave normally 
(specifically related to sleep and wakefulness) under a variety of metabolic conditions.  
While our studies did not reveal a molecular link between metabolism and 
sleep/wake behavior, they did reinforce established literature on the profound 
sleep/wake changes induced by dietary challenges. Roughly 50 years ago, Danguir and 
colleagues demonstrated the hyperarousal and hypersomnolent effects of fasting and 
hypercaloric diets, respectively, in rats (Jacobs and McGinty 1971; Danguir and 
Nicolaidis 1979; Danguir 1987).  HFD-induced increases in both NREM sleep and 
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sleep/wake fragmentation were more recently confirmed in mice (Jenkins, Omori et al. 
2006; Mavanji, Billington et al. 2012). However, the experiments herein is the first study 
to show rapid, reversible changes to sleep/wake architecture that could be both induced 
and rescued by diet. Further, we found that one week of HFD induced borderline 
significant changes to total wake time (Fig 3A, p=0.0628), but 8 weeks significantly 
reduced within-animal wakefulness (Fig 5D, p<0.0001). Therefore, these time points 
defining acute (1 week) and chronic (8 weeks) HFD will be used for future studies 
concerning diet-induced effects on sleep/wake behavior.  
We injected both control and mutant mice with leptin (3 mg/kg), but did not 
observe any sleep/wake differences. This was surprising because we did measure a 
modest (p=0.0514) reduction in food intake, indicating the efficacy of leptin. Further, 
Sinton et al found 1.3 mg/kg leptin significantly increased NREM time (at the expense of 
REM sleep) in ad lib fed animals (Sinton, Fitch et al. 1999). However, fasting (which 
naturally reduces leptin levels) prevented the behavioral effects of exogenous leptin. 
One interpretation of this study is that, during fasting, other circulating hormones (e.g., 
ghrelin) override the somnogenic effect of exogenous leptin. However, even the reported 
enhancement of NREM sleep during ad lib feeding is minor (<15 minutes). Thus, it is 
possible that leptin has, at best, minor to moderate effects on sleep architecture, which 
we were unable to recapitulate in our hands. 
In all, SF1-SIRT1 KO animals exhibit normal sleep/wake behavioral patterns 
under a variety of acute and chronic metabolic challenges compared to controls. 
However, the profound within-animal changes to sleep and wakefulness induced by diet 
changes can lay the foundation for future studies. Last, we did not find evidence that 
leptin administration changes sleep/wake behavior. 
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Figure A.1: Feeding regimen to test acute diet effects. WT and SF1-SIRT1 KO mice 
were randomized into two groups. Each red dot indicates when EEG-recorded sleep and 
the MMSLT was performed. Briefly, both groups were originally maintained on RC for 
one week and behavior was assessed. The following day, Group 1 mice were switched 
to HFD while Group2 mice were maintained on RC. One hour before beginning the sleep 
recording, all food was removed from Group 2 mice at ZT11, thus initiating the food 
restriction; MMSLT was conducted beginning at ZT12 the following day. All mice were 
then immediately switched back to RC for one week, which concluded with another 
sleep assessment. Beginning Week 4, Group 2 mice were switched to HFD while Group 
1 mice underwent the fasting protocol (food removed on Day 27). Finally, all mice were 
switched back to RC for one week prior to sacrifice. RC: Regular chow; HFD: High-fat 
diet; FR: Food restriction. Red dot: indicates behavioral recording. 
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Figure A.2: Metabolic phenotypes following acute dietary manipulations. A) One 
week of HFD significantly increases body weight, although FR (fasting) does not 
significantly decrease weight. This lack of reduction was likely due to animals trending 
towards increased weight over the 5 week protocol (shown in B). Importantly, the ‘RC’ 
shown in A refers to the Week 1 weight, when all animals consumed RC. C) Caloric 
intake is 0 kcal for fasted animals, but similar for RC- and HFD-fed mice. Nonetheless, 
HFD-fed animals gain more weight during the week that RC-fed animals (shown in A). 
D) Glucose is significantly reduced in fasted mice, but there is no effect of genotype. **** 
p<0.0001. 
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Figure A.3: Sleep phenotypes are affected by acute dietary manipulations. (A-C) 
Fasting significantly increases wake, decreases NREM, and has no effect on total REM 
sleep. Conversely, one week of HFD trends towards reduced wakefulness and 
increased NREM sleep; HFD increases REM sleep. (DE) Fasting consolidates 
sleep/wake bouts (evidenced by longer wake bout lengths) while HFD fragments 
wakefulness (evidenced by increased wake bout number). (F) The Murine Multiple Sleep 
Latency Test, or MMSLT, indicates the drive to sleep during the beginning of the active 
period. HFD significantly reduces sleep latency (indicating increased sleep drive); fasting 
trends towards longer sleep latency.  * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure A.4: Leptin injections reduce food intake, but does not alter sleep/wake 
behavior. (A) 24-hour caloric intake trends towards decreasing following leptin injections 
(p=0.0514). However, leptin does not significantly affect any measured sleep metric 
during the dark period (C-F). We did observe a genotype effect of REM sleep, with 
mutants spending less time in REM than controls (D). * p<0.05. 
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Figure A.5: Chronic HFD (8 weeks) increases body weight and changes sleep 
architecture in wildtype mice. (A) While all mice gained weight on HFD, one mutant 
mouse gained much more weight than the others. (B) Further, all mice except one 
exhibited decreased wakefulness after prolonged HFD. Therefore, we reanalyzed data 
omitting all mutant mice (n=3 mutants). (C) All control mice gain significantly more 
weight on HFD. (D) Chronic HFD causes significant within-animal decreases in wake 
and increases NREM sleep; REM is unchanged. (EF) Sleep fragmentation is worsened 
after HFD consumption. However, with the low sample size (n=4) and without proper 
controls (8 weeks of RC consumption), interpretability of this data is limited.  * p<0.05; 
**** p<0.0001.  
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